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NgCAM related cell adhesion molecule (NrCAM) is a cell adhesion receptor
found in the plasma membrane of the initial segment, nodes of Ranvier and
growth cone of neurons. It is a member of the Ll-CAM family of cell adhesion
molecules and together with other family members has an important role in the
development of the mammalian nervous system. The Ll-CAM family is
defined by its ability to bind to ankyrin proteins that in turn link the family
members to the underlying cytoskeleton. Until recently, ankyrin was the only
known cytoplasmic binding partner of NrCAM and subsequently little was
known of the cytoplasmic signalling pathways of the receptor. The aim of this
thesis was both to establish if any other proteins could bind to the cytoplasmic
terminus of NrCAM and to further examine the ankyrin-NrCAM interaction.
Three novel binding partners of the cytoplasmic terminus were discovered,
GIPC, SAP102 and GGA1. GEPC and SAPI02 contained PDZ domains and
appeared to be binding to the very last C-terminal amino acids of the NrCAM
cytoplasmic terminus. Both GIPC and SAP102 were developmentally regulated
in a similar manner to NrCAM in the mammalian brain and co-localised at the
plasma membrane of cells. A third potential binding partner was GGA1, which
appears to be binding via a VHS domain to the ankyrin binding motif of
NrCAM. Other Ll-CAM family members, LI and neurofascin, showed
different binding abilities for GIPC, SAP102 and GGA1, highlighting for the
first time the different cytoplasmic signalling pathways employed by the
ix
different family members. This was also true for the potential binding of the
Ll-CAM family to the members of the 4.1 superfamily. Members of the 4.1
family appeared to be binding to two different motifs in the cytoplasmic tails of
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NrCAM is a cell adhesion molecule that belongs to the Ll-CAM family of cell
adhesion molecules (CAMs) that in turn belong to the superfamily of
immunoglobulin-like domain containing cell adhesion molecules (IgCAMs).
Members of the Ll-CAM family have immunoglobulin G-like (IgG-like) domains
and fibronectin type Ill-like (FNIII-like) repeats in their extracellular cellular domain
and a short highly conserved cytoplasmic terminus of approximately 120 amino
acids. The other vertebrate Ll-CAM family members include LI, Close Homologue
ofLI (CHL1) and neurofascin.
I.I Cell Adhesion molecules.
Cells adhere to other cells and the extracellular matrix (ECM) via CAMs. The
three major CAMs of the nervous system are integrins, cadherins and the IgCAMs.
1.1.1 Integrins.
Integrins are composed of heterodimers of non-covalently associated a and (3
subunits, both of which mediate cell adhesion to the ECM and/or with other CAMs.
They are one of the oldest families of CAMs, for example the genes that code for
integrin |3 subunits are found in the primitive animal phyla Cnidaria and Porifera
(Brower et al., 1997). Both a subunits and |3 subunits are type 1 transmembrane
glycoproteins and specific aP combinations bind specific ligands. There are at least
18 different a subunits and eight different P subunits (Hynes, 2002). Most ECM
proteins are recognised by multiple integrins, e.g. at least 12 bind to fibronectin, and
most integrins recognise more than one ECM protein, eg 0.3Pi recognises
2
fibronectin, laminin, collagen, thrombosondin and fibrillin (Dzamba et al., 2001).
The cytoplasmic terminus of P subunits link integrins to the cytoskeleton via proteins
such as talin, a-actinin and filamin, and this linkage can lead to the formation of
focal adhesions between the cell and the ECM (Calderwood et al., 2000). Integrins
are important for cell migration, extracellular matrix assembly, regulation of tissue
specific gene expression, differentiation, cell survival and cell proliferation (Dzamba
et al., 2001). They are known to interact with members of the same family as
NrCAM for example LI (Mechtersheimer et al., 2001; Skaper et al., 2002; Thelen et
al., 2002) and CHL1 (Buhusi et al., 2003).
1.1.2 The cadherin superfamily.
This family is made up of four categories: 1).classical cadherins; 2). desmosomal
cadherins; 3). protocadherins and 4). cadherin related proteins (Radice and Takeichi,
2001). Most cadherins are single pass transmembrane glycoproteins, containing four
to 30 cadherin repeats (a conserved motif of 110 amino acids related to
immunoglobulin repeats) in the extracellular portion (Radice and Takeichi, 2001).
Cadherins are Ca2+ dependent, with Ca2+ ions binding between the cadherin repeats
making the molecules more rigid and protecting them from proteolytic cleavage
(Nagar et al., 1996). Classical cadherins have a protease processing sequence
K/RRXKR in their N-terminal signal sequence (Radice and Takeichi, 2001). This
sequence allows proteolytic processing of the precursor protein and is essential for
the activation of the cadherin. It is similar to a furin cleavage sequence found in
NrCAM and other members of the LI-CAM family (Posthaus et al., 1998; Posthaus
et al., 2003). In the nervous system cadherins are concentrated at synapses and have
a role in synaptogenesis and synapse stabilisation (Huntley et al., 2002).
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1.1.3 The immunoglobulin superfamily (IgCAMs).
IgCAMs can be associated with many different signalling molecules including,
non-receptor and receptor like protein tyrosine phosphatases (RPTP) and
serine/threonine kinases (Walsh and Doherty, 1997; Volkmer, 2001). They are
important in the development of the nervous system and have roles in cell migration,
axon guidance, myelination, learning and memory, and are implicated in certain
neurodegenerative disorders (Walsh and Doherty, 1997; Kamiguchi et al., 1998a;
Kamiguchi and Lemmon, 2000a; Bartsch, 2003). Subfamilies of IgCAMs are
categorised according to the number of IgG-like domains they possess, the presence
and number of FNIII-like repeats, their mode of attachment to the membrane and the
presence of a catalytic cytoplasmic domain (Figure 1-1) (Brummendorf and Rathjen,
1996; Volkmer, 2001). IgG-like domains are 70 to 110 amino acids long and consist
of highly conserved amino acid residues. They also contain two well-characterised
cysteine residues that form a disulphide bridge between two opposed P-sheets
(Atkins et al., 2001; Volkmer, 2001). FNIII-like repeats are approximately 90 amino
acids in length and contain conserved tyrosine and tryptophan residues. They too are
also composed of two opposing P-sheets but are not normally linked by a disulfide
bridge (Volkmer, 2001). The domain structure of the subfamilies of Ll-CAMS are
described in Figure 1-1 and include the NCAM family, the LI-CAM family, the F11
family, the IgLON family, the RPTP family and the DCC family. NrCAM is a
member of the Ll-CAM family of IgCAMs and interacts with members of the F11





















Figure 1-1. A schematic diagram of the domain structure of the immunoglobulin
superfamily members. The pale blue bar represents the plasma membrane.
Extracellular IgG-like domains are shown as green hemispheres, FNIII-like
repeats as red boxes and mephrin A5 RPTPjj. (MAM) domains as black boxes.
Intracellular phosphatase like domains are shown as black as ellipses. This Figure
is adapted from (Volkmer, 2001).
1.2 The Ll-CAM family.
This family possesses six IgG domains, three to five FNIIl-like repeats, a single
transmembrane region and a cytoplasmic terminus (Brummendorf et al., 1998).
Members of the family have an important role in nervous system development from
invertebrates to mammals.
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1.2.1 The Ll-CAM family gene.
Invertebrates have only one LI gene (Zhao and Hortsch, 1998). Invertebrate LI
homologs include tractin in leech, neuroglian in the fly and LAD-1 in nematode
worm (Brummendorf et al., 1998). There are four homologous LI type genes found
in vertebrates, LI (also known as Neuron glial associated Cell Adhesion Molecule
(NgCAM) in chick), CHL1, neurofascin and NgCAM related Cell Adhesion
Molecule (NrCAM, also known as Bravo) (Brummendorf et al., 1998). It is
postulated that these four proteins are the result of two gene duplication events after
the appearance of the first vertebrate LI gene (Hortsch, 2000). Both the NrCAM and
neurofascin genes (but not LI or CHL1) are subject to extensive exon splicing
(Hassel et al., 1997; Hortsch, 2000) and in the case of neurofascin this results in
alternative isoforms that are not only cell and tissue specific but also
developmentally regulated (Figure 1-2). The vertebrate members of the Ll-CAM
family are described in sections 1.2.1.1 to 1.2.1.4.
1.2.1.1 LI.
LI is the prototypical Ll-CAM family member, and after neural cell adhesion
molecule (NCAM), the most studied IgCAM molecule. This is unsurprising as
mutations in the LI gene in humans cause congenital developmental defects such as
Corpus callosum agenesis, mental Retardation, Adducted thumbs, Spastic paraplegia
and Hydrocephalus syndrome (CRASH) (Fransen et al., 1997; Kamiguchi et al.,
1998a; Kenwrick et al., 2000). In the adult LI contributes to learning and memory
and long term potentiation (Luthl et al., 1994; Welzl and Stork, 2003). LI knockout
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mice show a number of developmental abnormalities such as decreased axonal
association with non-myelinating Schwann cells, abnormal morphogenesis of cortical
dendrites, altered distribution of dopaminergic neurons and a reduced size of the
corpus callosum (Fransen et al., 1998; Demyanenko et at, 1999; Demyanenko et al.,
2001).
1.2.1.2 Neurofascin.
NrCAM is most closely related to neurofascin (Volkmer et al., 1992; Davis et al.,
1996). Neurofascin and NrCAM together account for 1% of the total membrane
protein in brain tissue (Davis et al., 1993; Davis and Bennett, 1994). The
neurofascin gene is subject to extensive alternative splicing (Hassel et al., 1997). In
adult brain some of the more commonly found isoforms are the 186 kDa, 155 kDa
and 140 kDa isoforms respectively (Davis and Bennett, 1993) (Figure 1-2).
Neurofascin 186 was cloned in 1992 (Volkmer et al., 1992). This splice variant
lacks the third FNIII-like repeat and has a mucin like sequence after the fourth FNIII-
like repeat (Davis et al., 1996). Neurofascin 155 has the third FNIII-like repeat but
lacks the mucin like sequence and neurofascin 140 lacks both the third FNIII-like
repeat and mucin sequence (Davis et at, 1996). Neurofascin 186 and neurofascin
155 are important molecules in the formation of myelin and the node of Ranvier
(Davis et al., 1996; Collinson et at, 1998; Lustig et at, 2001; Scherer and Arroyo,
2002). The central importance of neurofascin is probably best demonstrated by a
global neurofascin knockout mouse, which dies within a few days of birth (personal
communication Prof. P. Brophy, University of Edinburgh).
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1.2.1.3 CHL1.
This protein was first discovered as a cDNA clone similar in amino acid sequence
to LI (Tacke et al., 1987). CHL1 is able to promote neurite elongation, neurite
survival and is upregulated in axonal regeneration (Chen et al., 1999; Hillenbrand et
al., 1999; Chaisuksunt et al., 2000a; Chaisuksunt et al., 2000b; Zhang et al., 2000).
In the CHL1 knockout, murine axons are mis-guided and NCAM 180 expression is
upregulated (Montag-Sallaz et al., 2002). Mutations in the CHL1 gene are
associated with schizophrenia (Sakurai et al., 2002).
cellular
L1 and CHL1 Neurofascin 186 Neurofascin 155 Neurofascin 140 NrCAM
Figure 1-2. The domain structure of the Ll-CAM family in mammals. LI and
CHL1 have a similar structure. The three most common isoforms of neurofascin
have been shown. NrCAM's fifth fibronectin domain is not in all splice variants
of the protein. The pale blue bar represents the plasma membrane. Extracellular
IgG-like domains are shown as green hemispheres, FNIII-like repeats as red boxes
and mucin domains as red ellipses with an M. Cytoplasmic tails are homologous,
primarily around an ankyrin binding region.
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1.2.1.4 NrCAM.
Two independent groups identified NrCAM as an important Cell Adhesion
Molecule of the Nervous system. The first group identified NrCAM as the antigen of
a monoclonal antibody against biotinylated cell surface molecules of the chick optic
tectum (Rosa et al., 1990). The anti-NrCAM antibody was the second monoclonal
antibody raised using this investigation and was named Bravo (after the second letter
of the international phonetic alphabet) (Rosa et al., 1990). The second group
independently cloned the cDNA clone of chick NrCAM while characterising
polyclonal antibodies against denatured NgCAM and thus called it NgCAM related
Cell Adhesion Molecule or NrCAM (Grumet et al., 1991).
1.2.2 The Ll-CAM family cytoplasmic terminus.
The most highly conserved part of the Ll-CAM family proteins is their 85-148
amino acid residue cytoplasmic termini (Volkmer et al., 1992; Hortsch, 2000). The
sequence of NrCAM's cytoplasmic terminus has been 100 % conserved for more
than 200 million years of evolution, from chicken to mammals (Davis and Bennett,
1994; Lane et al., 1996). The strong conservation of the cytoplasmic terminus of the
LI family suggests that the family probably share important cytoplasmic signalling
events.
The most conserved region of the cytoplasmic terminus of Ll-CAM family
members is a 36 amino acid residue ankyrin-binding domain that appears in both
invertebrates and vertebrates (Zhang et al., 1998a; Hortsch, 2000). Ankyrins are a
family of proteins that link the Ll-CAMs to the spectrin-ankyrin cytoskeleton
(Zhang et al., 1998a).
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All of the vertebrate LI family member genes (except CHL1) contain an
alternatively spliced 12-nucleotide exon that codes for an RSLE amino acid sequence
that so far has only been seen in neuronal transcripts (Wang et al., 1998; Hortsch,
2000). This amino acid sequence is downstream of a tyrosine residue (i.e. YRSLE)
and gives rise to an YXXL motif. YXXL motifs are common in proteins that traffic
to the plasma membrane and the motif is essential for rapid internalisation of these
proteins from the plasma membrane (Bonifacino and Traub, 2003). The RSLE motif
in LI is necessary for the sorting of LI to the growth cone and receptor mediated
endocytosis ofLI (Kamiguchi etal., 1998b).
1.3 The NrCAM gene, transcription, translation and expression.
1.3.1 The NrCAM gene.
The human NrCAM gene has 34 exons and has been localised to chromosome
7q31.1-q31.2. (Lane et al., 1996; Dry et al., 2001). It codes for a protein with six
IgG domains and five FNIII-like repeats, a transmembrane sequence and a short
cytoplasmic terminus (Lane et al., 1996; Dry et al., 2001). It is extensively spliced
around the fifth FNIII-like domain and isoforms of NrCAM missing the entire fifth
FNIII-like domain have been identified in chick, rat and human (Lane et al., 1996;
Wang et al., 1998). The NrCAM gene has an exon that codes for a premature stop
codon that would give rise to an isoform of NrCAM without an ankyrin binding
motif (Dry et al., 2001).
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1.3.2 Transcriptional regulation of NrCAM expression.
The transcriptional regulation of NrCAM expression has been poorly defined to
date. Recent studies have shown that it may be downstream of the upregulation of
Hox transcription factors (Valerius et al., 2002) or downstream of a classical wnt
signaling pathway (Conacci-Sorrell et al., 2002).
Hox transcription factors are known to enhance LI expression (Crossin and
Krushel, 2000). Similarly the NrCAM gene is upregulated 2 fold in Human
Embryonic Kidney (HEK293) cells when Hoxall is expressed (Valerius et al.,
2002).
The expression ofNrCAM is induced by both P-catenin and a homologous protein
plakoglobin (Conacci-Sorrell et al., 2002). NrCAM has lymphocyte enhancer factor/
T cell factor (LEF/TCF) binding sites in its promoter region and dominant LEF-1
expression increases NrCAM expression (Conacci-Sorrell et al., 2002). Two
proteins, the human homologue of v-ski (SKI) and four and a half LIM domains 2
(FHL2) enhance P-catenin dependent activation of the NrCAM promoter in
melanoma cells (Chen et al., 2003). Therefore it is theorised that NrCAM
transcription may be downstream of a classical Wnt signalling pathway (Gottardi et
al., 2001). In this pathway wnt signalling via Frizzled and Dishevelled prevents the
degradation of P-catenin by the glycogen synthase kinase-3P (GSK-3), adenomatous
polyposis coli (APC) and axin degradation complex (Gottardi et al., 2001). This
results in a build up of p-catenin in the cytoplasm and nucleus of the cell. P-catenin
in the nucleus is able to bind to LEF-1/TCF transcription factors, act as a co-
activator, and induce the transcription of NrCAM. FHL2 and SKI potentiate the
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function of (3-catenin and induce NrCAM expression (Figure 1-3) (Gottardi et al.,
2001; Conacci-Sorrell et al., 2002; Chen et al., 2003).
1.3.3 NrCAM expression in the nervous system.
NrCAM is expressed in the axons and glia of the central nervous system (CNS)
and peripheral nervous system (PNS). Its temporal expression varies during
embryonic and postnatal development of the CNS and PNS and correlates to
important events such as cell proliferation, cell migration, axonal outgrowth and
myelination (Krushel et al., 1993). Northern blots show mRNA expression in
various human brain tissues including the amygdala, caudate nucleus, corpus
callosum, hippocampus, hypothalamus, substantia nigra, subthalamic nucleus and the
thalamus (Lane et al., 1996).
In the cerebellum NrCAM can be found in migratory and post-migratory granule
cells as well as post-migratory Purkinje neurons (Krushel et al., 1993; Sakurai et al.,
2001). NrCAM knockout mice are viable but exhibit subtle size difference in lobes
in vermis of the cerebellum (Sakurai et al., 2001). Anti-Ll antibody treatment
disrupts survival and maintenance of primary cultures of the cerebellar granule cells
(CGCs) from NrCAM knockout mice (Sakurai et al., 2001). Furthermore double
knockout mice without NrCAM or LI show severe cerebellar defects, which are
more extensive than if only one of the molecules were knocked out (Sakurai et al.,
2001). This suggests that both NrCAM and LI have an important role in granule cell
development of the cerebellum and that their role may be compensatory.
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Figure 1-3. Proposed signalling mechanism for the expression of NrCAM. The
pathway is based upon the findings of (Chen et a/., 2003) and (Conacci-Sorrell et
al., 2002). The diagram has been adapted from (Gottardi et al., 2001).
1.3.4 NrCAM expression outside of the nervous system.
It was originally believed that NrCAM was only expressed in the cells of the
nervous system (Krushel et al., 1993; Grumet, 1997). However in 1998 its mRNA
was shown to be highly expressed by the pancreas, adrenal glands and placenta
(Wang et al., 1998). Its roles outside of the nervous system are extensive, for
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example NrCAM protein is highly expressed in the cell membrane and at sites of
cell-to-cell contact of the acinar cells of the pancreas where it may play a role both in
cell adhesion and in preventing autodigestion of the pancreas by pancreatic enzymes
(Dhodapkar et al., 2001).
NrCAM is also expressed in endothelial cells (EC) that are important in
angiogenesis (Aitkenhead et al., 2002). During angiogenesis EC degrade the local
basement membrane, migrate into the stroma, proliferate, extend long pseudopodia
that go on to form capillary sprouts that in turn form hollow tubes and new blood
vessels. NrCAM has been found to show increased expression in vitro in tube
forming EC when compared to migrating and proliferating cells (Glienke et al.,
2000; Aitkenhead et al., 2002).
NrCAM is expressed in the lens of the eye, where it is essential for lens
transparency and the ordered arrangement of the lens fibre cells (More et al., 2001).
No other member of the Ll-CAM family is believed present in the lens and so in
NrCAM deficient mice the lens becomes disorganised and develops into a cataract in
the adult animal (More et al., 2001).
1.3.5 NrCAM over-expression in cancer.
NrCAM has also been hypothesised to have an important role in certain cancers.
Conacci-Sorrell et al. (2002) have shown that NrCAM is a target gene of the (3-
catenin/LEFl pathway (Figure 1-3 and section 1.3.2) and as such confers motility,
growth and tumourigenesis in NIH3T3 cells. They also showed that NrCAM
expression is increased in malignant melanoma lines, that NrCAM is highly
tumourgenic in nude mice and that increased NrCAM expression is observed in
human colon cancer tissue (Conacci-Sorrell et al., 2002). Other studies showed
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differential NrCAM expression during the progression of pancreatic cancers that may
correlate to their invasive/metastatic properties (Dhodapkar et al., 2001). NrCAM is
also over-expressed in malignant human brain tumours when compared to normal
brain tissue (Sehgal et al., 1998).
1.4 The structure and post-translational modification of the
NrCAM protein.
NrCAM is predicted to be a type 1 transmembrane protein with six IgG domains
and four to five FNIII-like repeats (Grumet, 1997). Its crystal structure has not been
solved and its three dimensional structure is undetermined.
1.4.1 The horse-shoe conformation of NrCAM.
The Ig domains of IgCAMs are believed to adopt two conformations. The first is
an open chain rod like structure (Figure 1 -4(A)) and the second a horse-shoe shape,
where the Ig-domains fold back in a sharp bend (Figure 1-4(B)). LI has been shown
to primarily exist in the horse-shoe conformation in solution (Schurmann et al.,
2001). This folding allows contact between the first and fourth IgG domains and the
second and third IgG domains (Figure 1-4(B)). It is not known whether NrCAM
adopts this confirmation. However axonin-1, one of NrCAM's binding partners
discussed below, is believed to interact with NrCAM when it adopts a horse-shoe
conformation and it has been suggested that NrCAM may be adopting a similar
conformation (Rutishauser, 2000).
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Figure 1-4. Proposed structures of the extracellular domain of NrCAM. A) shows a
rod like structure. B) shows the first two IgG-like domains folded back to generate a
horseshoe like structure. The pale blue bar represents the plasma membrane.
Extracellular IgG-like domains are shown as green hemispheres, FNIII-like repeats as
red boxes. This picture was adapted from Volkmer, 2001.
1.4.2 Glycosylation and NrCAM.
Glycosylation is a post-translational modification of a protein as it passes through
the endoplasmic reticulum and the Golgi apparatus. Sugar residues or glycans are
added to a protein backbone. The presence of these glycan chains can confer certain
properties onto the protein such as adhesion/repulsion of other proteins (Breen et al.,
1998). Glycosylation and glycoproteins play an important role in the correct
development and functioning of the CNS (Breen et al., 1998). It has not been
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reported whether NrCAM is subject to glycosylation; however neurofascin is subject
to N-linked and O-linked glycosylation (Volkmer et al., 1992; Volkmer et al., 1996)
and differential glycosylation of leech tractin has been shown to regulate neurite
extension (Huang et al., 1997; Jie et al., 1999; Jie et al., 2000).
1.4.3 Post-translational cleavage of NrCAM.
Figure 1-5 describes three of the possible conformations of NrCAM. It is still
unclear which of the three is the correct. Most work has been perfomed on chick
NrCAM. Full-length glycosylated chick NrCAM/Bravo is believed to be a 200 kDa
protein that exists as a heterodimer of 130/140 kDa and 60/80 kDa fragments
(Kayyem et al., 1992). The entirely extracellular 130/140 kDa sequence is believed
to non covalently associate with the 60/80 kDa membrane spanning fragment (Figure
1 -5(B)) (Kayyem et al., 1992).
Full-length glycosylated mammalian NrCAM is expected to be a protein of
approximately 180 kDa to 200 kDa (Davis et al., 1996). However most antibodies
made to the extracellular domain pick up bands of approximately 140 kDa (Davis
and Bennett, 1994; Davis et al., 1996; Volkmer et al., 1996; Lambert et al., 1997).
An antibody to common amino acid residues in the cytoplasmic terminus of all Ll-
CAMs is unable to detect this 140 kDa and so the 140 kDa band is unlikely to
contain the cytoplasmic terminus of NrCAM (Davis and Bennett, 1994; Davis et al.,
1996). Therefore mammalian NrCAM is cleaved in a similar method to chick









Figure 1-5. NrCAM may exist as one or more isoforms at the plasma membrane.
A) shows a single transmembrane molecule, B) a dimer of two molecules that are
cleaved and then associated at the third FNIII-like domain and C) a molecule that
when cleaved at the third FNIII-like domain secretes most of its extracellular
domain in to the ECM. The pale blue bar represents the plasma membrane.
Extracellular IgG-like domains are shown as green hemispheres, FNIII-like
repeats as red boxes.
1.4.3.1 The third FNIII-like domain.
The cleavage of NrCAM is believed to occur in the third FNIII-like domain
(Grumet, 1997). The third FNIII-like domain of all the Ll-CAMs with the exception
of neurofascin is highly susceptible to cleavage, particularly by members of the
serine protease superfamily (Hortsch, 1996). The third FNIIl-like domain of
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NrCAM, LI, neurofascin, CHL1, and NgCAM has been aligned using the
CLUSTALW software (Figure 1-6). Regions that have been shown to be subject to
serine protease cleavage have been highlighted. Highlighted in yellow are trypsin
cleavage sites, in red font is the plasmin cleavage site of LI and boxed areas are furin
cleavage sites.
1.4.3.2 Trypsin cleavage.
Trypsin is a serine protease and cleaves after the terminal arginine of an R/K-R
motif in a well-studied catalytic mechanism. Figure 1-6 (yellow highlight) indicates
a S-R/K-R motif that is common to LI, NrCAM and NgCAM. This site was
identified as potentially important for cleavage of chick NrCAM into 130/140 kDa
and 60/80 kDa fragments (Kayyem et al., 1992).
1.4.3.3 Plasmin/Plasminogen cleavage.
Plasmin is a serine protease that has an important role in the development of the
nervous system (Seeds et al1997). LI in cerebellar granule cell growth cones is
subject to the actions of exogenous plasmin which cleaves LI in its third FNIII-like
domain and releases a 140 kDa fragment in to the extracellular matrix (Nayeem et
al., 1999; Mechtersheimer et al., 2001). This cleavage is at two sites, the first site is
after the lysine of QRK (Figure 1 -6, red font) and the second site is after the lysine of
SKR (Figure 1-6 red font) (Nayeem et al., 1999; Stilletti et al., 2000). NrCAM has a
SKR motif (Figure 1-6, red font) and NrCAM is present in cerebellar granule cell
growth cones. Thus it is possible that NrCAM is also subject to plasmin cleavage. If
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NrCAM is indeed subject to plasmin cleavage the extracellular portion may be lost
into the ECM and it could adopt a conformation as described by Figure 1-5(C).
Sequence alignment of the third fibronectin domain of NrCAM to other members of the L1CAM family.
NrCAM (rat) A P G N V R V S V V N S T L A E A H W D P - V P P K S V
L1 (rat) S P E L E D I T I F N S s T V L V R W R P - V D L A Q V
Neurofascin 155 (rat) A P T E V K I R V L N S T A I S L Q W N R - V Y P D T V
CHL1 (rat) A P V I Q R V D V M N S T L V K V T w S S - I P K E T V
NgCAM (L1 in chick) Y P E N V G V E L L N S S T V R V R w T L G G G G P K E
Conserved residues P <D <D N S w
NrCAM (rat) R G H L Q G Y R I Y Y w K A Q S S S K| N R Rl H I E K K
L1 (rat) K G H L R G Y N V T Y w W K G S Q R K H R H V H K S
Neurofascin 155 (rat) Q G Q L R E Y R A Y Y w R E S S L L K N L W V S Q K R Q
CHL1 (rat) H G L L R G Y Q I N W w K T K S L L D G R T H P K E V N
NgCAM (L1 in chick) L R R L R G F R V L Y w R L G W V G E| R S R Rl Q A P P D
Conserved residues L + w
NrCAM (rat) I L T F Q G S K T H
L1 (rat) H M V V P A N T T S
Neurofascin 155 (rat) Q A S r P C D R P R
CHL1 (rat) I L R F S G Q R N S
NgCAM (L1 in chick) P P Q I P Q S P A E D p P P F P P V A L T V G G D A R G
Conserved residues
NrCAM (rat) G M L P G L Q P Y S H Y V L N V R V V N G K G E G
L1 (rat) A I L S G L R P Y s s Y H V E V Q A F N G R G L G
Neurofascin 155 (rat) G V V G R L F P Y s N Y K L E M V V V N G R G D G
CHL1 (rat) G M V P S L D P F s E F H L T V L A Y N S K G A G
NgCAM (L1 in chick) A L L G G L R P W s R Y Q L R V L V F N G R G D G
Conserved residues L P s N G G
Figure 1-6. Sequence alignment of the third FNIII-like domain of all four rat
LI-CAM family members and NgCAM of chick. Highlighted in yellow are
common trypsin cleavage sites, in red font is the plasmin(ogen) cleavage site of
mammalian LI and boxed areas are furin cleavage sites of NgCAM and NrCAM.
Accession numbers are NrCAM P97686, LI S36126, neurofascin AAL27854,
CHL1 CAA63972 and NgCAM A37967.
1.4.3.4 Furin cleavage.
Furin is a ubiquitously expressed 794 amino acid type 1 membrane protein that
has been found in all vertebrate cell lines and tissues examined (Nakayama, 1997). It
is a member of the proprotein convertase family and is involved in the cleavage of
proproteins to their active form. Proproteins cleaved by furin include human integrin
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a.3 and <X(, chains and the LI-CAM member in leech Tractin (Lehmann et al., 1996)
(Xu et al., 2003). At steady state, fiirin is localised principally in the trans-Golgi
network (TGN) were it cycles between the sorting compartment, the cell surface and
the early endosomes (Nakayama, 1997; Molloy et al., 1999; Thomas, 2002). Furin
cleavage can occur at the cell surface, in the endocytic pathway and in the
TGN/biosynthetic pathway (Nakayama, 1997; Thomas, 2002). Furin normally
cleaves after the carboxy terminus of the last arginine of the consensus sequence -R-
X-K/R-R and this motif can be found in the third FNIII-like domain of chick and
mammalian NrCAM (Nakayama, 1997; Thomas, 2002) (Figure 1-6, boxed). Furin
cleavage has not been studied in NrCAM however tractin also has the furin cleavage
motif RKRRSR in its third FNIII-like domain (Xu et al., 2003). Tractin is
constitutively cleaved in a furin dependent process so that the full length molecule
never reaches the plasma membrane (Xu et al., 2003). This gives rise to a
heterodimer consisting of the N-terminus and the C-terminus of the molecule that
bind to each other through non covalent interactions (Xu et al., 2003). It is currently
believed that furin is the principal protease responsible for NrCAM's cleavage
(Grumet, 1997) and that NrCAM adopts a conformation described by Figure 1-5 (B).
1.5 NrCAM in myelinated neurons.
In mature neurons NrCAM is normally found at sites of Na' channel clustering,
namely the nodes of Ranvier and the initial segment (Davis et al., 1996; Jenkins and













Figure 1-7. An illustration of NrCAM expression in a neuron. NrCAM is found
at the initial segment, the nodes of Ranvier and in growth cones. More detailed
pictures of the node of Ranvier and Growth cone are in Figure 1-8 and Figure 1-
10 respectivley.
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1.5.1 Nodes of Ranvier.
Gaps in the myelin sheath surrounding neurons were first discovered by light
microscopy by Ranvier in 1874 and have become known as nodes of Ranvier
(Rosenbluth, 1999). The node is essential for saltatory conduction and is rich in cell
adhesion molecules, ion channels and scaffolding proteins. NrCAM is one of the
pioneer molecules that play a role in the development of the node in the immature
animal.
1.5.1.1 Myelination and saltatory conduction.
Myelination has evolved as a means of increasing the conduction velocity of
nerves. Myelin consists of a stack of specialised plasma membrane sheets that is
produced by a glial cell that wraps itself around an axon. In the PNS the glial cells
are Schwann cells and in the CNS they are oligodendrocytes. The high phospholipid
content of the myelin sheath insulates the axon and reduces the ability of current to
leak out of the axon At regular intervals along the axon shaft there are gaps in the
myelin sheath called nodes of Ranvier, where Na4 channels are clustered at high
densities. These nodes are in direct contact with the extracellular fluid thus allowing
the flow of ions out of the axon. The result is a restriction of current flow to the
nodes. When an action potential is generated at one node of Ranvier it elicits a
current that flows passively along a myelinated segment until the next node of
Ranvier. The local current flow then generates an action potential in the
neighbouring segment, and the cycle is repeated along the length of the axon. The
excitation jumps from node to node and thus increases the conduction velocity of the
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axon (Salzer, 1997; Arroyo and Scherer, 2000; Salzer, 2003). This process is called
saltatory (from the Latin verb saltare to jump) conduction and was first described by
Tasaki (1939) and Huxley and Staempfli (1949) (Rosenbluth, 1999).
1.5.1.2 Regions within myelinated nerves.
After myelination the axon can be divided into four domains:
(1) The internode. This is the part of the axon covered in compact myelin.
(2) The paranode. Here the tightly wrapped glial myelin of the internode expands at
its extremities to form cytoplasm filled paranodal loops. The axon is connected to
the ends of these paranodal loops by septate like junctions (Figure 1 -8).
(3) The juxtaparanode. This is the region between the internode and paranode
(Figure 1-8).
(4) The node itself. Here Na+ channel clustering occurs. It is opposed by Schwann
cell microvilli in the PNS or an astrocytic process in the CNS (Salzer, 1997)
(Figure 1-8). NrCAM is found within the plasma membrane (axolemma) of the
node.
Multiple cell adhesion molecules have been identified within the membranes of
the axon and glial cells at the node, paranode and juxtaparanode (Scherer and
Arroyo, 2002). Currently it is believed that various adaptor proteins such as
ankyrins, members of the 4.1 superfamily or PDZ domain containing proteins link all
of these cell adhesion molecules to the cytoskeleton of their respective glial or
neuronal cell (Girault and Peles, 2002; Girault et al., 2003). The known cell















Figure 1-8. A schematic diagram of the molecular composition of the node of
Ranvier in the PNS Adapted from Trapp and Kidd (2000).
1.5.1.3 NrCAM is at the node.
The major component of the plasma membrane of the node are voltage gated Na
channels, namely Navl .2 channels during axon development and Navl .6 channels in
the adult axon (Kaplan et al., 2001; Girault et al., 2003). The Na+ channels are
composed of a pore forming a subunit and two |3 subunits. The (3 subunit can
associate with itself, tenascin R, contactin, neurofascin 186 and NrCAM (Ratcliffe et
al., 2001; Bhat, 2003; Salzer, 2003). In addition to Na+ channels the nodal
axolemma contains the Na'/Kf ATPase, NaVCa2' exchanger, neurofascin 186 and
NrCAM (Davis et al., 1996; Berghs et al., 2000; Girault and Peles, 2002).
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Clustered in the cytoplasm of the adult node are ankyrinG 480/270 kD and the
membrane skeletal protein PIV spectrin (Kordeli et ah, 1995; Lambert et al., 1997;
Bennett and Lambert, 1999; Berghs et ah, 2000). Ankyrin is the only known
cytoplasmic partner of NrCAM and the regulation of its binding to NrCAM is
discussed in section 1.8. In the node ankyrinG binds to the P subunits of the NaT
channels; the cytoplasmic terminus of neurofascin 186 and NrCAM, and links all of
the molecules in a complex (Girault and Peles, 2002; Lemaillet et ah, 2003). This
complex binds via ankyrinG to spectrin piV which in turn binds to the actin
cytoskeleton (Girault and Peles, 2002; Lemaillet et ah, 2003) (Figure 1-8). Notably
NrCAM and neurofascin 186 can associate with themselves, with each other or with
the pi subunit of the Na+ channel and so the NrCAM/neurofascin association with
ankyrinG at the node could be both indirect as well as direct (Lustig et ah, 2001;
Ratcliffe et ah, 2001).
1.5.1.4 NrCAM and neurofascin are important molecules in the early development
of the node ofRanvier.
Independent studies show that NrCAM and neurofascin are pioneer molecules that
potentially organise the subsequent clustering of Na' channels and ankyrins at the
sites of early node formation (Lambert et ah, 1997; Lustig et ah, 2001; Custer et ah,
2003). During the embryonic and postnatal development of a myelinating rat
neuron, both NrCAM and neurofascin cluster at early nodes of Ranvier before Na'
channel and ankyrinG begin to cluster (Lambert et ah, 1997; Custer et ah, 2003).
NrCAM null mice show a delay in Na+ channel and ankyrinG clustering (Custer et
ah, 2003), and neurofascin null mice are incapable of clustering Na1 channels
(personal communication, Prof. P. Brophy, University of Edinburgh). Furthermore a
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NrCAM-Fc fusion protein inhibits Na' channel and ankyrin clustering at nodes of
Ranvier by binding to and clustering neurofascin (Lustig et al., 2001). Thus
neurofascin is necessary for, and NrCAM enhances, the Na+ channel clustering at the
node of Ranvier.
1.5.2 NrCAM at initial segments.
The initial segment is the site at which synaptic inputs are integrated and the
action potential is initiated. Therefore voltage-dependent Na+ channels are also
localised at high density at the initial segment of the axon. Molecules that are co-
localised with Na+ channels at initial segments are similar to those found at the node,
and include piV spectrin, ankyrinG, neurofascin and NrCAM (Salzer, 2003).
However unlike the node, the initial segment of some CNS neurons have Kvl.l and
Kv 1.2 channels (Salzer, 2003).
NrCAM's role in the initial segment is as yet unknown. It appears at postnatal
day 9 in Purkinje neuron initial segments. This is 7 days after the first appearance of
ankyrinG and piV spectrin in the initial segment of the Purkinje neuron (Jenkins and
Bennett, 2001). Furthermore it is not clustered at initial segments in mice deficient
in ankyrinG (Jenkins and Bennett, 2001). Thus NrCAM is an unlikely candidate to
initiate protein assembly at initial segments. However it may be necessary for
stabilising the Na+ channel/ankyrinG/spectrin piV complex after clustering.
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1.6 Growth cones.
"... a concentration of protoplasm of conical form, endowed with
amoeboid movements " Cajal.
1.6.1 Defining the growth cone.
Axons emerge from neuroblasts, elongate and grow towards their postsynaptic
targets. The tips of these growing axons expand to form growth cones and were first
identified by Ramon y Cajal, in the 19th century, as the region of the axon
responsible for navigation towards a target (Sotelo, 2002).
1.6.2 Growth cone guidance.
Growth cones of axons are guided by a variety of cues that are attractive or
repulsive to the growth cone. Long-range guidance cues consist of factors secreted
by a target cell and short-range clues operate by contact mediated mechanisms
between receptors on the growth cone and ligands on either the ECM or other cells
(Tessier-Lavigne and Goodman, 1996). NrCAM can act as both a short-range
guidance clue and as a receptor in the growth cone (Grumet, 1997).
The structures and regions of the growth cone are described by Figure 1-9.
Filopodia are narrow finger like extensions of the growth cone that are capable of
extending tens of microns from the leading edge of the growth cone (Dent and
Gertler, 2003). They are highly dynamic structures that expand and contract at rapid
rates as well as having side-to-side movement (Wood and Martin, 2002).
Lamellipodia (membrane ruffles) are flattened fan like membranous extensions at the
leading edge of the growth cone that expand and contract as the growth cone
advances (Bamburg, 2003). There are three regions in the growth cone, the
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peripheral (P) domain, which contains the filopodia and lamellae, the central domain
(C), which contains the vesicles and organelles of the growth cone and the
transitional (T) domain, which acts as interface between the P and C domains
(Bamburg, 2003; Dent and Gertler, 2003).
The shape and movement of the growth cone, its lamellipodia and filopodia
depend on the underlying cytoskeleton (Bamburg, 2003; Dent and Gertler, 2003). F-
actin forms two types of actin structures in the growth cone: bundles of polarised F-
actin that extend from the filopodia as far as the T region; and a meshwork like array
that fills the bulk of the P region (Bamburg, 2003; Dent and Gertler, 2003).
Recruitment and activation of myosin lead to the retrograde flow of F-actin from the
leading edge of the growth cone to wards the C domain (Lin et al., 1996; Cramer,
1997; Suter and Forscher, 1998). Polymerisation of actin occurs near the leading
edge of the growth cone and depolymerisation at the back of the network, and this
results in a treadmilling of actin (Suter and Forscher, 1998). In one model of growth
cone advance cell adhesion molecules, for example NrCAM, bind to this retrogradly
moving actin network, while simultaneously binding to extracellular molecules
(Faivre-Sarrailh et al., 1999; Falk et al., 2004). This has the effect of slowing the
rate of retrograde movement of the actin cytoskeleton and as polymerisation
continues at the leading edge the growth cone advances (Mitchison and Kirscher,
1988; Lin and Forscher, 1995; Welch et al., 1997).
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Figure 1-9. The structure of growth cones. P is the peripheral domain, C is the
central domain and T is the transitional domain. Picture from Dent and Gertler,
2003.
The binding of the cell adhesion molecule to its extracellular ligand as well as
acting as a stabilising force for the growth cone also triggers localised intracellular
signalling cascades that can effect the movement and turning of the growth cone
(Jay, 1996). These signalling cascades include: localised calcium concentration
increases (Doherty et al., 2000; Dunican and Doherty, 2000), the activation of
mitogen-activated protein kinase (MAPK) cascades (Doherty et al., 2000), tyrosine
phosphorylation of the cell adhesion receptor for example by src kinases (Jay, 2001;
Suter and Forscher, 2001), activation of the small GTPases of the RHO family
(Dickson, 2001) and localised protein synthesis within the growth cone (Dickson and
Senti, 2002).
Attachment of the retrogradly moving cytoskeleton translocates the cell adhesion
molecule from the P domain to the C domain. Studies on LI have shown that LI in
the C-domain is endocytosed and transported along microtubules to the P-domain
where it is reinserted into the plasma membrane (Kamiguchi et al., 1998b;
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Kamiguchi and Lemmon, 2000b). Notably the endocytosis of LI is essential for
MAPK activation and is mediated by pp60src (Schmid et al., 2000).
1.7 The ectodomain interactions of NrCAM.
Most of NrCAM's known binding partners are to its ectodomain. These
interactions can be both homophilic and heterophilic, in cis and in trans (Mauro et
al., 1992; Suter et al., 1995; Sakurai et al., 1997). As with most members of the
IgCAM family homophilic interactions are Ca2+ and Mg2+ independent (Mauro et al.,
1992). NrCAM can act as both a ligand for receptors in growth cones and as a
receptor in growth cones (Grumet, 1997). NrCAMs extracellular binding partners
include axonin-l/TAG-l/TAX-1, F1 l/contactin/F3, Receptor protein tyrosine
phosphatase P (RPTPP) and neurofascin (Figure 1-10).
1.7.1 NrCAM and axonin-l/TAG-1 interactions guide neurons.
NrCAM and LI are both binding partners of axonin-1 a member of the F11 family
of IgCAMs (Figure 1-1) (Suter et al., 1995, Sonderegger, 1997; Lustig et al., 1999;
Pavlou et al., 2002). The NrCAM to axonin-1 interactions are complex and depend
on the molecules tertiary structures and cellular contexts. These interactions promote
cell-to-cell adherence and direct neurite outgrowth (Suter et al., 1995; Fitzli et al.,
2000; Pavlou et al., 2002). The effects of the NrCAM to axonin-1 interaction have
been studied in the spinal cord of chicks. In the developing chick spinal cord
NrCAM is expressed in the floor plate, which is a group of specialised glial cells at
the ventral midline. Axonin-1 is expressed on commissural fibres that have cell
bodies in the dorsal part of the spinal cord and extend their axons to the floor plate,
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where they cross and extend longitudinally. Antibodies against either NrCAM or
axonin-1 prevent approximately 50% of commissural axons from crossing the floor
plate midline both in vitro and in vivo (Stoeckli, 1998; Stoeckli and Landmesser,
1998; Raper and Tessier-Lavigne, 1999). Similarly, injection of a recombinant
fusion protein of NrCAMs ectodomain resulted in guidance errors for the
commissural axons at the floor plate in ovo (Lustig et al., 1999). In mice axonin-1 is
known as TAG-1 and the TAG-l/NrCAM interaction plays a similar role in directing
commissural axon crossing of the floor plate as it does in chicks. Murine models
show that contact with the floor plate itself may be responsible for the correct
localisation of NrCAM and TAG-1 in commissural neurons (Matise et al., 1999).
Interestingly, an NrCAM knockout mouse does not show errors in commissural
fibres crossing the floor plate of the spinal cord (More et al., 2001). This suggests
that other molecules can compensate for NrCAM's function of directing
commissural axon crossing of the spinal cord.
1.7.2 The NrCAM and Fll/contactin/F3 interaction affects neurite
outgrowth.
NrCAM can interact with F11 and so direct, guide, enhance and inhibit neurite
outgrowth depending on the cellular context studied (Falk et al., 2002). Fll is the
receptor for NrCAM in tectal neurons and antibodies against NrCAM or Fll inhibit
growth of chick tectal neurons on NrCAM coated substrates (Volkmer et al., 1996).
Conversely NrCAM serves as the axonal receptor in chick tectal neurons for
immobilised Fll (Morales et al., 1993; Zacharias et al., 1999). In both cases the
NrCAM-Fll interaction promotes both cell adherence and neurite outgrowth in the
chick tectal cells (Morales et al., 1993; Volkmer et al., 1996; Zacharias et al., 1999).
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Importantly, the NrCAM-Fll interaction is dependent on the cellular and
extracellular context. For instance in the presence of Tenascin-R (an ECM




























Figure 1-10. Summary of the known extracellular interactions of NrCAM and
their effects, when A) NrCAM acts as a receptor in neurons and B) NrCAM is the
ligand for receptors in neurons. NrCAM is shown in red. Binding partners are
shown in blue or green. See text for full details.
33
Chick retinal neurons also express NrCAM but these neurons do not extend
neurites when grown on a homogenous Fll substrate (Treubert and Brummendorf,
1998). They do however show an increased outgrowth rate on a mixed fibronectin
and Fll substrate when compared to outgrowth on fibronectin alone (growth on
fibronectin is generally believed to be due to integrins) (Treubert and Brummendorf,
1998). This increased rate of growth is dependent upon NrCAM binding to F11 and
could be explained by NrCAM enhancing the Pi integrin mediated outgrowth on the
fibronectin substrate (Treubert and Brummendorf, 1998). So in this system the
NrCAM/F 11 interaction enhances but is not necessary for neurite outgrowth, and
importantly suggests that NrCAM does not work alone.
NrCAM in murine cerebellar granule cells is a receptor for F3/contactin (Faivre-
Sarrailh et al., 1999). Granular cells from NrCAM deficient mice cannot extend
neurites on a F3 substratum in vitro (Sakurai et al., 2001). However NrCAM
deficient mice do not show significant misguidance or defasciculation of parallel
fibres of the cerebellum. Therefore NrCAM to F3 interaction must be compensated
for by 3ome other mechanism in vivo (Sakurai ct al., 2001).
1.7.3 RPTPP binds to NrCAM and contactin and forms a trimeric complex.
RPTPp is found in radial glial cells and astrocytes that are implicated in axon
guidance. Three isoforms exist and consist of two membrane receptor isoforms and
a soluble form commonly known as phosphacan (Sakurai et al., 1996).
RPTPp/phosphacan interacts with contactin via the carbonic anhydrase domain and
acts as a ligand to stimulate neurite outgrowth (Volkmer, 2001). Associated NrCAM
and contactin in tectal neurons act as a receptor for RPTPp/phosphacan (Sakurai et
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al., 1997). Thus a trimeric complex is formed between NrCAM, contactin and
RPTPp that stimulates the outgrowth of the neuron (Figure 1-10(A)). Interestingly
neurofascin can take NrCAM's binding site in the RPTPp/contactin complex when
NrCAM is absent (Sakurai et al., 1997). The C-domain of RPTPP
co-immunoprecipitates with contactin and NrCAM in wild type mice but in NrCAM
deficient mice RPTPP co-immunoprecipitates with contactin and a 150 kDa
neurofascin band (Sakurai et al., 1997).
1.7.4 Interaction of NrCAM and neurofascin.
NrCAM binds to neurofascin and co-precipitates with immunoprecipitated
neurofascin from embryonic chick retinae (Volkmer et al., 1996). NrCAM acts as
receptor for neurofascin in tectal neurons and induces neurite outgrowth (Volkmer et
al., 1996).
1.8 NrCAM has only one known cytoplasmic interaction.
While various binding partners for the ectodomain of NrCAM have been found
only one binding partner of the cytoplasmic terminus has been discovered to date.
Davis and Bennett reported that NrCAM as well as LI and neurofascin could
associate with ankyrins, a family of spectrin binding proteins (Davis and Bennett,
1994).
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1.8.1 Ll-CAMs bind to ankyrin proteins at a highly conserved amino acid
sequence.
The conserved cytoplasmic termini of LI-CAM family members includes a
binding site for ankyrins that is considered so important it is now one of the defining
criteria of what makes a LI-CAM family member (Hortsch, 2003). Ankyrins are a
family of cytoplasmic proteins that couple membrane proteins, such as voltage gated
Na+ channels and the Na'/K1 anion exchanger to the spectrin-actin cytoskeleton
(Davis and Bennett, 1994; Bennett and Chen, 2001; Hrniewicz-Janowska et al.,
2002). The family includes three genes coding for ankyrinG, ankyrinB and ankyrinRj
all of which have multiple splice variants (Bennett and Chen, 2001; Mohler et al.,
2002). 480/270-kD ankyrinG and 440/220-kD ankyrinB are the major isoforms
expressed in the developing nervous system. The membrane-binding domain of
ankyrins contains multiple domains called ank repeats and it is here that there are
two high affinity binding sites for Ll-CAMs (Michaely and Bennett, 1995; Bennett
and Chen, 2001). Therefore ankyrins can link two Ll-CAMs to ion channel proteins
and couple these to the spectrin cytoskeleton. This is especially important in the
formation of initial segments and nodes of Ranvier (Jenkins and Bennett, 2001;
Lustig et al., 2001).
Evidence from knockout mice demonstrates the importance of the LI-CAM and
ankyrin interactions in vivo. In LI knockout mice, ankyrin-B expression is reduced,
suggesting that LI may be involved in the regulation of the ankyrin-B gene, or the
maintenance of the protein's stability (Wiencken-Barger et al., 2004). Analysis of
NrCAM deficient mice and ankyrinB deficient mice show disorganised lens fibres at
PI that are virtually indistinguishable from each other, suggesting that they are both
essential for the correct development of the lens in mice (More et al., 2001).
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Figure 1-11. Alignment of the cytoplasmic terminus of the LI-CAM family.
Shown in green is the ankyrin binding domain common to all family members, in
blue is the FERM binding domain of neurofascin, in yellow are important residues
for AP-2 binding in LI, in pink are the amino acids of the class 1 FL)Z domains
and in red are the important lysines in for cytoskeletal binding in LI.
Ankyrin binds to a 25-30 amino acid sequence in the LI-CAM family cytoplasmic
termini that contains the motif SFIGQY (Garver et al., 1997; Zhang et al., 1998a)
(Figure 1-11). This sequence has been highly conserved from invertebrates to
vertebrates. The amino acids that have been shown to be necessary for ankyrin
binding have been marked in red in Figure 1-12, two are aromatic phenylalanines
and one is a negatively charged glutamic acid residue. The other two marked
residues are the serine and tyrosine of the SFIGQY motif. Both of these residues are
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commonly found mutated in patients with CRASH syndrome (Saugier-Veber et al.,
1998). The serine is mutated to a leucine and the tyrosine to a histidine in CRASH
syndrome and both these mutations reduce the ability of LI to recruit green
fluorescent protein tagged ankyrinG (ankyrinCl-GFP) to the membrane of human
embryonic kidney cells (Needham et al., 2001). Similarly in neurofascin, mutation
of the SF1GQY tyrosine to alanine, glutamic acid or histidine, reduced or eliminated
the receptors ability to recruit ankyrinG-GFP, however mutation of the tyrosine to a
phenylalanine had no effect on ankyrino-GFP recruitment (Zhang et al., 1998b).
Protein Species
CHL1 Human S ADS L V E Y G E G D H G L F S E D G S F I G A Y
CHL1 Mouse S ADS L V E Y G E G D Q S I F N E D G S F I G A Y
L1 Human, primate,rat & mouse S D D S L A D Y G G S V D V Q F N E D G S F I G Q Y
NqCAM Chicken (L1 homolog) S EDS L A G Y G G S G D V Q F N E D G s F I G Q Y
Neurofasnin Human, rat, mouse & chick S D D S L V D Y G E G G E G Q F N E D G s F I G Q Y
NrCAM Human, rat, mouse & chick S D D S L V D Y G E G V N G Q F N E D G s F II G Q Y
Conserved S - D S L V/A - Y G E G S V/G -/+ V/G Q F N E D G s F II G A/Q Y
Figure 1-12. The amino acids for the ankyrin binding site of the LI-CAM
vertebrate family.
1.8.2 Tyrosine phosphorylation inhibits ankyrin binding to Ll-CAMs.
Importantly phosphorylation of the SFIGQY tyrosine residue abolishes ankyrin
binding to both neurofascin (Garver et al., 1997; Tuvia et al., 1997) and LI (Gil et
al., 2003). Tyrosine phosphorylation of Ll-CAMs is necessary for the development
and growth of the embryonic brain. General NrCAM tyrosine phosphorylation in
developing rat brain is at a maximum during the embryonic stages of the developing
rat brain reducing to approximately one third of embryonic levels when the rat
reaches maturity (Garver et al., 1997). During development of the neonatal
cerebellum granule cells migrate from their site of proliferation via the external
germinal layer (EGL) and the molecular layer (ML) to the internal granule cell layer
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(IGL). FIGQY phosphorylated Ll-CAMs are found in the EGL and ML (pre
migratory and migratory cells) and to a much lesser degree in the IGL (post
migratory cells) (Jenkins et al., 2001).
1.8.3 The role of ankyrinB in the growth cone.
Currently, ankyrinG is thought to be important in stabilising structures such as the
node of Ranvier but ankyrinB plays a more dynamic role in structures such as growth
cones (Melendez-Vasquez et al., 2001). As discussed in section 1.6.2, NrCAM and
LI are bound to the retrogradely moving cytoskeleton of the growth cone. Studies of
neurite initiation in DRG neurons show that ankyrinB can bind to the retrogradely
moving cytoskeleton and initiate neuritogenesis via its interaction with
unphosphorylated LI (Nishimura et al., 2003). However whether this binding
between LI, ankyrin and retrogradely moving cytoskeleton continues as the growth
cone develops is unclear. Studies in neuroblastoma cell lines show that ankyrinB
does not bind to the retrogradely moving cytoskeleton, instead it restricts
unphosphorylated LI to a non-dynamic cytochalasin D insensitive pool of actin
(Figure 1-13) (Gil et al., 2003). Phosphorylated LI is bound to the retrogradly
moving cytoskeleton via an unknown mechanism. Therefore it is hypothesised that
there is at least one other molecule that can link LI (and presumably NrCAM) to the
retrogradly moving cytoskeleton in growth cones. The most popular candidates in
the literature for this protein are: a-actinin, proteins of the 4.1 superfamily and
proteins with class 1 PDZ domains.
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Figure 1-13. A proposed model of LI and ankyrinB binding in growth cones (Gil
et al., 2003). AnkyrinB binding to unphosphorylated LI in the growth cone is a
stabilising adherent interaction that links LI to the actin meshwork via spectrin.
Tyrosine phosphorylation of LI at the SFIGQY motif inhibits ankyrin binding and
allows LI molecules to bind to the retrogradly moving actin cytoskeleton via an
unknown mechanism
1.9 The first seven amino acids of the cytoplasmic terminus of LI
are sufficient to tether it to the actin/myosin cytoskeleton.
In B28 glioma cells the LI cytoskeletal anchorage, its cell surface expression and
organisation, all depend on its cytoplasmic terminus rather than its ectodomain
(Dahlin-Huppe et al., 1997). This anchorage to the cytoskeleton is mediated through
the first seven amino acids of the cytoplasmic terminus, namely KRSKGGK, of
which the seventh, and to a lesser extent, fourth lysine are the most important for
cytoskeletal anchorage (Dahlin-Huppe et al., 1997). NrCAM's first seven amino
acids are RRNKGGK and it shares the important lysine residues (Figure 1-11, red
highlight). It has been suggested that this domain may be responsible for the
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recruitment of a-actinin to NrCAM in the lamellipodia of B104 cells in regions
where it binds to TAG-1 covered beads (Falk el al., 2004).
1.10 Ll-CAMs bind to the cytoskeleton via 4.1 superfamily
members.
The 4.1 superfamily of include 4.1, ezrin, radixin, moesin, merlin, MIR and willin
(Bretscher et al., 2000, Gunne-Moore, unpublished results). The C-terminal domain
of 4.1 superfamily proteins binds directly to actin filaments, whilst the N-terminal
either 1). binds directly to transmembrane glycoproteins or 2). binds indirectly to
membrane proteins via adaptor molecules such as ERM-binding phosphoprotein 50
(EBP50)/Na+/H+ exchange-regulatory factor (NHERF) (Chishti el al., 1998;
Bretscher et al., 2000). This N-terminal binding is via a protein domain called the
4.1/ezrin/radixin/moesin (FERM) domain (Chishti et al., 1998; Bretscher et al.,
2000). 4.1 superfamily proteins concentrate in and are involved in the formation and
functioning of microvilli, filopodia, membrane ruffles and cell adhesion sites
(Bretscher et al., 2000).
1.10.1 The 4.1 superfamily has an important role in growth cones and
development of the nervous system.
Radixin and moesin have important roles in neuronal growth cones. In chicks
removing radixin interferes with growth cone form and function. Radixin staining is
localised to the leading edge in chick neuron growth cones and its expression is
reduced during growth cone collapse (GonzalezAgosti and Solomon, 1996).
Microscale chromophore assisted laser inactivation of radixin in chick DRG growth
cones causes a 30 % reduction in lamellipodia size (Castelo and Jay, 1999). In rat
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double suppression of both moesin and radixin, protein synthesis is necessary to
interfere with the structure and dynamics of rat cultured neurons (Paglini et al., 1998)
suggesting redundancy between both proteins functions.
1.10.2 Ezrin binds to LI and neurofascin, and co-localises with NrCAM.
The cytoplasmic terminus of LI contains a neuronal-specific amino acid
sequence, RSLE and this sequence is essential for the sorting of LI to the axonal
growth cone (Kamiguchi et al., 1998b) (Figure 1-11, yellow highlight). A yeast two-
hybrid screen has shown that the first 406 amino acids of ezrin (encoding the FERM
domain) binds to a region of the cytoplasmic terminus of the neuronal LI isoform.
This is after the membrane spanning region and up to, but not including, the ankyrin
domain (Dickson et al., 2002).
Both ezrin and willin have been pulled out of a sciatic nerve cDNA library using
the C-terminus of neurofascin as bait. Retesting of the ezrin and willin clones
showed that the interaction was between the FERM domain of ezrin/willin and a
RKDKEETEGNESSE sequence just C-terminal of the ankyrin binding sequence of
of neurofascin (unpublished results Gunn-Moore et al) (Figure 1-11, blue highlight).
Though the binding of NrCAM to ezrin has not yet been proven, NrCAM
co-localises in membrane protrusions with both actin and ezrin in KTCTL60 cells
(Conacci-Sorrell et al., 2002).
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1.11 NrCAM has a class 1 PDZ binding motif.
NrCAM has a class 1 PDZ domain and so proteins such as PSD-95 have been
suggested as possible binding partners (Davis et al., 1996). PDZ domains are named
after the first three proteins in which a PDZ domain was identified: PSD-95, DLG
and ZO-1. They are sometimes called GLGF proteins after four critical residues in
their ligand-binding site. They are rare in non-metazoans and may have evolved
with multi-cellularity (Harris and Wendell, 2001).
PDZ Domain Consensus binding sequence
Class 1 S/T-X - 0
Class 2 O -X - <D
Class 3 X -X - 0
Class 4 (Other) X -X - X
Figure 1-14. The system used to classify PDZ binding motifs per Harris and
Wendell (2001).
PDZ domain containing proteins are nearly always located near the plasma
membrane and are usually restricted to specific membrane regions such as synapses
or regions of cell-cell contact. They function mainly in the organisation and
clustering of signalling complexes at the plasma membrane and the maintenance of
cell polarity; but occasionally have their own signalling capabilities (Fanning and
Anderson, 1999; Rongo, 2001). However, some PDZ domain containing proteins
have a more dynamic distribution and are believed to traffic their interacting proteins
within the cell (Sheng and Sala, 2001).
The globular PDZ domain consists of approximately 80-90 amino acids, folded
into six (I-strands and two a-helices (Fanning and Anderson, 1999; Harris and
Wendell, 2001; Sheng and Sala, 2001). PDZ domains recognise four to eight C-
terminal amino acid motifs of transmembrane molecules, such as cell adhesion
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molecules and ion channels (Fanning and Anderson, 1999; Harris and Wendell,
2001; Sheng and Sala, 2001). Very occasionally they can recognise non C-terminal
amino acid residues that have folded into a sharp |3-turn that mimics a carboxyl
terminus (Hillier et al., 1999).
The residues of a PDZ binding motif are numbered from the C- terminal residue
(Po) in the direction of the N-terminus (P-i, P-2, P-3 P-4 etc.) (Fanning and Anderson,
1999; Harris and Wendell, 2001). In general the Po and P_2 residues are considered
most critical for PDZ domain recognition of the membrane receptor and this is the
basis of the current classification system of PDZ binding motifs (Figure 1-15)
(Fanning and Anderson, 1999).
Under this system NrCAM has a class 1 PDZ binding motif. In a class 1 PDZ
domain the Po residue of the ligand points directly into the base of a large
hydrophobic pocket, and the size of this pocket determines what residue it prefers in
this position. For example EBP50's Po pocket of its first PDZ domain is larger than
normal and this may explain its preference for a leucine residue at Po. (Harris and
Wendell, 2001; Sheng and Sala, 2001). The P.2 residue fits into a pocket containing
a histidine, the N-3 nitrogen of which can hydrogen bond to the hydroxyl group of
either a serine or threonine of the ligand (Harris and Wendell, 2001; Sheng and Sala,
2001).





M - N - S - F - V - COOH
1 - Y - S - L - A - COOH
A - V - A - L - E - COOH





Figure 1-15. Classification of the PDZ binding domains of the vertebrate
Ll-CAM family members per Harris and Wendell (2001).
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Chapter 2: Methods and procedures.
All products were obtained from Sigma unless otherwise stated. See appendix 1
for a list of suppliers.
2.1 Molecular biology and cloning procedures.
2.1.1 Polymerase chain reaction (PCR).
PCR was performed using pfuTURBO® DNA polymerase (Stratagene) in
accordance with the manufacturer's instructions in the buffer supplied together with
200 |_iM dNTPs (Promega), 0.5 pM forward and reverse primers (Invitrogen) and a
10 ng template.
2.1.2 Agarose gel electrophoresis and gel purification.
Linearised plasmid DNA, PCR products, and DNA fragments produced by
restriction digests were separated based on molecular weight using agarose gel
electrophoresis. Agarose was melted in tris-borate ethylenediamine-tetraacetic acid
buffer (TBE) buffer (0.45 M Tris-borate, 10 mM EDTA, pEI 8.3) and ethidium
bromide was added to a final concentration of 0.5 pg/ml and poured into and set in a
AGTI submarine gel casting apparatus unit (VWR). 20 % 6X agarose gel loading
buffer (50 % glycerol, 49.75 % TBE and 0.25 % bromophenol blue) was added to the
sample. Samples with DNA fragments of > 1 kB were loaded onto I % (w/v)
agarose gels and samples < 1 kB onto 2 % (w/v) agarose gels. If the gel was being
used for analytical purposes (i.e. sizing and quantification of the DNA), 1 kB or
100 bp DNA ladders were loaded into the lanes beside the samples, in 1 % and 2 %
gels respectively. Gel electrophoresis was carried out in TBE at 60 V for 45 minutes
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to 1 hour. Analytical gels were visualised using UV light and were photographed by
a digital camera (Mitsubishi 85 mm lens, from Thistle Scientific). If the DNA in the
gel was to be subjected to further cloning procedures the DNA was visualised under
low intensity UV (230V-50Hz, Ultratec Ltd) and excised from the gel using a clean
scalpel (preparation gels). DNA excised from preparation gels was then recovered
from the agarose using the Promega Wizard® SV Gel and PCR Clean-UP System kit
as per the manufacturer's instructions.
2.1.3 Restriction Enzyme Digest.
Restriction digest enzymes (Promega) were used according to the manufacturer's
instruction using the buffers supplied. In general, 10 units of the restriction enzyme
were used to digest 1 gg of plasmid DNA or PCR product for 1 hour at the
recommended temperature. Restriction enzyme reactions were subsequently
terminated by heat inactivation (65 °C incubation for 15 minutes). Cut plasmids
were then alkaline phosphatase treated (see 2.1.4). Restriction digested DNA that
was to be used in further restriction digests or ligation reactions was extracted into
nuclease free water using the Promega Wizard® SV Gel and PCR Clean-UP System
kit as per the manufacturer's instructions.
2.1.4 Alkaline phosphatase treatment of restriction enzyme digested
plasmids.
Phosphate groups were removed from cut plasmid vectors with 5' overhangs by
the addition of 1 unit of calf intestinal alkaline phosphatase (CIAP) (Promega) for
30 minutes at 37 °C followed by the addition of a further unit of CIAP and a second
30-minute incubation at 37 °C. 3' and blunt end cut plasmid vectors were treated by
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the addition of 1 unit of CIAP for 15 minutes at 37 °C and then 15 minutes at 56 °C.
This procedure was repeated with a further unit of CIAP.
2.1.5 Bacteria culture.
All culturing of bacteria was done under aseptic conditions unless otherwise
stated. Bacteria were cultured overnight at 37 °C in Luria Broth (LB) (Sigma
L3522) supplemented with the appropriate antibiotics (ampicillin 100 pg/ml,
chloramphenicol 34 pg/ml, kanamycin 50 pg/ml and tetracycline 10 pg/ml) (all
Melford laboratories).
2.1.6 Preparation of calcium chloride competent cells.
5 ml ofE. coli was cultured overnight at 37 °C as described in 2.1.5. 50 ml of LB
were inoculated with 500 pi of overnight culture and the culture were grown in a
1.5 litre flask (37 °C, 210 r.p.m) for approximately 2 hours. When the absorbance of
the bacterial culture reached 0.3 to 0.4 units at a wavelength of 600 nm the culture
was transferred to a pre-chilled 50 ml plastic centrifuge tube. The tube was
centrifuged at 3500 g for 10 minutes at 4 °C. The supernatant was discarded and the
pellet was resuspended in 20 ml of ice-cold filter sterile 100 mM CaCb and
incubated on ice for 30 minutes. Bacteria were spun down at 1500 g for 5 minutes
and the pellet was resuspended in 1 ml of 100 mM CaCh. Bacteria were left on ice
for a further 30 minutes and either used immediately or DM SO was added to a final
concentration of 10 % by gentle swirling and the cells stored at -70 °C for up to
4 weeks.
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2.1.7 Preparation of magnesium super competent cells.
Frozen glycerol stocks of DH5a were thawed and streaked onto a LB agar plate
and cultured overnight at 37 °C. About ten to twelve large colonies were isolated
using a metal hoop or sterile pipette tip and inoculated into 250 ml of SOB (2 %
(w/v) tryptone, 0.55 % (w/v) yeast extract 10 mM NaCl, 10 mM KC1, 5 mM MgS04
and 5 mM MgCb) in a 1.5 litre flask and grown for two days at 18 °C, at 210 r.p.m,
until the cell titre reached A6oo of 0.6. The flask was removed from the incubator and
placed on ice for 10 minutes. The culture was transferred to six pre-chilled sterile
50 ml centrifuge tubes and spun at 2500 g for 10 minutes at 4 °C. The pellets were
resuspended in a total of 80 ml of ice-cold filter sterile TB buffer (10 mM PIPES,
55 mM MnCl2, 15 mM CaCb, 250 mM KC1; pH 6.7) and incubated on ice for
10 minutes and spun down together at 2500 g for 10 minutes. The pellet was
resuspended in 20 ml of TB buffer and DMSO was added to a final concentration of
7 % by gentle swirling. After incubating on ice for 10 minutes the competent cells
were aliquoted into 2 ml cryotubes, snap frozen in liquid nitrogen and stored in liquid
nitrogen until required.
2.1.8 Ligation reactions.
Ligation reactions were performed using T4 ligase (Promega) in accordance with
the manufacturer's instructions.
2.1.9 Transformation of competent E.coli strains.
Bacteria were transformed by adding either 0.5 pi of plasmid DNA or 10 pi of
ligation reaction mixture to either, 200 pi of standard calcium chloride competent
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cells or, 50 pi of magnesium ion super competent cells, and incubated on ice for
20 minutes. Bacteria were heat shocked at 42°C for 45 seconds and incubated on ice
for a further 3 to 4 minutes. The bacterial culture was made up to 1 ml, with either
LB or SOC medium (2 % (w/v) tryptone, 0.55 % (w/v) yeast extract 10 mM NaCl,
10 mM KC1, 5 mM MgSCL, 5 mM MgCb and 20 mM glucose), and incubated at
37 °C with vigorous shaking (210 r.p.m) for 1 hour. 100 pi of the culture medium
were spread on to an agar plate containing the appropriate selection antibiotic(s) for
the plasmid and E.coli strain. The remaining bacteria were pelleted (13000 g;
10 seconds) resuspended in approximately 100 pi of culture medium and plated on a
second agar plate. Agar plates were placed agar side up into a 37 °C incubator
overnight. The next day single colonies were isolated for inoculation into LB for
further screening.
2.1.10 Preparation of plasmid DNA.
Small-scale preparation of DNA for analysis, cloning and yeast two-hybrid
purposes was prepared using the Qiagen QIAprep® spin miniprep kit in accordance
with the manufacturer's instruction. Large-scale preparation of DNA for analysis,
cloning, yeast two-hybrid procedures and transfection into mammalian cell lines was
prepared using the Qiagen® plasmid midi kit in accordance with the manufacturer's
instructions. DNA for transfection of primary cells was prepared using the
EndoFree® Plasmid Maxi Kit in accordance with the manufacturer's instructions.
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2.1.11 Preparation of glycerol stocks of transformed E. coli.
Glycerol stocks were prepared from overnight bacterial cultures. 600 pi of
cultures were mixed with 400 pi of sterile 50 % glycerol in sterile milli-Q H2O
(MQH2O) (18 Q) and stored at -70°C.
2.2 Cell culture.
All plastic-ware used was from Nunc at VWR unless otherwise stated.
2.2.1 General cell culture.
All cell lines were maintained at 37 °C in the presence of 5 % CO2. COS-7
(laboratory stocks), SK-N-SH (ECACC), B104 -NrCAM (a kind gift from Dr. C.
Faivre-Sarrailh, University of Marseille, France) and CHO.E17 (laboratory stocks)
cells were routinely cultured in Dulbecco's modified Eagle medium (DMEM)
supplemented with 10% (v/v) foetal calf serum (FCS) (Globepharm), 2 mM
L-glutamine, 100 units/ml of penicillin (pen.) and 0.1 mg/ml streptomycin (strep.).
Human Embryonic Kidney (HEK293) cells (ECACC and laboratory stocks) were
routinely cultured in minimum essential medium (MEM) supplemented with 10 %
FCS, 5 % (v/v) non-essential amino acids, 2% L-glutamine, 100 units/ml of pen. and
0.1 mg/ml strep. L0V0 cells (ECACC) were routinely cultured in nutrient mixture F-
12 Ham supplemented with 10 % FCS, 2 mM L-glutamine, 100 units/ml of pen. and
0.1 mg/ml strep. All stable cell lines were maintained in their normal medium above
supplemented with 1 mg/ml G-418 sulfate (geneticin) (Melford laboratories). T-75
flasks (80 cm3, VWR) were used for routine culture of all cell types.
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2.2.2 Passage or splitting cell lines.
Cells were passaged prior to reaching confluence by first washing the flask with
pre-warmed trypsin-EDTA (0.25 % (w/v) trypsin, 0.5 mM EDTA in phosphate
buffered saline (PBS)), and then incubating with trypsin-EDTA for 1 to 5 minutes,
depending on cell type. Detached cells were separated by pipetting and seeded into
flasks or onto Petri dishes/coverslips (VWR) at appropriate seeding densities.
2.2.3 Freezing down of cell lines.
Liquid nitrogen stored stocks were prepared by trypsin-EDTA treating near
confluent flasks and pelleting detached, separated cells (2000 g, 5 minutes, room
temperature). Pelleted cells were resuspended in 50 % FCS, 40 % normal growth
medium for that cell line (see above) and 10 % DMSO and 1 ml aliquots were
pipetted into cryotubes. The cryotubes were brought to -80 °C slowly by placing in a
cryo 1 °C freezing container (Naglene) in a - 80°C freezer from 5 hours to overnight.
Cryotubes were then placed in liquid nitrogen for long term storage.
2.2.4 Breaking out of cell lines.
Cell stocks were recovered by thawing for 1 minute in a 37 °C water bath and
placing in a T75 flask together with 15 ml of the appropriate cell culture medium.
Media was changed 24 hours later to remove DMSO.
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2.2.5 Transfection of cell lines.
Cell lines were routinely transfected using lipofectamine™ reagent. The
appropriate amount of DNA (usually 0.05-1.0 pg per 35 mm dish, 1.0-2.0 pg per
60 mM dish, 2.0-5.0 pg per 90 mM dish and 2.5-6.0 pg per 80 mM flask) was
incubated with four times the volume in micro litres of lipofectamine™ reagent to
1.0 pg of DNA in reduced serum Optimem™ medium for 30 minutes. Dishes/flasks
of cells to be transfected were washed twice in an appropriate volume of Optimem1 M
(pre-warmed to 37 °C) and the lipofectamine/DNA transfection mix was added and
made up to the appropriate volume using pre-warmed Optimem. Optimem1 M was
removed from the dishes/flasks after 5 hours to 6 hours incubation at 37°C
incubation and replaced with the normal medium for the cell line as described 2.2.1.
2.2.6 Transfection of primary cerebellar granule cells.
4 x 106 P7 mouse cerebellar granule cells (CGC) were co-nucleofected with 2 pg
HA-NrCAM and 2 pg FLAG-ezrin, using the Amaxa mouse neuron nucleofector™
kit (Amaxa biosystems) according to the manufacturer's instructions. Transfected
neurons were seeded onto 60 mm dishes containing glass coverslips pre-coated with
poly-D-lysine and fibronectin as described 2.2.7.
2.2.7 Coating coverslips.
Poly-D-lysine coverslips were prepared by covering the coverslip surface with
50 pg/ml poly-D-lysine in sterile PBS for 2 hours. The coverslips were washed
twice with sterile DMEM before use. Laminin coated coverslips were prepared by
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covering coverslips with 20 pg/ml laminin, in sterilised PBS. Fibronectin coated
coverslips were prepared by covering coverslips with 10 pg/ml fibronectin in
sterilised PBS, for 2 hours. The coverslips were washed twice with sterile DMEM
before use.
2.2.8 Making stable cell lines.
The HEK293 stable cell lines were made by transfecting three to four T75 flasks,
at 30-40 % confluencey, with 7 pg of the relevant DNA per flask using
Lipofectamine1M protocol described above and in accordance with the
manufacturer's instructions. Cells were grown for 48 hours after transfection in their
normal growth medium. Medium was then supplemented with 1 mg/ml G418-
sulfate and the cells were maintained in this medium thereafter.
2.2.9 Cloning out stable cell lines.
Stable cell lines were cloned out by plating HEK293 cells at low seeding densities
(typically 10 to 50 cells) on to 90 mM plates. Plates with seeding densities low
enough to select for individual colonies were chosen, selected colonies were
enclosed and separated from the rest of the plate by placing a sterile stainless steel
ring around the colony. Individual colonies were trypsinised (as described above)
and grown in an individual well of a 16 well plate to 80-90 % confluency.
2.2.10 Fixing and staining cells for immunofluorescence microscopy.
All cell lines with the exception of transient NrCAM transfected HEK293s, were
seeded onto 35 mm dishes containing an uncoated glass cover slip and transfected
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with the appropriate DNA as described in 2.2.5. Transient NrCAM transfected
HEK293s, were seeded onto 35 mm dishes containing a glass coverslip pre-coated
with either fibronectin or laminin as described in 2.2.7 and transfected as described
in 2.2.5. Transfected CGC neurons were seeded onto 60 mm dishes containing two
glass coverslips pre-coated with both poly-D-lysine and fibronectin as described in
2.2.7. Cell lines and CGCs were treated the same way unless specified.
Post-transfection, cells were washed three times in ice cold PBS pH 7.4 and fixed in
ice-cold paraformaldehyde (4 % (w/v) in PBS) for 10 minutes at room temperature.
Cells were washed 4 times in PBS and cell lines and CGCs were permeabilised with
(0.2 % and 0.1 % (w/v) respectively) Triton X-100 for 5 minutes. If phalloidin
staining of actin was used, undiluted Alexa568-phalloidin (Invitrogen) was diluted
one in a hundred and 100 pi was added to each slide in a humidified chamber and
allowed to incubate at room temperature for 15 minutes. Cells were washed three
times in PBS and incubated for 1 hour at room temperature with the appropriate
primary antibodies at the appropriate concentrations (1/200 anti-GIPC (Santa Cruz),
1/500 anti-HA (Roche), 1/300 anti-FLAG M2-FITC, 1/500 anti-NrCAM (a kind gift
from Dr. C. Faivre-Sarrailh, University of Marseille, France), 1/2000
anti-neurofascin (a kind gift from Prof. Peter Brophy, University of Edinburgh) in
3 % bovine serum albumin in PBS. If GIPC immunostaining was being performed,
cells were washed 3 times with PBS and incubated for 1 hour at room temperature
with a 1/200 dilution of anti-goat antibody before incubations with anti-rabbit or
anti-mouse Alexa Fluor® 568 (this prevented cross-reaction of antibodies). Cells
were washed 3 times in PBS and incubated for 1 hour at room temperature with
Alexa Flour® 568 anti-mouse IgG 1/1000 for HA-NrCAM and HA-neurofascin
staining or Alexa Flour® 568 anti-rabbit IgG 1/1000 for anti-NrCAM and anti-
55
Neurofascin staining. Following three washes in PBS coverslips were mounted on
glass slides using the aqueous mountant moviol, plus 1 % DAPI. Images were
recorded on a Zeiss Axiovert SI00 2TV Delta-Vision Restoration microscope
(Applied Precision) using a 60X Zeiss Planachromat objective and a CCD-13 00-
Y/HS camera (Roper Sci and processed by constrained iterative deconvulation using
SoftWorx (Applied Precision).
2.3 Protein assays and Western blot.
2.3.1 Protein concentration assay.
Protein concentration was assayed using Bradford's reagent (Sigma B6916).
Samples to be assayed were diluted with a mixture of deionised water and cell
extraction buffer to a final volume of 500 pi, to which 500 pi of Bradford reagent
was added. Absorbance was measured at 595 nm, and protein concentrations
calculated using a standard curve created using known concentrations of BSA
(Promega).
2.3.2 Protein expression of GST-NrCAM.
5.0 ml of pGEX-NrCAM transfected BL21 C+ E. coli were cultured overnight in
LB, 100 pg/ml ampicillin and 25 pg/ml chloraphemicol. This 5 ml culture was
added to 500 ml of fresh LB, 100 pg/ml ampicillin and 25 pg/ml chloraphemicol and
grown to A^oo 0.3. A 1 ml sample of the culture was spun at 13000 g for 2 minutes
and the pellet resuspended in 50 pi protein sample buffer (PSB); this was an
uninduced control. Isopropyl-P-D-thiogalactopyranoside (IPTG) was then added to
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the E. coli to a final concentration of 5 mM and the cells grown for a further 3 hours.
A further 500 |al culture sample was spun at 13000 g for 2 minutes and the pellet
resuspended in 100 p.1 PSB; this was an induced control. Both uninduced and
induced controls were run on a sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS PAGE) gel. The gel was stained with Coomassie brilliant blue
stain (see section 2.3.8), and protein expression was seen as a protein band between
40 kDa and 50 kDa in the induced sample and not the uninduced sample. The
remaining E. coli were spun for 10 minutes at 5000 g, the cell pellet was washed in
ice cold PBS, the sample was re-spun, the supernatant was removed and the pellet
snap frozen by immersion in liquid nitrogen. Pellets were stored at -70 °C for a few
days or used immediately. 15 ml of ice-cold lysis buffer (100 mM Tris pH 8.0,
50 mM NaCl, 5 mM EDTA, IX Roche protease inhibitors (Cat. No. 1 697 498) and
1 mM phenylmethylsulfonyl fluoride (PMSF) was added to the sample which was
then lysed by vigorous pipetting and then left on ice for 20 minutes. Further lysis
was carried out using sonication (6 x 10 second bursts with 45 second rests on ice)
and then by adding 1 % (v/v) Triton X-100. Lysed cells were tumbled at 4 °C for
20 minutes and cell debris were removed by centrifugation (12000 g, 10 minutes at
4 °C). GST-NrCAM was purified by coupling to reduced glutathione (GSFI) beads.
Beads had previously been washed by tumbling in PBS 5 mM EDTA at 4 °C for
5 minutes and by removing the supernatant by centrifugation (2000 g, 5 minutes at
4 °C). The supernatant from the lysed cells was added to the washed beads and
tumbled for 45 minutes at 4 °C. The GST-NrCAM coupled beads were washed three
times in PBS 5 mM EDTA as already described and then place in a 10 ml column
and the PBS 5 mM EDTA added to a total volume of 10 ml. GST-NrCAM was
eluted from the column using 10 ml of 50 mM Tris pH 8.0, 10 mM reduced
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glutathione and fractions were taken in 1.0 ml aliquots. A 100 pi sample from each
fraction was taken and the remainder snap frozen in liquid nitrogen and stored at
-70 °C. Fractions containing GST-NrCAM were verified using a mixture of UV
spectroscopy and SDS PAGE. 80 pi of each fraction were diluted in 920 pi of
MQH20 (18Q) and their absorbance read at 280 nm. PSB was added to the
remainder and equal volumes of sample were run on an SDS PAGE gel and stained
using Coomassie blue as described below. The concentration of fractions that
contained significant amounts of GST-NrCAM was measured using the Bradford
assay as described in 2.3.1.
2.3.3 Sodium orthovanadate activation.
A solution of sodium orthovanadate was prepared by bringing a 200 mM solution
to pH 10.0 using either NaOH or HC1 as appropriate. The sample was boiled until
colourless and then cooled to room temperature. The solution was brought back to
pH 10.0 and the boiling, cooling pHing procedure repeated until the solution
remained colourless and stabilised at pH 10.0.
2.3.4 Treatment of positive controls for phophotyrosine assays.
Equal volumes of a freshly prepared 0.341 % H2O2 and activated sodium
orthovanadate were mixed together and 50 pi of the solution added to each 90 mM
dish to be treated. After a five-minute incubation at 37 °C each dish was extracted in
ice-cold radio-immunoprecipitation assay (RIPA) buffer (Tris-HCl 50 mM, pH 7.4,
1 % NP-40, 0.25 % Na-deoxycholate) with PMSF (1 mM), aprotinin (1 pg/ml),
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leupeptin (1 pg/ml), pepstatin (1 pg/ml), Na.3V04 (1 mM) and NaF (1 mM) as
described below.
2.3.5 General preparation of tissue culture samples for SDS-PAGE,
immunoprecipitation and GST pull-down assays.
All procedures were carried out at 4 °C. Cultured cells were washed twice in
calcium free Dulbecco's phosphate buffered saline (DPBS) and the appropriate
volume of cold lysis buffer added (see appendix 2 for lysis buffers, normal buffer
used was RIPA, pH 7.4, with the Roche cocktail of protease inhibitors). Cells were
scraped from cell culture dishes, and lysed by vigorous pipetting and then left on ice
for 20 minutes. Cell debris was removed by centrifugation (12000 g, 10 minutes at
4 °C). If the cell extract was to be used for immunoprecipitation or pull-down
assays, a second centrifugation step was routinely done.
2.3.6 Whole brain, cerebellum and CGC sample preparation.
Postnatal day 7 (P7) whole mouse brain, isolated cerebellum and CGC cultures
maintained for up to 7 days in vitro (DIV), were prepared for Western blotting with
anti-NrCAM, anti-GIPC or anti-SAP102. Whole brain was prepared by adding 2 %
SDS, 1 M Tris, 0.5 mM PMSF and the Roche cocktail of protease inhibitors (Cat.
No. 1 697 498), followed by brief sonication to solubilise the tissue. Cerebellum was
homogenised using a 1 ml Wheaton glass homogenisor (Fisher) in the presence of
PBS and protease inhibitors (Roche Cat. No. 1 697 498). 300 pg samples of
cerebellum were stored at -70 °C for further use. An aliquot was solubilised by
tumbling in GHB1 (see appendix 2) at 4°C for 30 minutes and the cellular debris
removed by centrifugation (14000 g for 10 minutes). CGC samples were solubilised
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by adding 1 % Triton-XlOO, 0.5 mM PMSF, and a mixture of protease inhibitors
(Roche Cat No 1 697 498) in PBS. Samples were incubated at 4 °C for 10 minutes
and centrifuged at 14000 g for 10 minutes to separate the pellet and supernatant
fractions.
2.3.7 SDS-PAGE.
Unless otherwise stated SDS-PAGE was performed using Invitrogen's NuPAGE®
polyacrylamide gel system as per the manufacturer's instructions. When necessary
SDS PAGE gels were also prepared in house. The resolving gel was made first. The
gel solution was prepared (8-10 % (v/v) acrylamide, 0.37 M Tris-HCl pH 8.8,
0.1%w/v SDS) and polymerisation agents (10 % (w/v) ammonium persulfate
(APS), 20ptl NNN'N'-Tetramethylethylenediamine (TEMED)) were added to it. The
resulting mixture was poured gently into a gel-casting rig and covered with water-
saturated butanol. When the gel was set the butanol was removed, the stacking gel
was prepared (acrylamide 4.7 % (v/v), 0.121 M Tris-HCl pH 6.8, 0.46 % (v/v) SDS),
the gel was polymerised (10 %(w/v) APS, 20 pi TEMED), and the polymerised
mixture poured gently upon the stacking gel, a comb was placed on top, and the
polymerised mixture was allowed to set at room temperature. Gels were stored in a
moist atmosphere for up to 3 days at 4 °C.
Samples were prepared as described above and reduced in NuPAGE® LDS
Sample Buffer (4X) at 70 °C for 10 minutes (for Invitrogen gels) or reduced in
standard sample buffer 0.001 % (w/v) bromophenol blue, 4.3 % (w/v) dithiothreitol,
1 % (w/v) glycerol, 0.06 M Tris-HCl pH 6.8, 2.2 % (w/v) SDS) at 100°C for 5
minutes if "in house" gels were being used.
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When analysing proteins of less than 100 kDa, samples were loaded onto
Invitrogen NuPAGE® Novex® 4-12 Bis-Tris gel together with 5 pi of SeeBlue®
Plus2 protein standards. When analysing proteins greater than 100 kDa, samples
were loaded onto Invitrogen NuPAGE® Novex 3-8% Tris-Acetate gel together with
5.0 to 7.5 pi of HiMark® high MW protein standards. If in house gels were being
used 6.0 pi of Prestained Protein Marker, Broad Range (New England BioLabs
INC.) was run with the protein samples.
2.3.8 Coomassie staining of SDS-PAGE gels.
Gels were stained using Coomassie stain solution (0.1 % (w/v) Coomassie
brilliant blue R-250, 45 (v/v) % methanol, 10 % (v/v) glacial acetic acid for 5 to 10
minutes at room temperature. Superfluous Coomassie brilliant blue was removed
using multiple changes of destain solution (10 % (v/v) glacial acetic acid, 40 % (v/v)
methanol) for several hours at room temperature. Gels were subsequently dried
using Promega's gel drying kit in accordance with the manufacturer's instructions.
2.3.9 Transfer of proteins separated by SDS-PAGE to nitrocellulose.
Proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane
using NuPAGE® transfer buffer by Invitrogen supplemented with appropriate
amounts of methanol and antioxidant in accordance with the manufacturer's
instructions. Transfer was completed at 30 V for 1 hour (for proteins <100 kDa) or
25 V for 1 hour (proteins >100 kDa). Transfer was verified by staining membranes
with Ponceau S solution (0.1 % Ponceau S (w/v), 5 % acetic acid) for 3 minutes to
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5 minutes at room temperature. Excess Ponceau S was removed by washing with
distilled water.
2.3.10 Western blotting.
The Western blotting protocol was adapted for the requirements of different
primary antibodies. All Western blot procedures used are detailed in appendix 3. In
general the following protocol was used. Protein binding sites on Western blot
membrane were blocked in 5 % (w/v) fat free powdered milk in TBS-T (0.5 %) (TBS
(0.05 M Tris, 0.138 M NaCl, 0.0027 M KC1, pH 8.0) + 0.5 % (v/v)
polyoxyethylenesorbitan monolaurate (Tween-20)) either at 4 °C overnight or
2 hours at room temperature. Blots were washed with TBS-T (0.1 %) and incubated
with the primary antibody for 1 hour in 3 % (w/v) fat-free powdered milk in TBS-T
(0.1 %) for 1 hour. Primary antibody was removed by washing the blot three times,
for 10 minutes with TBS-T (0.1 %). Blots were incubated with HRP conjugated
antibody diluted with 3 % (w/v) fat free powdered milk in TBS-T (0.1 %) for 1 hour
at room temperature and was removed by washing the blot three times, for
10 minutes with TBS-T (0.1 %). Immunoreactive bands were visualised with
chemiluminescence (Pierce) as per the manufacturers instructions.
2.3.11 GST pull-down assay.
Cell extracts were prepared as described in section 2.3.5. 2 X 37.5pl of unwashed
GSH-sepaharose were aliquoted in to two clean microluge tubes and washed twice in
the appropriate extraction buffer (see appendix 2 and 2.3.5) by centrifugation (2000 g
for 1 minute at 4 °C). 10 pg of GST or GST-NrCAM were added to each tube and
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the volume made up to 500 pi with extraction buffer and the fusion protein allowed
to couple to the beads by tumbling at 4 °C for 2 hours. Cell extracts were prepared
as described in 2.3.5 and pre-cleared by tumbling with 50 pi of washed GSH-
sepharose for 1 hour at 4 °C. The supernatant was removed from the GST protein
coupled beads by centrifugation (2000 g for 1 minute at 4 °C) and equal volumes of
pre-cleared cell extract added to each tube. Beads and cell extracts were tumbled
together for 2 hours at 4 °C. The beads were then washed a minimum of five times
and a maximum of ten times with lysis buffer by centrifugation at 12000 g, 4 °C for
10 seconds and removal of supernatant using a syringe. The proteins were extracted
in 4 X NuPAGE® SDS buffer and denatured by heating to 70 °C for 10 minutes.
SDS-PAGE and Western blot were performed as described 2.3.10.
2.3.12 Immunoprecipitation using monoclonal anti-HA antibodies and protein
A.
A cell extract was prepared as described above in RIPA buffer (Tris-HCl 50 mM,
pH 7.4, NP-40 1 %, Na-deoxycholate 0.25 %) with PMSF (1 mM), aprotinin
(1 pg/ml), leupeptin (1 pg/ml), pepstatin (1 pg/ml), Na3VC>4 (1 mM) and NaF
(1 mM). The cell extract was pre-cleared by tumbling with 10 mg of washed protein
A-sepharose for one hour at 4 °C. A further 3 mg of protein A-sepharose was
prepared by washing in 1 ml RIPA buffer and spinning at 12000 g for 10 seconds,
RIPA buffer was removed using a syringe and this procedure repeated three times. A
sample of the clarified cell extract was taken and the remainder added to washed
sepharose beads together with 3 pi of monoclonal anti-HA antibodies (Santa Cruz)
and tumbled at 4 °C for 2 hours. The beads were then washed a minimum of five
times and a maximum of ten times with RIPA buffer by centrifugation at 12000 g,
63
4 °C for 10 seconds and removal of supernatant using a syringe. The proteins were
extracted in 4X NuPAGE® SDS buffer and denatured by heating to 70 °C for
10 minutes. SDS-PAGE and Western blots were performed as described 2.3.10.
2.3.13 Immunoprecipitation using high affinity rat monoclonal anti-HA
antibodies (Roche) and goat anti-rat IgG (whole molecule) agarose.
A cell extract was prepared as described above either in RIPA (Tris-HCl 50 mM,
pH 7.4, NP-40 1 %, Na-deoxycholate 0.25 %) with Roche protease inhibitors (Cat.
No. 1 697 498) or when tyrosine phosphorylation was being carried out in RIPA with
PMSF (1 mM), aprotinin (1 pg/ml), leupeptin (1 pg/ml), pepstatin (1 pg/ml),
Na3VC>4 (1 mM) and NaF (1 mM). The cell extract was pre-cleared by tumbling
with 10 pi of washed (RIPA) goat anti-rat IgG (whole molecule) agarose for 1 hour
at 4 °C. A further 8 pi of goat anti-rat IgG (whole molecule) agarose was prepared
by washing in 1 ml RIPA buffer and spinning at 12000 g for 10 seconds, RIPA
buffer was removed using a syringe and this procedure repeated three times. A
sample of the clarified cell extract was taken and the remainder added to washed
agarose beads together with 4 pi of rat monoclonal anti-HA antibodies (Roche) and
tumbled at 4 °C for 2 hours. The beads were then washed seven times with RIPA
buffer by centrifugation at 12000 g, 4 °C for 10 seconds and removal of supernatant
using a syringe. The proteins were extracted in 4 X NuPAGE® SDS buffer and
denatured by heating to 70 °C for 10 minutes. SDS-PAGE and Western blot were
performed as described 2.3.10.
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2.3.14 Immunoprecipitation of GIPC using goat anti-GIPC antibodies and
anti-goat beads.
A cell extract was prepared as described above in RIPA (Tris-HCl 50 mM, pH
7.4, NP-40 1 %, Na-deoxycholate 0.25 %) with Roche protease inhibitors (Cat. No. 1
697 498). The cell extract was pre-cleared by tumbling with 10 pi of washed (RIPA)
rabbit anti-goat IgG (whole molecule) agarose for 1 hour at 4 °C. A further 8 pi of
rabbit anti-goat IgG (whole molecule) agarose was prepared by washing in 1 ml
RIPA buffer and spinning at 12000 g for 10 seconds, RIPA buffer was removed
using a syringe and this procedure repeated three times. A sample of the clarified
cell extract was taken and the remainder added to washed agarose beads together
with 4 pi of goat polyclonal anti-GIPC antibodies (Santa Cruz) and tumbled at 4 °C
for 2 hours. The beads were then washed seven times with RIPA buffer by
centrifugation at 12000 g, 4 °C for 10 seconds and removal of supernatant using a
syringe. The proteins were extracted in 4 X NuPAGE® SDS buffer and denatured by
heating to 70°C for 10 minutes. SDS-PAGE and Western blot were performed as
described 2.3.10.
2.3.15 Immunoprecipitation using monoclonal anti-HA beads.
A cell extract was prepared as described above either in RIPA (Tris-HCl 50 mM,
pH 7.4, NP-40 1 %, Na-deoxycholate 0.25 %) with Roche protease inhibitors (Cat.
No 1 697 498) or when tyrosine phosphorylation was being carried out in RIPA with
PMSF (1 mM), aprotinin (1 pg/ml), leupeptin (1 pg/ml), pepstatin (1 pg/ml),
Na3VC>4 (1 mM) and NaF (1 mM). Tumbling with 100 pi of Rabbit IgG agarose for
1 hour at 4 °C pre-cleared the cell extract. 40 pi of 1:1 anti-HA agarose was
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prepared by washing in 1 ml RIPA buffer and spinning at 12000 g for 10 seconds,
RIPA buffer was removed using a syringe and this procedure repeated five times. A
sample of the clarified cell extract was taken and the remainder added to washed
agarose beads and tumbled at 4 °C for 2 hours. The beads were then washed a
minimum of five times and a maximum of ten times with RIPA buffer by
centrifugation at 12000 g, 4 °C for 10 seconds and removal of supernatant using a
syringe. The proteins were then extracted in 4X NuPAGE® SDS buffer and
denatured by heating to 70 °C for 10 minutes. SDS-PAGE and Western blot were
performed as described 2.3.10.
2.3.16 Tandem affinity purification.
All procedures were carried out at 4 °C unless otherwise stated. Cultured cells
grown on 140 mm diameter tissue culture dishes were washed twice in ice cold PBS.
Cells were scraped from each cell culture dishes into 1 ml of PBS. Cells were
pelleted (1200 g, 3 minutes) and the pellet lysed by rotation in 1 ml of lysis buffer
(50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % (v/v) NP-40, 15 % (v/v)
glycerol, IX Roche cocktail of protease inhibitors (Cat. No. 1 697 498), and 1 mM
PMSF) for 30 minutes. Cell debris was removed by centrifugation (14000 g,
15 minutes at room temperature). 50 pi samples of the supernatant were retained,
and then Rabbit IgG beads (20 pi) were coupled to N-TAP constructs within the
remaining supernatant by tumbling at 4 °C for 2 hours. The coupled beads were
centrifiiged (2000 g, 4 °C, 1 minute) and the supernatant was removed using a
syringe. Beads were washed 3 times in 1 ml TBS- (0.05 %)T (50 mM Tris pH 7.4,
150 mM NaCl, 0.5 % (v/v) Tween-20) and twice in 50 pi TEV cleavage buffer
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(TCB) (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1 % (v/v) NP-40, 0.5 mM EDTA,
1 mM dithiothreitol). The beads were resuspended in 20pl TEV cleavage buffer and
0.5pl (50U) of TEV protease (Invitrogen) added and tumbled overnight at 4 °C. The
supernatant was transferred to a fresh tube and the IgG beads were washed with
TCB. Supernatants were combined and supplemented with three volumes of
calmodulin binding buffer (CBB) (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1 %
NP-40, 10 mM p-mercaptoethanol, 1 mM imidazole, 1 mM magnesium acetate,
2 mM CaCh) and a further 3 nM CaCh. 40 pi of washed calmodulin beads
(Stratagene) were added to the supernatants and the beads were rocked for 2 hours to
allow the CBP portion of the protein complex to bind the calmodulin beads. The
beads were thoroughly washed with CBB, then the remaining protein complex was
eluted by four washes of calmodulin elution buffer (10 mM Tris-HCl, pH 8.0,
150 mM NaCl, 0.1 % NP-40, 10 mM P-mercaptoethanol, 1 mM imidazole, 1 mM
magnesium acetate, 2 mM EGTA) and one wash of a high salt solution (50 mM
Tris-HCl pH 8.0, 1 M NaCl, 2 mM EGTA). These elutes were combined and
SDS-PAGE and Western blot were performed as described 2.3.10.
2.3.17 Affinity purification of rabbit NrCAM cytoplasmic terminus
antibodies.
3 ml of packed gel, a-amino hexyl sepharose 4B was measure into a 15 ml plastic
centrifuge tube and packed by centrifugation at 1200 g for 5 minutes and the alcohol
containing supernatant removed. The gel was washed in double its volume of ice-
cold PBS, which was removed by centrifugation as described above. This wash step
was repeated three times and the washed gel was finally resuspended in 2 ml ofPBS.
200 pi of N,N-dimethylformamide (DMF) containing 5 mg of sulfo-MBS (Pierce)
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was added to the gel suspension, mixed thoroughly and tumbled at room temperature
for 2 hours. The gel was packed and washed three times with two volumes of PBS
as already described. 10 mg of NrCAM peptide in 800 pi of 10 mM HC1 (pH 6.0
using 0.1 M NaOH) was coupled to the MBS activated gel by tumbling both together
overnight at room temperature. The matrix was then washed in two volumes of 1 M
Tris-HCl pH 7.6 and then 2 volumes of 0.2 M glycine pH 2.6 and finally 2 volumes
of PBS. 5 ml of week-8 NrCAM rabbit anti-serum was added to the packed peptide-
matrix and allowed to couple by tumbling overnight at 4 °C. The slurry was added
to a 10 ml column and allowed to settle. The column was washed three times with
10 ml of PBS. The antibody was eluted using 2X3 volumes of 0.2 M glycine and
collected as 0.5 ml fractions in 1.5 ml plastic tubes, already containing 0.5 ml of 1 M
Tris-HCl pH 7.6. The fractions most likely containing antibodies were marked as
ones that registered a pH drop on litmus paper. The column was washed in
3 volumes of glycine and stored in PBS 0.01 % sodium azide.
2.3.18 Removal of primary and secondary antibodies from a Western blot.
The nitrocellulose membrane was washed three times for ten minutes in 10 mis of
distilled water and then incubated for 45 minutes in stripping buffer (0.2M glycine
pH 2.2, 0.1 % SDS, 1.0% Tween-20) at room temperature. The membrane was then
washed a further three times for ten minutes in 10 mis of distilled water and
incubated with the primary and secondary antibody previously used as described in
section 2.3.10.
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2.3.19 PNGAse F treatment of cells.
NrCAM glycosylated protein within crude cell extracts and extracts from
immunoprecipitations was denatured in Glycoprotein denaturing buffer (NEB: 0.5%
SDS, 1% P-mercaptoethanol) at 100 °C for 10 minutes. Two equal volume samples
of denatured protein were then incubated in G7 reaction buffer (NEB: 50 mM
Sodium Phosphate, pH 7.5 @ 25 °C) supplemented with 1% NP-40 (NEB). One
sample of denatured protein was treated with 500 units of peptide: N-glycosidase F
(PNGase F) and the second sample left untreated. Both samples were incubated
overnight at 37 °C and analysed by SDS-PAGE and Western blot as described
sections 2.3.7 to 2.3.10.
2.4 Yeast and the Yeast two-hybrid Assay.
2.4.1 General care and details on Y190 strain.
All culturing of yeast was done under aseptic conditions unless otherwise stated.
Untransfected Y190 were cultured overnight at 30 °C in YPAD (1 % (w/v) yeast
extract (Difco), 2 % (w/v) peptone (Difco), 2 % (w/v) glucose, 0.01 % (w/v) adenine
hemisulfate) liquid medium or on YPAD agar plates. Transfected Y190 were
cultured overnight at 30 °C in omission liquid medium (0.67 % (w/v) Yeast nitrogen
base without amino acids (Difco), 2 % (w/v) glucose and 0.067 % synthetic drop out
mix) or on omission media agar plates. Drop out mix included all of the following
amino acids less the amino acid(s) being selected for: 2.0 g adenine hemisulfate,
2.0 g arginine-HCl, 2.0 g histidine-HCl, 2.0 g isoleucine, 4.0 g leucine, 2.0 g lysine-
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HC1, 2.0 g methionine, 3.0 g phenylalanine, 2.0 g serine, 2.0 g threonine, 3.0 g
tryptophan, 2.0 g tyrosine, 1.2 g uracil and 9.0 g valine.
2.4.2 Li Acetate method of transformation.
Yeast strain Y190 was co-transformed using the lithium acetate/single-stranded
carrier DNA/polyethylene glycol (LiAc/ss-DNA/PEG) protocol developed by the
Gietz laboratory (Agatep et al 1998). 2.5 x 108 yeast cells were inoculated into
YPAD medium that was pre-warmed to 30 °C. The cells were incubated at 30 °C
and 200 r.p.m until the cell titre reached 2 x 107 cells per ml. Cells were harvested
by centrifugation at 3000 g for 5 minutes at 21 °C. Cells were washed in 10 ml of
sterile distilled water by re-centrifugation and decanting off the supernatant. Cells
were resuspended in 1.0 ml of 100 mM lithium acetate, which was allocated in ten
100 pl-aliquots in micro-centrifuge tubes. The cells in each tube were pelleted and
the lithium acetate supernatant removed. The following reagents were added in the
following order to each cell pellet; polyethylene glycol 3350 (50 % w/v) 240 pi,
lithium acetate 1.0 M 36 pi, carrier single stranded DNA (10 pg) 50 pi, sterile
distilled water, pAS2-l bait construct (1 pg) and pACT2 construct (1 pg) 36 pi. The
cells were resuspended by vortexing and incubated at 30 °C for 30 minutes. The
cells were then heat shocked in a water bath at 42°C for 30 minutes, pelleted at
7000 g on a bench centrifuge and gently resuspended in 1.0 ml of sterile distilled
water. 200 pi of each cell suspension was plated onto an agar plate lacking leucine
and tryptophan (W'L) and grown at 30°C for 3 to 4 days.
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2.4.3 The filter lift assay.
Positive interaction between proteins was tested for (3-galactosidase activity by the
filter lift assay as described by Parchaliuk et al (1999). Sterile 7.5 cm diameter
Whatman grade 1 paper was soaked in a solution of 10 ml Z buffer (60 mM
Na2HPO4.7H20, 40 mM NaH2PO4.H20, 10 mM KCL and 1 mM MgSO4.7H20, pH
7.0), 0.5 ml of 20 mg/ml 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal) in
DMF and 27 pi mercaptoethanol, and placed into an 8.0 cm diameter Petri dish.
Clean dry filter paper was placed over the surface of colonies growing on W"L" plates
using a forceps. The colonies were transferred to the filter paper, which was then
placed in liquid nitrogen. After the paper was frozen completely it was removed
from the liquid nitrogen and allowed to defrost at room temperature. This freeze
thaw cycle was repeated and then the defrosted paper placed on top of the wetted
filter paper in the Petri dish. The filter papers were then incubated at 37 °C for 3
hours and then at room temperature (in the dark) for a further 20 hours.
2.4.4 Preparation of glycerol stocks of transformed Y190.
Glycerol stocks were prepared from overnight Y190 cultures. 600 pi of culture
were mixed with 400 pi of sterile 50 % glycerol in sterile MQH20 and stored at -
70 °C.
2.4.5 Extracting DNA from yeast.
Two or three colonies of pACT2 library plasmid expressing were grown overnight
in 3 mis of L" liquid media. This starter culture was inoculated (100 pi) into three
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more 3 ml L" cultures and grown overnight. Each one of the three overnight cultures
were pelleted in a microfiige tubes, using a bench centrifuge, the supernatants were
discarded and 200 pi of yeast lysis buffer (10 mM Tris-HCL, 100 mM NaCl, 1 mM
EDTA, 2 % (v/v) Triton X-100, 1 % (w/v) SDS) was added to each pellet. 0.45 pm
sterile glass beads were added to just below the liquid level and the microfuge tubes
were vortexed for a minimum of 60 seconds. 200 pi of phenol-chloroform mixture
were then added to the microfuge tubes and the mixture was vortexed for a further 60
seconds. The aqueous layer was extracted by centrifuging the mixture for two
minutes, using a bench centrifuge, and then transferring, by pipetting, the top
(aqueous layer) into a fresh clean microfuge tube. This aqueous layer was cleaned a
second time using a further 200 pi of phenol- chloroform, centrifugation and transfer
steps as previously described. All three aqueous layers were then added to the same
Qiagen miniprep column. The manufactures protocols were then followed
(described in section 2.1.10). Briefly the columns were centrifuged for one minute in
a bench centrifuge and the supernatant was discarded. The column was washed by
adding 500 pi of buffer EB and centrifuging for one minute and then discarding the
supernatant. The column was washed a second time with buffer PE, using the same
procedure. The DNA was eluted from the column using 50 to 100 pi of sterile
MQH20 at 70 °C.
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Chapter 3. The Yeast Two-Hybrid Library
Screen.
3.0 Introduction: General principles of the yeast two-hybrid
library screen.
No protein acts in isolation, most proteins are part of dynamic protein-protein
complexes which enable/disable and/or modify the proteins function. Therefore to
fully explore NrCAM's functions a first step would be to establish its binding
partners. Although several of NrCAM's extracellular binding partners have been
published, only one intracellular binding partner (ankyrin) has been shown to date
(Davis et al., 1996; Grumet, 1997). Taking into consideration the 100 % amino acid
conservation of NrCAM's cytoplasmic terminus from chick to human (Davis and
Bennett, 1994; Lane et al., 1996) it is therefore suggested that NrCAM may have as
yet unidentified binding partners. To explore this possibility it was decided to screen
a cDNA yeast two-hybrid library for potential binding partners.
The yeast two-hybrid assay is a method of detecting interacting proteins in the
nucleus of a yeast cell (Fields and Song, 1989). The method takes advantage of the
modular nature of transcription factors. Transcription factors can be divided into two
distinct domains, a DNA binding domain (BD) and a transcription-activating domain
(AD) (Ptashne and Ma, 1988). Both the AD and BD are independently non
functional as transcription factors; however, when both domains are brought into
close proximity they act as a normally active transcription factor (Fields and Song,
1989; Bartel and Field, 1997; Gietz and Woods, 2002a).
The yeast two-hybrid method used in this thesis is described in Figure 3-1 and is
based upon Clontech's MATCHMAKER Two-Hybrid system 2
(http://www.icb.ufmg.br/~prodap/2003/tectrans/dhclontech.pdf). The DNA sequence
of the cytoplasmic terminus of NrCAM was cloned in frame into pAS2-l (Clontech)
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(Figure 3-1 (A)), and this was called the bait plasmid. A cDNA library from a rat
developing brain was cloned in frame into pACT-2 plasmids Figure 3-1 (B) and these
plasmids were called the prey plasmids. The bait plasmid encoded for a chimeric
protein that consisted of the BD of the yeast GAL4 trans-acting transcription factor
N-terminally fused to the relevant NrCAM cytoplasmic terminus. The prey plasmids
encoded for the AD of the yeast GAL4 trans acting transcription factor N-terminally
fused to potential binding partners of NrCAM (Figure 3-1 (C) and Figure 3-1 (D).
Interactions between the BD-bait fusion protein and an AD-prey fusion protein bring
the GAL4 AD and GAL4 BD into close proximity, activate the transcription factor
and initiate the transcription of reporter gene(s) in the genome (Fields and Song,
1989). If the BD-bait fusion protein and an AD-prey fusion protein do not interact
the transcription factor is not activated and the reporter genes are not transcribed.
The Y190 yeast strain has two reporter genes HIS3 and LacZ incorporated into its
genome (Durfee and et, 1993) (Figure 3-1 (E)). This allows identification of
interacting proteins as those that will enable the yeast colonies to both 1) grow on
media lacking the amino acid histidine and 2) express functional P-galactosidase that
can cleave 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (x-gal) to give a blue
product. The general principles of the yeast two-hybrid screen are described in
(Bartel and Field, 1997; McAlister-Henn etal., 1999; Gietz and Woods, 2002a).
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C. The BD-bait fusion protein. D. The AD-prey fusion protein.
E. Interaction of the BD-bait and AD-prey fusion proteins in the yeast nucleus




Figure 3-1. General principles of the yeast two-hybrid assay. A) The bait
plasmid. B) The prey plasmid. C) A chimeric protein consisting of the BD of
GAL4 N-terminally fused to the bait protein. D) A chimeric protein of the AD of
GAL4 N-terminally fused to the prey protein. E) Binding of the bait and prey
protein will bring both parts of the GAL4 transcription factor into close proximity
and initiate the transcription of reporter genes. See text for details.
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3.1 The yeast two-hybrid library screen.
The library screening procedures that were carried out are summarised in Figure 3-
2 and are described briefly below.
3.1.1 Cloning of the bait and library plasmids.
3.1.1.1 The NrCAM bait plasmid.
The DNA sequence encoding the intracellular C-terminal region of rat NrCAM
(NrCAM-CT) (amino acids 1102-1215; accession number U81037) was amplified by
PCR from a developing rat optic nerve library and sub-cloned into pAS2-l (Clontech)
(Figure 3-3).
3.1.1.2 The Library plasmids.
A developing rat brain cDNA library was sub-cloned into the pACT2-AD
(Clontech) vector (a gift from Prof. P. Brophy, University of Edinburgh).
3.1.2 Initial testing of the bait.
3 .1.2.1 Autonomous reporter activation ofbait and yeast cell toxicity.
A number of initial tests are recommended before commencing a large scale
library screen (Gietz et al., 1997). pAS2-l NrCAM CT was tested for toxicity,
inappropriate auto-activation and appropriate activation of the LacZ gene using the
filter lift assay as previously described (section 2.4.3). Briefly the pAS2-l NrCAM
CT vector together with the appropriate pACT vector were co-transformed into Y190
77
2. Initial testing of bui
The bait: GAL4-BD rat NrCAM
C-terminus in pAS2-l.
Tested for autonomous
reporter activation of bait
and yeast cell toxicity.




Determined optimal library to
bait ratio.








4. Performance of the
yeast two-hybrid
library Screen.
Co-transformed both plasmids into Y190
using a 60X scale up of optimised
transformation procedures. Plated onto
W- L" H+ 45mM 3 AT+ plates.




GAL4-AD rat brain library plasm id
isolated in yeast using cycloheximide.
Plasmid extracted from yeast using
mechanical and detergent lysis, followed
by phenol chloroform extraction.
Transformed the interacting plasmid into DH5a. The
replicated plasmid was minipreped using Qiagen® protocol.
DNA was sequenced. The sequences were compared to
NCBI protein database.
Figure 3-2. A flow chart of the two-hybrid library screen method used in this
thesis. Steps 1 to 7 (grey boxes) were carried out in this order. White boxes are















2. The plasmid construct pSPORT
NrCAM CT was digested using
restriction enzymes EcoRI and BamHI.
The fragment containing NrCAM CT was
purified.
1. The plasmid pSPORT NrCAM CT
encoding the rat sequence (amino acids
1102-1215, accession number U81037)
was generated by PCR from an rat optic
nerve library and cloned into pSPORT
using restriction sites EcoRI and BamHI










3. The empty pAS2-l plasmid was
digested with restriction enzymes EcoRI
and BamHI, and then purified. The
purified NrCAM CT fragment and the
cut vector were ligated together and then
transformed into DH5a. This resulted in
the production of a new plasmid
construct called pAS2-l NrCAM CT
which was sent for DNA sequencing.
Figure 3-3. Cloning strategy for the production of the plasmid pAS2-l NrCAM
CT. Full details of materials and methods are described in chapter 2 and
accompanying text.
and grown on tryptophan and leucine deficient (W~ L") agar plates. After three days
yeast colonies were transferred on to filter papers, the yeast cell walls were lysed by
snap freezing in liquid nitrogen and the lysed yeast were incubated in x-gal
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containing buffer. The strength of the interaction of the bait and prey plasmid was
assessed as the time taken for P-galactosidase to cleave x-gal to a blue product. A
ranking system was introduced as described in Table 3-1
Time taken to go blue Binding Strength Ranking
within 30 minutes
30 to 60 minutes
one to two hours
two to six hours










Table 3-1. The ranking system in this thesis, to rank binding strengths of
interacting proteins in the yeast two-hybrid.
To ensure that NrCAM does not auto-activate, i.e. that the BD-NrCAM CT fusion
protein was not sufficient to initiate transcription of the lacZ gene without an
interacting AD fusion protein, 1 pg of the pAS2-l NrCAM CT plasmid was
transformed together with 1 pg of empty pACT vector into Y190 and the filter lift
assay was performed (section 2.4.3). The expression of the pAS2-l NrCAM-CT
plasmid in the yeast nucleus without an interacting protein did not induce
p-galactosidase to cleave x-gal to a blue product and it was concluded that the
pAS2-l NrCAM CT did not auto-activate.
To ensure that NrCAM was expressing correctly in the yeast nucleus and that it
interacted normally with an already established cytoplasmic binding partner of
NrCAM, 1 pg of ankyrinR (amino acids 14-515) in pACT (a gift from Prof. P Brophy,
University of Edinburgh) was co-transformed into Y190 with 1 pg of pAS2-l
NrCAM CT. Transformed colonies were allowed to grow on W" L" agar plates, the
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filter lift assay was performed and colonies containing the pAS2-l NrCAM CT
plasmid and the pACT ankyrinR plasmid went blue within 30 minutes, indicating a
strong interaction. Thus it was established that the pAS2-l NrCAM CT plasmid was
expressing correctly and could therefore identify potential cytoplasmic interacting
protein partners. These results also confirmed the suitability of the yeast strain Y190
for use with this bait as the LacZ gene had been correctly activated.
3.1.2.2 Choosing a 3 AT concentration.
The Y190 strain contains two reporter genes HIS3 and lacZ (Durfee and et, 1993).
Yeast colonies that contain interacting BD and AD fusion proteins are able to grow
on agar plates lacking the amino acid histidine (H") and can express P-galactosidase
and cleave x-gal. The design of the library screen requires both of these reporter
genes to eliminate non-interacting colonies. The first elimination step disregards
colonies not able to grow on H" plates. The second elimination step eliminates
colonies unable to cleave x-gal (Figure 3-2, step 4).
However, the Y190 yeast strain is leaky for HIS3 expression and can grow on H"
plates. The addition of the chemical 3-amino-l,2,4-triazole (3AT) to the yeast's
growth medium is necessary to quench the background expression of the HIS3 gene
product (Durfee and et, 1993). Thus the optimal 3 AT concentration for Y190
transfected with the NrCAM bait had to be established. The 3 AT concentration was
optimised by plating Y190 transformed with bait on a series of W~ H" at 3 AT
concentrations of 0, 20, 30, 35, 40, 45, 55, 50, 60 and 80 mM. This experiment was
performed three times. A 3 AT concentration of 45 mM was selected as optimal
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because after one week as it allowed only small (<lmm) colonies to grow. This
relatively high concentration for 3 AT is typical of concentrations found by other
groups when using a combination of Y190 and the pAS2-l vector (Parchaliuk et al.,
1999a; Furuyama and Sassa, 2000; Kim et al., 2002).
3.1.3 Determination of library transformation yield and efficiency.
Before performing a large-scale library screen it is recommended that the
transformation procedure be optimised for the bait, library and yeast strain being used
(Gietzetal., 1997).
3.1.3.1 Optimal library to bait ratio.
The standard high-efficiency transformation protocol described in section 2.4.2
(Agatep et al., 1998; Gietz and Woods, 2002b) was used to co-transform Y190 with
2 pg of bait plasmid together with increasing concentrations of pACT2 rat brain
library DNA (0.5 pg, 1 pg and 2 pg). Transformed Y190 were plated onto W" L" agar
plates and the yeast colonies were counted after three days growth. Transformation
efficiencies for the increasing quantities (plus or minus the standard error of the mean
(n=3)) of library cDNA were calculated to be 2.3 x 104 ± 0.1 x 104, 2.7 x 104 ±
0.3 x 104 and 3.0 x 104 ± 0.09 x 104 colony forming units per pg of DNA
respectively. As library transformation efficiency was not statistically different when
using 1 pg or 2 pg of library cDNA it was decided to use 1 pg of library cDNA on
economic grounds.
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3.1.3.2 Bait and library simultaneous transformation versus sequential
transformation.
The efficiency of the sequential transformation of bait plasmid and then library
plasmid was compared with the efficiency of co-transformation of bait and library
plasmids. The standard high-efficiency transformation protocol (section 2.4.2)
(Agatep et al., 1998; Gietz and Woods, 2002b) was used to transform Y190 with 2 pg
of bait plasmid. The pAS2-l NrCAM CT expressing colonies were grown for three
days on agar plates lacking the amino acid leucine (L"). The pAS2-l NrCAM CT
expressing colonies were inoculated into L" liquid medium and the pAS2-l NrCAM
CT expressing yeast cells were transformed with library plasmids (section 2.4.2)
(Agatep et al., 1998). Y190 that had been transformed with both plasmids were
plated onto W~ L" agar plates and the number of colonies that grew after three days
were counted. This experiment was repeated twice. On both occasions efficiencies
were found to be approximately 100th of co-transformation efficiencies reported
above. It was decided that the co-transformation protocol would be used for the
library screen to maximise transformation efficiency.
3.1.3.3 Optimisation ofduration of42 °C heat shock.
The standard high-efficiency transformation protocol (section 2.4.2) was used to
transform Y190 with 2 pg of bait plasmid and 1 pg of library plasmids with two
amendments to the standard protocol:
1) The heat shock at 42 °C was performed on individual transformations for 15
minutes, 30 minutes and 60 minutes.
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2) Only 10 |iil (normally 200pl) of each transformation mixture was plated on to
three 90 mm W L" agar plates.
Yeast colonies were counted three days later. The mean number of colonies (plus
or minus the standard error of the mean (n=3)) for increasing heat shock time was
found tobe3±l, 10±3 and 35 ± 9 colonies respectively. Thus it was decided to
heat shock for one hour when performing the large scale transformation experiment.
3.1.4 Transforming with library DNA.
Once the efficiency tests were completed and an optimal protocol chosen a large-
scale library screen was performed. A 60X scale up of the normal transformation
procedure was chosen as this was calculated to be sufficient to cover the library once.
120 pg of bait plasmid and 60 pg of library plasmids were co-transformed into Y190
using the standard protocol (section 2.4.2) (Agatep et al., 1998; Gietz and Woods,
2002b). 420 pi of the transformation mixture was plated on to ninety five-150 mm
W" L" H" 3AT+ agar transformation plates and 10 pi of transforming mixture on to
four-90 mm W" L" agar efficiency test plates. The efficiency test plates were counted
three days after the transformation procedure was carried out and the transformation
efficiency of the screen plus or minus the standard error of the mean was calculated to
be 5.78 x 104 ± 0.972 x 104 colony forming units per pg of DNA. 60 pg ofDNA was
transfected therefore 3.468 x 106 ± 0.586 x 106 clones were transformed. The
complexity of the library was 3.3 x 106 independent clones. Therefore, the yeast two-
hybrid screen had covered the whole cDNA library at least once. The large
transformation plates were incubated at 30 °C for 21 days in loosely fitting bags.
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3.1.4.1 Selecting the yeast two-hybrid positives.
Transformation plates were checked for positive colonies after four days of
incubation at 30 °C. Positive colonies were chosen that were observed to grow faster
than the background growth, the colony was circled and given a library reference
number. The circled colonies were further observed every day for the first week and
every second day for a further two weeks. When the diameter of the colonies had
reached approximately two to three millimetres they were plated in triplicate on to
fresh W~ IS H~ 3AT+ agar plates. In total 519 positive colonies were circled and re-
plated on to W~ IS H" 3AT+ agar plates. After 3-5 days (depending on the rate of
growth) the colonies growing on the fresh W" L~ H~ 3 AT" agar plates were tested for
(3-galactosidase activity by filter lift assay (section 2.4.3) (Parchaliuk et al., 1999b).
33 out of 519 positive colonies went blue after the first filter lift assay. These "blue
colonies" were plated onto another fresh W" L" H" 3 AT1 agar plates and retested using
the filter lift assay. Only 31 of the 33 "blue colonies" were still positive for (3-
galactosidase activity after a second filter lift assay was performed. Of the 31
colonies 18 colonies went blue within 30 minutes and were considered strong
interactions.
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3.1.5 Isolating the pACT2 interacting plasmid.
3.1.5.1 Cycloheximide selection for colonies that have lost the GAL4 BD-bait
plasmid.
The Y190 yeast strain carries the Cyhr2 mutant allele and so is cycloheximide
resistant (Harper et al., 1993). The pAS2-l plasmid encodes the dominant wild type
CHS2 gene and transformation of the plasmid into Y190 makes the yeast strain
sensitive to cycloheximide. Yeast cells containing both plasmids will spontaneously
loose the pAS2-l plasmid while retaining the pACT2 plasmid if plated onto
cycloheximide containing media (http://www.icb.ufmg.br/~prodap/2003/
tectrans/dhclontech.pdf). The 31 blue colonies from section 3.1.4 were plated onto
cycloheximide containing W L" agar plates. Colonies growing on these plates were
picked and re-plated onto both L" plates and W" plates. Colonies that grew on L" but
not on W~ plates (i.e. contained the library plasmid only) were stored at 4°C. One
colony did not grow on the cycloheximide containing W L" agar plate and 30 out of
the 31 yeast colonies were available for DNA extraction in 3.1.6 below. The filter lift
assay was used to test the 30 colonies for auto-activation of the pACT2-AD library
plasmid as they grew on the L" agar plates (colonies not expressing a pAS2-l bait
plasmid should not be able to activate the lacZ gene and cleave x-gal). No colonies
were found to be auto-activating at this step.
3.1.6 Extracting DNA from yeast and retransformation into DH5a.
DNA was extracted from the 30 yeast colonies (section 2.4.5) and the entire DNA
solution was then transformed into super competent DH5a (section 2.1.9). The
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replicated DNA was extracted from this E.coli strain (section 2.1.10) and 200 ng to
300 ng of the DNA was sent to the Sequencing Service of the University of Dundee
for sequencing (http://www.dnaseq.co.uk).
3.1.7 Identification of potential candidate proteins that may bind NrCAM.
Sequences received from the University from Dundee were checked against their
Chromas file (http://www.technelysium.com.au/chromas.html) to ensure accuracy.
They were then put into the correct frame and the nucleotide sequence translated to
an amino acid sequence using the EXPASY translation tool
(http://us.expasy.org/tools/dna.html). The resulting translated sequence was then
compared against the NCBI database (http://www.ncbi.nlm.nih.gov/) of July/August
2002 and again in March/April 2004. Two of the thirty cDNAs clones did not give a
clean DNA sequence despite being sequenced twice. The 28 remaining library clones
are described in Table 3-2.
Of these 28 clones, 8 encoded for DNA binding proteins, collagen, viral DNA and
short peptides. DNA binding proteins and collagen are common false positives found
in most yeast two-hybrid screens (Hengen, 1997). There were two short peptide
sequences. One was 34 amino acids and the other 8 amino acids. The sequences of
both peptides had no corresponding matches in the BLAST search of the NCBT
database and were not considered to be real protein products that could interact with
NrCAM. Therefore these eight clones were immediately dismissed as unlikely
candidates (Table 3-2).
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Matched to protein database Strength of Interaction Unlikely Auto- Potential
<30min >30min candidate activation Candidates
Ankyrin B 10 9 1 10
SAP 102 3 2 1 3
PSD-95 1 1 1
GIPC 2 1 1 2
VHS of GGA1 1 1 1
RanBPM 3 3 3
DNA binding proteins 4 4 4
Collagen 1 1 1
Viral DNA 1 1 1
Short Peptides 2 2 2
Total library clones 28 16 12 8 3 17
Table 3-2. Identification of clones selected by the yeast two-hybrid screen,
(section 3.1.7).
The remaining 20 clones were subjected to a second test for auto-activation. 1 p.g
of empty pAS2-l vector cDNA and 1 pg each library cDNA plasmid was
transformed into Y190 using the standard protocol (Agatep et al., 1998; Gietz and
Woods, 2002b) (2.4.2) and plated onto W~ L" agar plates. The colonies were tested
for P-galactosidase activity using the filter lift assay protocol. The scoring system
used is as described in Table 3-1. The results are given in Table 3-2. All of the
RanBPM colonies went blue within the first 15 minutes and were eliminated as false
positives. This left a remaining 17 potential candidates (Table 3-2).
3.2 Analysis and description of the potential NrCAM binding
candidates.
3.2.1 Ankyrins.
Ten of the positive clones encoded for the membrane binding sequence of
ankyrinB (ankyrin2). NrCAM's interaction with ankyrin has already been described
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(Davis and Bennett, 1994). The best matches in the NCBI database are shown in
Table 3-3. Seven of the interactions were selected from W L" H" 3 AT ' agar plates in
the first week, two in the second week and one in the third week (Table 3-3). When
performing the filter lift assay nine of the colonies went blue within 30 minutes and
were considered strong interactions
3.2.2 SAPI02.
Three of the positive clones coded for part of the cDNA of Synapse associated
protein 102 (SAP 102) and one encoded for the cDNA of postsynaptic density-95
(PSD-95/SAP90). SAPI 02 and PSD-95 are two members of the
membrane-associated guanylate kinase (MAGUK) family (Fujita and Yoshihisa,
2000). MAGUKs are a family of signalling molecules that are characterized by their
three PSD95/Dlg/ZO-l (PDZ) domains, a single src homology 3 (SIB) domain and a
guanylate kinase domain (GUK) (Fujita and Yoshihisa, 2000).
Protein Interaction strength
Name accession Selected <30 mins. >30 niin.
4A XP_342338 Week 1 1
10A XP 342338 Week 1 1
16A-1 2003319A Week 1 1
4D-1 Q01484 Week 1 1
22A Q01484 Week 1 1
21A Q01484 Week 1 1
27B2A CAB42644 Week 1 1
57B-2 Q01484 Week 2 1
68B-2 Q01484 Week 2 1
37B S37431 Week 3 1
Table 3-3. Identification of the ten-ankyrin clones isolated by the yeast two-
hybrid screen.
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Two of the clones (RL48A(2) and RL29B) had been selected as fast growing
colonies on W L" H" 3AT+ agar plates in week one and were considered strong
interactions as colonies went blue within 30 minutes when the filter lift assay was
performed. Both of these clones encoded for the three PDZ domains and the SH3
domain of SAP102 (amino acids 54-623 accession number U53367) (Muller et al.,
1996) but minus an alternatively spliced region (amino acids 120-137). They did not
code for a stop before running into the pAC2-AD vector sequence. Therefore, the
expressed protein has an additional seven amino acids before encountering the stop
encoded for by the pACT2-AD vector (Figure 3-4).
The third SAP 102 clone (RL71D) had been selected as a fast growing colony on a
W~ L* H" 3AT+ agar plate in week three and was considered a weak interaction as
colonies went blue within two hours when the original filter lift assays were
performed (section 3.1.4.1). This clone contained three PDZ domains of SAP 102
(amino acids 96-533 accession number U53367) (Muller et al., 1996) and a single
proline followed by a stop. It included the amino acids of the alternatively spliced
region (amino acids 120-137) that were not found in RJL48A(2) and RL29B but are






PDZ — PDZ PDZ — SH3 GK H
1 120137 623 835
1 // PDZ PDZ PDZ SH31 //
54 120 137 623







Figure 3-4. Alignment of the protein domains encoded by the rat library cDNA
clones RL48A, RL29B and RL71D against the protein domains of full length
SAP102 as described by accession number U53367. PDZ domains have been
shown in grey, other protein domains have been shown in green. Additional
amino acids encoded by the rat library clone not normally encoded by SAP102
DNA are shown in blue.
3.2.3 PSD-95.
The PSD-95 clone (RL65B) had been selected as fast growing colony on a W L"
H" 3AT+ agar plate in week two and was considered a moderate interaction as
colonies went blue within 60 minutes when the original filter lift assays were
performed as described in 3.1.4.1. This clone contained the cDNA coding for the
first two PDZ domains of PSD-95 (amino acids 71-258 accession number




Figure 3-5. Alignment of the protein domains encoded by the rat library cDNA
clone RL65B against the protein domains of full length PDS-95 as described by
accession number NP 062567. PDZ domains have been shown in grey, other
protein domains have been shown in green. Additional amino acids encoded by
the rat library clone not normally encoded by PSD-95 DNA are shown in blue.
3.2.4 GTPC.
Two of the positive clones encoded for the cDNA of GAIP interacting protein
C terminus 1 (GIPC1). GIPC1 along with GIPC2 and GIPC3 are members of the
GIPC family. GIPCs are proteins with a central PDZ domain and GEPC homology
(GH1 and GH2) domains (Katoh, 2002) (Figure 3-6). Two of the clones
(RL16B(C)(2) and RL6C(2)) had been selected as fast growing colonies on W L" FT
3AT+ agar plates in week one and week two respectively. RL16B(C)(2) was
considered a strong interacting plasmid as colonies went blue within 30 minutes when
the filter lift assay was performed and RL6C(2) was originally considered a weak
interacting plasmid as colonies went blue after two hours when the filter lift assay
was performed (section 3.1.4.1).
RL16B(C)(2) encoded for sequence 5' of the published start of GIPC. This 5'
sequence included 36 nucleotides followed by the published promoter of GIPC
(accession number NM 053341). The cDNA then encoded for amino acids 1-215 of
accession number NP 445793 followed by 22 amino acids to a stop (Figure 3-6)
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(Bunn et al., 1999). The pACT-AD vector is designed to express the GALA AD
followed by all the encoded amino acids to the first stop. Thus the RL16B(C)2
plasmid expressed amino acids not normally expressed by native GIPC such as the





1 58 126 129 218 239 328 333
GH1 PDZ
1 58 126 129 215
GH1 PDZ
1 58 126 129 215
Figure 3-6. Alignment of the protein domains encoded by the rat library cDNA
clones RL16B(C)2 and RL6C(2) against the protein domains of full length GIPC
as described by accession number NP 445793. PDZ domains have been shown in
grey, other protein domains have been shown in green. Additional amino acids
encoded by the rat library clone not normally encoded by GIPC DNA are shown
in blue.
RL6C(2) encoded for sequence 5' of the published start of GIPC. This 5'
sequence included 36 nucleotides followed by the published promoter of GIPC
(accession number NM 053341). The cDNA then further encoded for amino acids 1 -
215 of accession number NP 445793 followed by 126 amino acids to a stop (Figure
3-6).
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3.2.5 The VHS domain of GGA1.
The RL68C clone encoded for the Vps27, Hrs and STAM (VHS) domain of Golgi-
localized, gamma-ear-containing, Arf binding protein I (GGA1) (amino acids 1-161
of accession number AAF05707 (Boman et al., 2000). GGAs are described in Figure
3-7 and consist of an N-terminal VHS domain, followed by a ~20 amino acid proline
rich sequence, which in turn is followed by a GGA and TOM (GAT) domain, an
unstructured variable amino acid hinge segment and finally a y-adaptin ear (GAE)
domain (reviewed Boman, 2001; Hirst et al., 2001). The cDNA of RL68C did not
code for a stop before running into the pAC2T-AD vector sequence. Therefore, the
expressed protein has an additional seven amino acids before encountering the stop
encoded for by the pAC2T-AD vector. The RL68C clone had been selected as a fast
growing colony on W~ L" H" 3 AT' agar plates in week two. RL68C was considered a
strong interacting plasmid, as colonies went blue within 30 minutes when the filter
lift assay was performed (section 3.1.4.1) (Figure 3 7).
Figure 3-7. Alignment of the protein domains encoded by the rat library cDNA clone
RL68C against the protein domains of full length GGA1 as described by accession
number AAF05707. Protein domains have been shown in green. Additional amino
acids encoded by the rat library clone not usually normally coded for by GGA1 are
shown in blue.
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3.3 Cloning of new NrCAM and Ll-CAM bait plasmids.
The interaction of the clones described in Table 3-2 had been confirmed by two
filter lift assays on W" L" H" 3AC agar plates (section 3.1.4.1). However there are
two potential problems in relying upon these assay results:
1. More than one library plasmid could potentially be transfected into and hence
expressed by an individual colony of yeast. Thus the cDNA that was isolated from
the yeast colonies in sections 3.1.5 and 3.1.6 may not have been the plasmid coding
for the true NrCAM-interacting protein but ofa second non-interacting plasmid.
2. The colonies require the continuous interaction of the BD-NrCAM CT and the
AD-prey fusion proteins to allow robust growth on media lacking histidine and
containing 3 AT. This additional selection pressure may have increased LacZ gene
expression by the yeast over what may have occurred on a W" L" agar plate.
To eliminate these possibilities the relative binding strengths of each of the
colonies listed as potential candidates in Table 3-2 were re-tested. 1 pg of the pAS-1
NrCAM CT was co-transformed with 1 pg of each of the seven library clones into
Y190 yeast. The transformed yeast were plated onto W L" agar plates and grown for
three days after which the filter lift assay was performed (section 2.4.3). This assay
was repeated on two separate occasions and the results are shown in Table 3-4. The
binding of NrCAM to ankyrinR plasmid was used as a positive control for the assays.
From Table 3-4 only five of the seven library plasmids reconfirmed as an interacting
protein, as the shorter SAP102 clone RL71D and the PSD-95 clone RL65B failed to
go blue within 6 hours. Of the five remaining interactions, all showed a weaker
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binding strength, as measured by the filter lift assay, then had been found on W~ L" H'
3 AT agar plates.
Protein Library Clone Strength of interaction
AnkyrinR N/A Mil
SAP102 RL48A(2) and RL29B +++
SAPI 02 RL71D -
PSD-95 RL65B -
G1PC RL16B(C)(2) and RL6C(2) +++
VHS RL68C +++
Table 3-4. Re-transformation and re-testing of plasmids isolated by the yeast
two-hybrid library screen. The filter lift assay results as reported in section 3.1.9.
3.3.1 Cloning ofNrCAM C-terminal deletion bait plasmids.
A set of filter assays were performed on the five remaining library plasmids to
establish the region in the cytoplasmic terminus of NrCAM that binds to the library
proteins. Three pAS2-l NrCAM plasmids were designed that would encode for part
of the cytoplasmic terminus of NrCAM as described in Figure 3-8 and Figure 3-9.
One of these plasmids (pAS2-l NrCAM 1 -22) encoded for the first 86 amino acids of
the NrCAM cytoplasmic terminus and included the sequence of the proposed
ankyrin-binding site of NrCAM. The second plasmid pAS2-l NrCAM 20-2 encoded
for the last 58 amino acids of the NrCAM cytoplasmic terminus and which include
the ankyrin-binding domain. The third plasmid pAS2-l NrCAM 21-2 encoded the
last 28 amino acids of the NrCAM cytoplasmic terminus, which do not include the
ankyrin-binding domain. Thus these plasmids would be able to distinguish between
binding cytoplasmic binding partners of NrCAM that bound N-terminally and C-
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terminally and cytoplasmic binding partners that bound in the region of the ankyrin-
binding domain.
NrCAM CT
1. The plasmid pSPORT NrCAM CT
encoding the rat sequence) amino acids
1102-1215, accession number U81037)
was used as a PCR template. The
ankyrin-binding domain of NrCAM has
been shown in green and the remainder
of the cytoplasmic sequence of NrCAM
in red.
2. PCR sense primers NrCAM 1,
NrCAM 20 and NrCAM 21 were
designed to add the EcoRI restriction
enzyme site to the 5' of the NrCAM
encoding sequence. PCR anti-sense
primers NrCAM 2 and NrCAM 22 were
designed to add the BamHl restriction
enzyme site to the 3' cDNA of the
NrCAM encoding sequence (see
appendix 4 for primer sequences).
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3. The amplified PCR products "NrCAM 1-22", "NrCAM 20-2" and NrCAM 21-2";
and the empty plasmid pSPORT were digested with the restriction enzymes EcoRI
and BamHI. Separate ligations of each PCR product and the cut vector were carried
out and the individual ligations transformed into DH5a. This resulted in the
production of three new plasmids called pSPORT NrCAM 1-22, pSPORT NrCAM
20-2 and pSPORT NrCAM 21-2.
NiCAM 1-22 3 amHI
EcoR





















The plasmid constructs pSPORT NrCAM 1-22, pSPORT NrCAM 20-2 and
pSPORT NrCAM 21-2 were digested using restriction enzymes EcoRI and
BamHl. The fragments containing NrCAM 1-22, NrCAM 20-2 and NrCAM 21-
2 were purified. The empty pAS2-l plasmid was digested with restriction
enzymes EcoRI and BamHI, and then purified. The purified NrCAM 1-22,
NrCAM 20-2 and NrCAM 21-2 fragments were individually ligated to cut vector
and then transformed into DH5a. This resulted in the production of three new
plasmids constructs called pAS2-l NrCAM 1-22, pAS2-l NrCAM 20-2 and
pAS2-l NrCAM 21-2 which were sent for DNA sequencing.










Figure 3-8. Cloning strategy for the production of the plasmids pAS2-l NrCAM
1-22, pAS2-l NrCAM 20-2 and pAS2-l NrCAM 21-2. Full details of materials
and methods are described in chapter 2 and accompanying text.
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33.2 Cloning of bait plasmid pAS2-l NrCAM Y86>E.
Dr. F. Davey of the University of St Andrews generated another pAS2-l NrCAM
bait plasmid with a single amino-acid mutation from tyrosine to glutamic acid at
position 86 of the cytoplasmic rat sequence (this is amino acid 1187 of accession
number U81037). This plasmid substitutes a negatively charged amino acid for the
tyrosine of the FIGQY sequence in the ankyrin binding site and is believed to mimic
a phosphorylated tyrosine at this position (Zhang et al., 1998a). The plasmid was
called pAS2-l NrCAM Y86>E.
3.3.3 Cloning of bait plasmid pAS2-l LI and pAS2-l neurofascin.
It was also decided to test the various plasmids against other members of the
Ll-CAM family. The cytoplasmic domain of human LI (Ll-CT, amino acids 1143-
1257; accession number NP 000416) was generated by PCR from a human image
clone (image:6569796) supplied by the IMAGE consortium and cloned in frame into
pAS2-l. The intracellular portion of neurofascin (neurofascin CT amino acids 1065-
1175 of neurofascin 155; accession number AY061639) was cloned in frame into
pAS2-l by Dr F. Gunn-Moore, University of St Andrews.
3.4 Analysis of the potential binding partners to NrCAM C-
terminal deletions and to other members of the Ll-CAM
family.
The binding of the different C-terminal deletions of NrCAM and of full length
neurofascin CT and full length LI CT to the potential binding partners (Ankyrin,
SAP102, GIPC, VHS) was tested using the filter lift assay (section 2.4.3). The
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binding of all of the proteins to AnkynnR was used as a positive control. Figure 3-9
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Figure 3-9. Testing of the library plasmids against differing LI-CAM baits.
AnkyrinR in pAS2-l was used as a positive control. The LI-CAM plasmids and
NrCAM plasmids have been shown diagrammatically. Green boxes represent the
ankyrin domain. The dark blue box is the FERM binding domain in neurofascin
and the paler blue boxes are the equivalent amino acids in LI and NrCAM. The
dark pink boxes are the PDZ domains of neurotascin and NrCAM. The paler pink
box is the equivalent amino acids in LI. Binding strengths were scored using the
system outlined in Table 3-1.
3.4.1 Ankyrin binding.
AnkyrinR bound to LI, neurofascin and NrCAM as was expected (Davis and
Bennett, 1994). pAS2-l NrCAM 1 -22 and pAS2-l NrCAM 20-2 both encode for the
amino acids defined as being the ankyrin binding site (Figure 3-9, green highlight)
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and both plasmids bound to ankyrin as expected. pAS2-l NrCAM 21-2 does not
include the ankyrin binding site and showed no interaction with ankyrin as expected.
Furthermore the substitution of a glutamate for the essential tyrosine in the FIGQY
amino acid sequence of the NrCAM ankyrin-binding domain abolished the binding of
ankyrin to NrCAM. Thus the pAS2-l plasmids were behaving as would be expected
with respect to ankyrin binding and were suitable for testing the binding preferences
of the library plasmids.
3.4.2 SAP102.
RL48A(2) and RL29B encoded for the same amino acids of SAP102 (Figure 3-4)
and these two plasmids gave indistinguishable filter lift assay results from each other.
Therefore, both have been included in Figure 3-9 under SAP102. The SAP102
proteins did not bind to either neurofascin CT or LI CT but did show a strong
interaction with NrCAM CT (Figure 3-9). When comparing the binding of the
various different length NrCAM plasmids to SAP 102 it can be seen that all NrCAM
plasmids bound strongly to SAPI02 except for the plasmid which does not code for
the C-terminal 28 amino acids of NrCAM (pAS2-l NrCAM 1-22). Notably a
plasmid consisting of only the C- terminal 28 amino acids of NrCAM (pAS2-l
NrCAM 21-2) did bind to SAP102. Thus showing that the last 28 amino acids of
NrCAM are sufficient and necessary for binding of SAP102.
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3.4.3 GIPC binding.
The two RL16B(C)(2) and RL6C(2) clones encoded for the same amino acids of
GIPC (Figure 3-6) and these two plasmids gave indistinguishable filter lift assay
results from each other. Therefore both have been included in Figure 3-9 under
GIPC. The binding of these GIPC clones to NrCAM and to the other LI -CAMs was
notably similar and dissimilar when compared to the binding of the SAP102 clones to
NrCAM. Like SAP102 both GIPC clones showed a strong interaction (as measured
by the filter lift assay) with the full NrCAM CT but did not bind to LI CT. Unlike
SAP102 however the GIPC clones showed a strong interaction with neurofascin CT.
When comparing the binding of the various different length NrCAM plasmids to
GIPC the results where similar to SAP102. The plasmid, which does not encode for
the C-terminal 28 amino acids of NrCAM (pAS2-l NrCAM 1-22) did not bind to
GIPC, however a plasmid consisting of only the C- terminal 28 amino acids (pAS2-l
NrCAM 21-2) did bind. Thus showing that the last 28 amino acids of NrCAM are
sufficient and necessary for GIPC-NrCAM binding.
3.4.4 VHS domain binding.
The binding of the VHS domain of GGA1 (RL68C) to NrCAM and to the other
LI-CAMs was notably similar and dissimilar to the binding of the ankyrinR to
NrCAM. Like ankyrinR the VHS clone showed a strong interaction with NrCAM CT
and neurofascin CT. Unlike ankyrinR however the VHS clone did not appear to
interact with LI CT. When comparing the binding of the various different length
NrCAM plasmids to the VHS clone the results where similar to ankyrinR. pAS2-l
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NrCAM 1-22 and pAS2-l NrCAM 20-2 both encode for the amino acids defined as
being the ankyrin binding site (Figure 3-9, green highlight) and both plasmids bound
to the VHS domain. pAS2-l NrCAM 21-2 does not include the ankyrin binding site
and showed no interaction with the VHS. Furthermore the substitution of a glutamate
for the essential tyrosine in the FIGQY amino acid sequence of the NrCAM ankyrin-
binding domain abolished the binding of the VHS domain to NrCAM. Thus it would
appear that the VHS site binds to the ankyrin binding domain of NrCAM and that the
substitution of a negatively glutamate for a tyrosine at position 86 in NrCAM inhibits
VHS binding.
3.5 Analysis and description of the published binding partners of
SAP102 and GIPC.
It was noted from the results above that the final 28 amino acids of NrCAM were
sufficient to bind to both SAP102 and GIPC. An analysis of SAP102's and GIPC's
other published binding partners highlighted the residues within NrCAM to which
both proteins may be binding. Table 3-5 and Table 3-6 show all of SAP102's and
GIPC's published binding partners. As can be seen from both tables the majority of
proteins that bind to both SAP102 and GIPC bind via the last four amino acids of
their cytoplasmic termini. These last four amino acids bind to the PDZ domains of
SAP102 or GIPC and are called PDZ binding motifs (Bezprozvanny and Maximov,
2001). The most important residues of the PDZ binding motifs are the most
C-terminal residue (called P0) and the third to last residue (called P-2)
(Bezprozvanny and Maximov, 2001).
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Protein that binds to SAP102 Reference(s):
Receptors - Class 1 PDZ P-3 P-2 P-l P0
NR2B subunit of the NMDA (Lau et al., 1996; Muller et al., 1996;
receptor E S D V Sans et al., 2000)
ErbB4 N T V V (Huang et al., 2002)
Inward rectifier potassium channel
Kir2.2 E S E I (Leonoudakis et al., 2004)
(Larsson et al., 2003; Lim et al.,
Megalin D S E V 2002)
Plasma membrane calcium ATPase
isoform PMCA4b E T S V (DeMarco and Strehler, 2001)
Serotonin receptor 5HT2C I S s V (Becamel et al., 2004)
Cytoplasmic - Class 1 PDZ P-3 P-2 P-l P0
Stargazin T T p V (Ives et al., 2004)
CRIPT Q T s V (Lim et al., 2002)
Cypin S S s V (Firesteinet al., 1999)
P51-nedasin (isoform S) S S s V (Kuwahara et al., 1999)
Sec8 I T T V (Sans et al., 2003)
SynGAP. Q T R V (Kim et al., 1998)
APC V T S V (Makino et al., 1997)
SH3 interactions
PyK2 (Seabold et al., 2003)
Calmodulin (Masuko et al., 1999)
To the GK domain of PSD95 (Masuko et al., 1999; Shin et al.,
To the GK domain of SAP 102 (Shin et al., 2000)
GK interactions
Guanylate kinase associated
protein (GKAP) (Kim et al., 1997)
Receptors - associating
Kainate receptor subunit Glur6
and KA2 (Garcia et al., 1998)
Table 3-5. Published binding partners of SAP102. Binding partners have been
analysed under the regions in SAP102 to which they bind. P-0, P-l, P-3, P-4 are
the C-terminal amino acids in SAP102's binding partner that are known to bind to
the PDZ domain of SAPI 02.
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Protein that binds to GIPC Reference(s):
Receptors: PDZ binding P-3 P-2 P-l P0
HTVL-1 Tax oncoprotein E T E V (Rousset et al, 1998)
HTVL-1 Tax oncoprotein E T E A (Rousset et al., 1998)
RGS-GAIP S S E A (De Vries et al., 1998)
GLUT1 D S Q V (Bunn et al., 1999)
a-actinin-1 E S D L (Bunn et al, 1999)
KIF-1B E T T V (Bunn et al., 1999)
M-SemF S S E A (Wang et al., 1999)
Neuropilin 1 Y S E A (Cai and Reed, 1999)
Syndecan-4 E F Y A (Gao et al., 2000)
gp75 Q S V V (Liu et al., 2001)
Integrin a 6A T S D A (Tani and Mercurio, 2001)
Integrin a 6B E s Y S (Tani and Mercurio, 2001)
Integrin a 5 T s D A (Tani and Mercurio, 2001)
Type HI receptor S s T A (Blobe et al., 2001)
5T4 N s D V (Awan et aL, 2002)
Megalin S s E V (Lou et al., 2002)
B1 Adrenergic receptors E s K V (Hu et al., 2003)
LDH Y T E c (Hirakawa et al., 2003)
Dopamine receptor D2 I L H c (Jeanneteau et al., 2004)
Dopamine receptor D3 I L S c (Jeanneteau et al., 2004)
CD93 G T D c (Bohlson et al, 2004)
Other PDZ
TrkA (Lou et al, 2001)
Non PDZ binding partners
Dopamine receptor D2 (Jeanneteau et al., 2004)
Dopamine receptor D3 (Jeanneteau et al., 2004)
Myosin VI (Bunn et al., 1999)
GIPC (Bunn et al., 1999)
Table 3-6. Published binding partners of GIPC. Binding partners have been
analysed under the regions in GIPC to which they bind. P-0, P-l, P-3, P-4 are the
C-terminal amino acids in GIPC's binding partners that are known to bind to the
PDZ domain of GIPC.
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3.6 Testing whether the last three amino acids of NrCAM are
necessary for NrCAM to bind to SAP102 and/or GIPC.
Like the majority of SAP102's and GIPC's binding partners NrCAM also has a
C-terminal PDZ binding motif namely -NSFV-COOH. As shown in Figure 3-9 the
NrCAM clone that does not have this motif (pAS2-l NrCAM 1-22) is the only
NrCAM clone not to bind to SAP 102 and GIPC. It was therefore decided to test if
the binding of SAPI 02 and GIPC to NrCAM depended on the presence of NrCAM's
PDZ binding motif A plasmid was designed that had the P0 (S), P-l (F) and P-2 (V)
residues of NrCAM deleted. This should eliminate a functional PDZ binding domain
as described by (Bezprozvanny and Maximov, 2001). The cloning of this plasmid is








1. The plasmid pSPORT NrCAM CT
encoding the rat sequence (amino acids
1102-1215, accession number U81037)
was used as a PCR template.
2. PCR primers NrCAM 1 and NrCAM
32 were designed 1) eliminate the coding
sequence for the last three amino acids of
the NrCAM and 2) to add the EcoRI
restriction enzyme and the BamHl
restriction enzyme site to the NrCAM
encoding sequence (see appendix 4 for
primer sequences).
Figure 3-10 Continued on next page
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3. The amplified PCR products
"NrCAM 1-32" and the empty
plasmid pSPORT were digested with
the restriction enzymes, EcoRI and
BamHI. The PCR product and the cut
vector were ligated together and then
transformed into DH5a. This resulted
in the production of a new plasmid




4. The plasmid construct pSPORT
NrCAM 1-32 APDZ was digested
using restriction enzymes EcoRI and
BamHl. The fragment containing
NrCAM was purified.





















5. The empty pAS2-l plasmid was digested with
restriction enzymes EcoRI and BamHI, and then
purified. The purified NrCAM 1 -32 APDZ and the
cut vector were ligated together and transformed
into DH5a. This resulted in the production of a
new plasmid constructs called pAS2-l NrCAM 1-
32 APDZ which were sent for DNA sequencing.
TRP1
Figure 3-10. Cloning strategy for the production of the plasmid pAS2-l NrCAM
1-32 APDZ. Full details of materials and methods are described in chapter 2 and
accompanying text.
The pAS2-l NrCAM 1-32 APDZ plasmid did not encode a functional PDZ
binding domain. Therefore, if NrCAM CT bound to the PDZ domains of SAP102
and GIPC then NrCAM 1-32 APDZ would not show any binding. This was tested
using the filter lift assay as described in 2.4.1. The results are shown in Figure 3-11.
NrCAM CT bound to both SAP102 and GIPC as before. However, the
cytoplasmic terminus of NrCAM without its terminal three amino acids (SFV-
COOH) did not show any binding to SAP102 or GIPC. LI CT, which does not have
a PDZ domain, did not bind to SAP102 or GIPC. Neurofascin CT, which has the
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three C-terminal acids, SLA bound to GIPC but not to SAP102. Thus the binding of
NrCAM to S API 02 and GIPC was dependent of the last three amino acid residues.
GIPC SAP102
(aa 1-215) (aa 54-623)
Ankyrin FERM PDZ
NrCAM CT j|ii§ FIGO ■ ■
1102
NrCAM 1 32 APDZ pjf. FIGQ ■ ■
1102 1212
LI CT FIGQ ■ ■
1143




Figure 3-11. Testing of the library plasmids against an NrCAM bait without a PDZ
binding domain. The LI-CAM plasmids and NrCAM plasmids have been shown
diagrammatically. Green boxes represent the ankyrin domain. The dark blue box is
the FERM binding domain in neurofascin and the paler blue boxes are the
equivalent amino acids in LI and NrCAM. The dark pink boxes are the PDZ
domains of neurofascin and NrCAM. The paler pink box is the equivalent amino
acids in LI. Binding strengths were scored using the system outlined in Table 3-1.
3.7 Discussion of results.
A developing rat brain cDNA library of 3.3 x 106 independent clones was screened
for interaction with the cytoplasmic terminus of NrCAM. 17 potentially interacting
clones were isolated from the library as potential binding partners. Ten clones
encoded for the membrane-binding region of ankyrine, four clones encoded for PDZ
domain containing regions of two members of the MAGUK family, SAPI 02 and
PSD-95, two clones encoded for the PDZ domain containing region of GIPC and one
clone encoded for the VHS domain of GGA1.
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3.7.1 Ankyrin binding.
The majority of the interacting clones contained the membrane-binding region of
cDNA of ankyrinB (Table 3-2). NrCAM together with the rest of the LI -CAM family
had already been reported as associating with ankyrins (Davis and Bennett, 1994) and
it is known that the membrane-binding domain of ankyrins has two high affinity
binding sites for Ll-CAMs (Michaely and Bennett, 1995; Bennett and Chen, 2001).
AnkyrinB is the most abundantly expressed ankyrin molecule in the nervous system
(Bennett and Chen, 2001) and it has been suggested that the NrCAM-ankyrinB
interaction is important for the correct development of the lens in mice (More et al.,
2001). Thus the abundance of ankyrinB clones isolated by the library screen was an
expected result. Interestingly no ankyrino or ankyrinR clones were isolated. Full
length ankyrinR has been shown to bind to the NrCAM bait (Table 3-4, Figure 3-9f)
however ankyrinR is only found at very low expression levels within the nervous
system (Bennett and Chen, 2001). Therefore there may have been no ankyrinR cDNA
clone in the library. Flowever ankyrino is reported to be an abundantly expressed
protein in the developing nervous system (Bennett and Chen, 2001) and to associate
with NrCAM at the node ofRanvier (Lambert et al., 1997; Lustig et al., 2001; Custer
etal., 2003) and at initial segments (Jenkins and Bennett, 2001). It is not known why
no ankyrinG clones were isolated.
Ankyrins bind to neurofascin at a highly conserved amino acid motif in their
cytoplasmic termini that ends with the amino acid motif FIGQY (Garver et al., 1997;
Zhang et al., 1998a). Figure 3-9 shows that this same motif is also required for the
NrCAM and ankyrin binding. If the tyrosine residue of FIGQY is phosphorylated
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ankyrin biding to neurofascin and LI is abolished (Garver et al., 1997; Tuvia el al.,
1997; Gil et al., 2003). Similarly when the tyrosine was mutated to a negatively
charged amino acid, glutamate, ankyrin binding to neurofascin was abolished (Zhang
et al., 1998b). A similar mutation of the NrCAM CT has shown the same effect. In
Figure 3-9 pAS2-l NrCAM Y86>E failed to bind to ankyrinR. Additionally a library
screen performed by Dr. F. Davey of the University of St Andrews using the pAS2-l
NrCAM Y86>E plasmid as bait did not select any ankyrin clones. The
phosphorylation of NrCAM at this tyrosine and its interaction with ankyrin will be
examined further in chapter six.
3.7.2 GIPC binding.
GAIP Interacting Protein C terminus (GIPC) (rat) (De Vries et al., 1998) was
cloned by several independent groups in the late 1990s and subsequently has several
names including Tax Interacting Protein -2 (TIP-2) (human) (Rousset et al., 1998),
GLUT1 C-terminal Binding Protein (GLUT1CBP) (rat) (Bunn et al., 1999),
Neuropilin-1 Interacting Protein (N1P-1) (rat) (Bunn et al., 1999), M-SemF
cytoplasmic domain associated protein (SEMCAP-1) (mouse) (Wang et al., 1999)
and synectin (mouse) (Gao et al., 2000). The Xenopus sequence was cloned in 2001
and is called Kermit (Tan et al., 2001). The GIPC family consists of three known
members GIPC (GIPC1), GIPC2, GIPC3. All three proteins have a central PDZ
domain and two conserved GEPC homology domains GH1 and GH2 (Katoh, 2002)
(Figure 3-6).
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The PDZ domain of GIPC is the only protein domain of known function within the
molecule. Table 3-6 shows the currently known binding partners of GIPC. 21 out of
25 of the binding partners interact with the PDZ domain of GIPC via their terminal
four amino acids. The consensus motif of these amino acids is X-S/T-X-V/A/L-
COOH (Table 3-6). From the PDZ classification system described by Harris and
Wendell this is a class 1 PDZ domain although a slightly atypical one in that it prefers
smaller hydrophobic residues at PO such as alanine and valine and not the bulkier
residue of isoleucine (Harris and Wendell, 2001). Importantly GIPC does not
necessarily require a hydrophobic residue at PO. This is illustrated by the integrin
subunit a6p where the PO amino acid is a serine (Tani and Mercurio, 2001) (El
Mourabit et al., 2002) and the LDH receptor, the Dopamine receptors D2 and D3 and
the CD93 receptor where the P0 amino acid is a cysteine. The P-2 residue shows a
similar promiscuity yet selectivity. In 18 out of 21 proteins it is a hydroxyl
containing serine or threonine residue but in Syndecan -4 the P-2 residue is a bulky
hydrophobic phenylalanine (Gao et al., 2000) and in the dopamine receptor it is a
leucine (Jeanneteau et al., 2004).
The part length GIPC clones selected from the library both possessed a PDZ
domain. Furthermore these clones appear to bind to the C-terminal end of the
NrCAM cytoplasmic terminus (Figure 3-9). The three most C-terminal amino acids
of NrCAM NSFV-COOH are described as a typical class I PDZ domain binding
motif (Bezprozvanny and Maximov, 2001; Harris and Wendell, 2001; Sheng and
Sala, 2001). The NSFV-COOH motif is also consistent with the amino acid motif X-
S/T-X-V/A/L-COOH that is preferred by the PDZ domain of GIPC. It was
investigated whether the GIPC library clones bound other LI family members. The
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cytoplasmic portion of both rat LI and rat neurofascin (Figure 3-9) were tested
against GEPC cDNA. GIPC did not interact with LI however GIPC did interact with
neurofascin. LI does not possess a PDZ domain-binding motif, as its C-terminal
amino acids are VALE-COOH. Neurofascin has a PDZ domain binding motif
YSLA-COOH and has been reported to bind to syntenin a PDZ domain containing
protein (Koroll et al., 2001). Furthermore this motif is in agreement with the amino
acid motif X-S/T-X-V/A/L-COOH that GIPC normally prefers. Taken together these
results suggest that NrCAM may be binding to PDZ domain found in the GIPC
clones. To confirm this the last three residues of the NrCAM cytoplasmic segment
were deleted. This prevented NrCAM from binding to GIPC (Figure 3-11). It was
decided to further investigate the interactions of NrCAM with GIPC by co-
localisation studies and pull-down assays. These results will be discussed in full in
chapter four.
3.7.3 SAPI02 binding.
SAP 102 is a member of the membrane associated guanylate kinase family proteins
(MAGUKs) that are composed of three tandem N-terminal PDZ domains followed by
a src homology 3 (SH3) domain and C-terminal guanylate kinase domain (GK). The
most characterised SAPI02 interaction has been with the NR2B subunit of the
NMDA receptor. All three PDZ domains of SAP102 interact with the C-terminal
(E)S/TXV/I/L-COOH amino acids of the NR2B subunits in vitro (Lau et al., 1996;
Muller et al., 1996). Phosphorylation of the serine in the NMDA receptor C-terminal
motif interferes with SAP102 binding and reduces NMDA receptor expression at the
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cell surface (Chung et al., 2004). The first two PDZ domains (and to a certain extent
the third) of SAPI 02 bind to Sec8, a member of the exocyst complex (Sans et al.,
2003) and the SAP102/Sec8 interaction may have a role in trafficking the NMDA
receptor to the plasma membrane (Sans et al., 2003). The majority of the other
published binding partners of SAP102 are also to one or more of its PDZ domains
and all of these proteins have an XS/TXV/I/L-COOH consensus motif in their
cytoplasmic segments (Table 3-5).
The part length SAP102 clones selected by the library screen possessed all three
PDZ domains of SAPI 02. Furthermore these clones appear to bind to the C-terminal
end of the NrCAM cytoplasmic terminus (Figure 3-9). The four most C-terminal
amino acids of NrCAM are NSFV-COOH and are consistent with an S/TXV/I/L-
COOH consensus motif. It was investigated whether SAP102 library clones bound
other LI family members (Figure 3-9). Neither LI nor neurofascin interacted with
SAP102. Neurofascin also has a PDZ domain binding motif of YSLA-COOH
(Koroll et al., 2001) that is not consistent with the S/TXV/I/L-COOH consensus motif
preferred by SAP102. This is due to an alanine substitution at the P0 position for the
larger valine, leucine or isoleucine residues. LI's C-terminal amino acids are VALE-
COOH and therefore it does not possess a PDZ domain-binding motif. Taken
together these results suggest that NrCAM may be binding to one or more PDZ
domains found in SAP102. Deletion of the terminal SFV-COOH residues ofNrCAM
confirmed this, as all binding to SAP102 was abolished (Figure 3-11). Therefore it
would appear that NrCAM is binding to one or more PDZ domains of SAP 102.
However it was noted that a plasmid of SAP102 (RL71D) that had all three PDZ
domain of SAP102 but no SH3 or GK domain (Figure 3-4) failed to interact with
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NrCAM in the experiment described by Table 3-4. This is surprising if all that
NrCAM needs to interact with SAP102 are functional PDZ domain. Notably RL71D
did not encode amino acids 534 to 623 of SAPI02 that were encoded by the RL48A
and RL29B plasmids that did interact with NrCAM (Figure 3-4). These amino acids
code for the SH3 domain of SAP102. It is therefore possible that SH3 domain of
SAP102 is necessary for NrCAM and SAP102 binding. It is also possible that the
amino acids 534 to 623 were necessary for the correct folding of the SAP 102 PDZ
domains and that misfolding of RL71D had occurred.
It was decided to further investigate the interactions of NrCAM with SAP102 by
co-localisation studies and pull-down assays. These results will be discussed in full
in chapter four.
3.7.4 The binding of the VHS domain of GGA1.
The library screen also identified the VHS domain of the GGA1 protein as a
potential interaction with the NrCAM cytoplasmic terminus. There are three GGAs
in humans, GGA1, GGA2 (Vear) and GGA3 (Boman et al., 2000; Dell'Angelica et
al., 2000; Hirst et al., 2000). The GGAs are localised to the trans Golgi network
(TGN) and vesicles in the cytoplasm (reviewed Boman, 2001) and deletion of the two
GGA genes found in yeast result in trafficking defects from the TGN to early/and or
later endosomes (reviewed Boman, 2001). Thus the GGA proteins are believed to
function mainly in the trafficking receptors from the trans Golgi network (TGN) to
the early/late endosome (Bonifacino, 2004). All three human GGAs have been
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highly conserved throughout evolution and are believed to bind to and traffic the
same receptors (Boman, 2001; Bonifacino and Traub, 2003).
The VHS domain of the GGAs are essential for their trafficking function (Hirst et
al., 2001) and recognise DXXLL (where D is an essential aspartate, X can be any
amino acid and LL are two hydrophobic residues (normally both leucine)) amino acid
motifs in cytoplasmic terminus of receptors (Bonifacino, 2004). These signals are
present in several transmembrane proteins and cargo proteins that cycle between the
trans Golgi network (TGN) and the endosome. Mannose-6-phosphate receptors
(M 6-Ps) and sortilin are receptors for newly synthesised acidic hydrolases and
neurotensin respectively (Nielsen et al., 2001; Bonifacino and Traub, 2003). Both
receptors have a DXXLL motif in their cytoplasmic termini and the VHS domain of
GGAs is thought to sort receptors from the TGN to the endosome (Nielsen et al.,
2001; Puertollano et al., 2001; Bonifacino and Traub, 2003).
Three rules for recognition of the VHS domain of amino acids in the cytoplasmic
segment of receptors have been defined by (Bonifacino, 2004):
1. The cytoplasmic terminus of the receptor must contain an "acidic cluster
dileucine" or DXXLL sequence (Bonifacino, 2004). There are two notable features
of this motif: a.) the dileucine repeat can sometimes be replaced by other hydrophobic
residues for example in SorLA the dileucine is replaced by a methionine and a valine
(i.e. DXXMV not DXXLL) (Jacobsen et al., 2002). b.) the essential aspartate of the
DXXLL is often found near a cluster ofacidic residues (Bonifacino, 2004).
2. Serine residues are often found within or one to three positions N-terminal to
DXXLL signals. For example the VHS domain of GGA1 binds to the DISLL
sequence of BACE, the serine of which can be phosphorylated. Phosphorylation of
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the serine increases the affinity of GGAs for the BACE protease (He et al., 2003;
Shiba et al., 2004; von Arnim et al., 2004).
3. The sequence is usually located near to the carboxyl terminus of the receptor
(reviewed Bonifacino, 2004). However this is not always true, for example both
GGA1 and GGA3 have a DXXLL motif in their hinge domain. These sequences can
bind to the VHS domain of the same protein and both of these sequences are
significantly upstream of the C-terminal end of the GGA protein (Doray et al., 2002).
If you apply these rules to Ll-CAMs there are two potential "acidic cluster
dileucine" sequences in their ankyrin binding domains as shown by Figure 3-12. The
first is a DXXLV/A motif and the second is a DXXFI motif (Figure 3-12). All of
these motifs have essential aspartate residues in acidic clusters (D and E residues are
shown in yellow). All of the potential motifs have a serine (shown in red font) within
the DXXLL sequence (number 64 and 81 for NrCAM) and the first potential DXXLL
has a serine one amino acid N-terminal to the DXXLL sequence (number 61 for
NrCAM). Interestingly an aspartate residue that may provide a COOH group that
mimics the C-terminal of a chain of amino acids follows the first DXXLV/A amino
acid sequence. Thus both of these sequences would satisfy the criteria described by
(Bonifacino, 2004) above.
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L1 CT L G D| D * * * * G G S V D V Q F N E G G Q Y
Neurofascin CT Q E S D D L V D Y G E G G E G Q F N E D G F 1 G Q Y
NrCAM CT E D D 0 L V D Y G E G V N G Q F N E D G S F 1 G Q Y
NrCAMY86<E E D D D L V D Y G E G V N G Q F N E D G Q F 1 G Q E
aa number NrCAM 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86
""Normally L1 would have LADY in this position.
Figure 3-12. The potential GGA-VHS binding amino acid sequences of the Ll-
CAM family plasmids used in this thesis. Boxed are the ankyrin binding
domains. Highlighted in blue are essential aspartates. Highlighted in green are
dileucine like repeats. Highlighted in yellow are acidic clusters. Potentially
important serine residues are shown in red font. Numbers are the amino acid
position of the residue in the cytoplasmic terminus of rat NrCAM (without
RSLE). See text for details.
The NrCAM and neurofascin plasmids used in Figure 3-9 both have a DXXLV
motif in their cytoplasmic terminus and both bound to the VHS plasmid (Figure 3-
12). The LI cytoplasmic terminus used in this assay was missing the normal LADY
amino acid sequence found in the cytoplasmic terminus of most LI isoforms and did
not have the first DXXLA sequence normally found. This sequence did not bind to
the VHS of GGA1 (Figure 3-9 and Figure 3-12). Thus there is some evidence that
the DXXLV/A sequence may be necessary for VHS binding. However pAS2-l
NrCAM Y86<E has a normal DXXLV sequence but did not bind to the VHS
plasmid. It is unclear as to why a substitution of a glutamic acid for a tyrosine should
interfere with VHS binding. Perhaps the negative residue causes a conformational
change in the ankyrin-binding domain?
Thus, it is concluded that the highly conserved ankyrin bind site of the LI-CAM
family has the potential to bind to the VHS domain of the GGAs. The possible
functions of the VHS domain binding to NrCAM interaction are discussed in Chapter
7.
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Chapter 4. The examination of the potential
interactions between NrCAM and GIPC/
SAPI02.
r
4.0 Introduction: The potential cytoplasmic binding partners of
NrCAM.
In Chapter 3, three putative NrCAM binding partners were identified GIPC,
SAP102 and the VHS domain of GGA1. Both GIPC and SAPI 02 interacted with the
C-terminal class 1 PDZ binding motif of NrCAM, and the VHS domain interacted
with the ankyrin-binding domain of NrCAM. The amino acid sequences within the
cytoplasmic tail of NrCAM to which GIPC, SAP102 and the VHS domain bound,
were consistent with similar conserved amino acid sequences in the cytoplasmic tails
of other membrane proteins already known to interact with GIPC, SAP102 and the
VHS domain. Mutation studies of the NrCAM cytoplasmic tail showed that there
were essential amino acids in for these interactions, the elimination/mutation of
which prevented the NrCAM/putative binding partner interaction. The case for
NrCAM binding was further strengthened as the putative interacting proteins all had
different binding profiles among the LI-CAM family and the binding appeared
dependent on certain conserved amino acids.
However, it remained to be shown whether these interactions were biologically
relevant. Therefore, a set of experiments was designed to establish whether NrCAM
was expressed at the same time and place as the putative binding partners thus
making biological interactions between the proteins possible. A second set of
experiments were attempted to reconfirm the interaction within mammalian cell
extracts. It was hoped that the times and locations within the brain/cell that the
NrCAM putative binding partner interaction occurs, as established by these
experiments, would suggest the biological role of these interactions.
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As both the GIPC and SAP102 interactions with NrCAM were likely to be similar
(they were both interacting with the last three amino acids of NrCAM's cytoplasmic
tail) they were further analysed first.
4.1 Are NrCAM and the potential binding partners expressed at
the same time in brain development?
4.1.1 Western blot analysis of early brain development.
To ensure that it is feasible for NrCAM to bind to the PDZ proteins both NrCAM
and the respective PDZ protein should be expressed in the brain at the same time.
Brains were dissected from rat embryos/pups at embryonic day 14 (E14), El6 and
E20 and postnatal day 7 (P7). It had been previously reported that SAP] 02 did not
readily solubilise in most detergents (Muller et al., 1996) therefore freshly prepared
rat brains were homogenised by sonication and solubilised in 2 % sodium dodecyl
sulfate (SDS) as described in (2.3.6). 100 pg of brain samples were separated on two
10 % SDS-PAGE gels (for NrCAM and SAP102 immunostaining) and one 12 %
SDS-PAGE gel (for GIPC immunostaining) and transferred onto nitrocellulose
transfer membrane. The membranes were probed with antibodies for NrCAM, GIPC
and SAP102 as described in section (2.3.10) and appendix (3).
NrCAM showed increased expression in the rat brain during embryonic and
postnatal development (Figure 4-1). The biggest change in NrCAM expression
occurred between El 4 and El 6. A minimum of two bands was seen at all stages of
development from E20 onwards. One was a lower molecular weight band of
approximately 110 kDa. A large diffuse band of approximately 160 kDa to 200 kDa
was much more strongly expressed. At P7 there was a third NrCAM band of
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approximately 116 kDa. The multiple protein sizes of NrCAM may reflect either
N-linked glycosylation of the extracellular domains or furin protease like cleavage
within the third fibronectin like (FNIII-like) domain of NrCAM. Both of these
possibilities are examined in Chapter 6. However it was noted at this stage that the
larger molecular weight of NrCAM was predominant in all brain samples and was





Figure 4-1. NrCAM, GIPC and SAP102 expression in developing brain.
A) NrCAM expression in rat developing brain. B) GIPC expression in rat
developing brain. C) SAPI 02 expression in rat developing brain. Lanes 1 to 4
are 100 pg of rat brain homogenates of various ages: Lane 1 is El4, lane 2 is
E16, lane 3 is E20 and lane 4 is P7. For methods see section 2.3.10 and appendix
3.
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GIPC did not show changes in expression level during embryonic and postnatal
development. One band of approximately 39 kDa was seen for all brain
developmental stages tested (Figure 4-1). SAP102 was not detectable on Western
blot at E14 (Figure 4-1). At El 6 SAP102 was detected as a single band of
approximately 100 kDa. SAP102 expression levels remained at the El 6 expression
level at E20 and P7.
Therefore in summary both NrCAM and GIPC were expressed at all
developmental stages tested. GIPC expression levels remain constant while NrCAM
expression levels greatly increased at E16. SAP102 was not expressed at a detectable
level until El6, which coincides with NrCAM's rapid increase in expression levels.
Thus it appears that SAP102 but not GIPC may be developmentally regulated in
whole brain in a similar manner to NrCAM. In order for NrCAM to interact with
either GIPC or SAP102 both proteins must be expressed in the same subset of
neurons/glial cells. Therefore it was decided to see if GIPC and SAP 102 were
expressed in a particular neuronal population that was already known to express
NrCAM.
4.1.2 NrCAM and the PDZ proteins are expressed in the same neurons.
NrCAM was found in cerebellar granule cells (CGCs) where it has an important
role in granule cell migration and development (Krushel etal., 1993; Faivre-Sarrailh
et al., 1999; Sakurai et al., 2001). Hence it was decided to see if GIPC and SAP102
were also present in CGCs. CGCs were extracted from P7 mouse pups and cultured
on poly-D-lysine coated 90 mm dishes. The CGCs were cultured for up to seven
days and cell extracts were prepared by solubilising the cells in 1 % Triton-XlOO in
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the presence of protease inhibitors as described in section (2.3.6). 90 pg CGC
samples were separated on two NuPAGE® Novex 6-12% Bis-Tris Gels (for G1PC
and SAP 102 immunostaining) and one NuPAGE® Novex 3-8% Tris-Acetate gel (for
NrCAM immunostaining) and transferred onto nitrocellulose transfer membrane (see
section 2.3.9). The membranes were probed for NrCAM, GIPC and SAP102 as
described in section 2.3.10 and appendix 3.
NrCAM did not show changes in expression level during development of CGCs in
vitro (Figure 4-2). A minimum of two bands was seen at all stages of development.
One was a lower molecular weight band of approximately 130-140 kDa the second
band was approximately 180 kDa. At later stages of development there was a third
band of approximately 170 kDa. The NuPAGE® Novex 3-8% Tris-Acetate together
with HiMark™ protein markers gives an accurate measurement of high molecular
weight proteins when compared to other SDS-PAGE gels and markers
(http://www.invitrogen.com) and thus the sizes of NrCAM on this gel were
considered more accurate than the sizes shown in Figure 4-1. This will be discussed
further in Chapter 6. Unlike the whole brain samples in Figure 4-1 the lower
molecular weight bands of NrCAM were more heavily expressed than the larger
molecular weight bands.
GfPC expression in CGCs increased after three days in vitro but did not show
changes in expression level thereafter. One band of approximately 39 kDa was seen
for all CGC developmental stages tested (Figure 4-2). SAPI 02 expression in CGCs
did not show changes in expression level for up to seven days in vitro. One band of
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Figure 4-2. NrCAM, GIPC and SAP 102 expression in CGCs. A) NrCAM
expression in CGCs. B) GIPC expression in CGCs. C) SAPI 02 expression in
CGCs. Lanes 1 to 6 are 90 pg CGC extracts ofvarious days in vitro (D1V): Lane
1 one DIV, lane 2 is two D1V, lane 3 is four DIV, lane 4 is five DIV and lane 6 is
seven DIV. For methods see section 2.3.10 and appendix 3.
In summary NrCAM, GIPC and SAP102 were expressed by CGCs that were
cultured for up to 7 DIV. At 3 DIV, all three proteins were at their maximum
expression levels and this expression remained constant up to 7 DIV.
126
4.2 Sub-cellular location of NrCAM, GIPC and SAP102.
Thus both GIPC and SAP102 were expressed in CGCs cultured in vitro. However
if NrCAM interacts with one or both of the PDZ proteins, both NrCAM and the PDZ
protein should be expressed in the same part of the cell at the same times. Ideally
CGCs would be immunostained for endogenous levels of NrCAM, GIPC and
SAP102 and areas of co-localisation would be identified as areas where the two
proteins could potentially interact within the cell.
4.2.1 GIPC co-localisation studies.
4.2.1.1 HA-NrCAM and endogenous GIPC co-localisation in HEK293 cells.
A kind gift of a plasmid vector encoding for HA-NrCAM was received from Dr.
Faivre-Sarrailh, Marseille, France. It encoded for the signal peptide of NrCAM
followed by the HA epitope (YPYAVPDYA) followed by the full-length rat NrCAM
sequence (as published Davis et al., 1996). The vector encoding for HA-NrCAM
cDNA was transfected into Human Embryonic Kidney 293 (HEK293) cells and the
cells that stably expressed the vector were selected by G418 antibiotic containing
media as described in section 2.2.8. Figure 4-3 shows a Z-section of the upper
surface of a single HEK293 cell stably expressing HA-NrCAM. It shows a punctate
HA-NrCAM immunostaining in the plasma membrane, as Z-sections below this
image showed decreasing HA-NrCAM immunostaining except at the edges of the cell
(not shown). Therefore, GIPC immunostaining shown in Figure 4-3 is near to or just
below the plasma membrane. GIPC immunostaining was punctate in its appearance
as had been previously reported (Lou et al., 2001) and in contrast to HA-NrCAM,
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punctate GIPC immunostaining was seen throughout the cytoplasm in lower Z-
section (not shown). As indicated by arrows in Figure 4-3 (C), HA-NrCAM and
GIPC showed areas of co-localisation in the plasma membrane.
4.2.1.2 HA-NrCAM and endogenous GIPC co- localisation in B104 cells.
To determine whether this co-localisation was cell type specific, B104
neuroblastoma cells stably expressing the same HA-NrCAM construct were also
immunostained for NrCAM and GEPC expression (HA-NrCAM stably transfected
B104 cells were a kind gift from Dr. Faivre-Sarrailh, University of Marseille,
France). As indicated in Figure 4-4 GIPC co-localised with stably expressed HA-
NrCAM at the plasma membrane in regions of HA-NrCAM expression. Thus, GIPC
co-localisation with stably expressed HA-NrCAM was not cell type specific.
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Figure 4-3. A Z Section of a HEK293 cell stably expressing HA-NrCAM. A)
HA-NrCAM immunostaining was performed using an anti-HA rat monoclonal
antibody and anti-mouse Alexa 568 conjugated antibody and is shown in red. B)
Endogenous G1PC immunostaining was performed using a goat antibody to the
N-terminus of GIPC and an anti goat FITC conjugated antibody and is shown in
green. C) Co-localisation between both proteins occurs were HA-NrCAM is most
highly expressed (arrows). The nucleus of the cell has been stained with DAPI
and is shown in blue. See methods 2.2.10.
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NrCAM
Figure 4-4. A Z Section of a B104 cell stably expressing HA-NrCAM. A) HA-
NrCAM immunostaining was performed using an NrCAM rabbit polyclonal
antibody and anti-rabbit Alexa 568 conjugated antibody and is shown in red. B)
Endogenous GIPC immunostaining was performed using a goat antibody to the
N-terminus of GIPC and an anti goat FITC conjugated antibody and is shown in
green. C) Co-localisation between both proteins occurs at (arrow). The nucleus
of the cell has been stained with DAPI and is shown in blue. See methods 2.2.10,
appendix 3B.
4.2.1.3 Co-localisations studies of GIPC1.3GFP with HA-NrCAM.
The partial co-localisation of GIPC and NrCAM suggested that this interaction
could be transient. Therefore, it was decided to explore real time imaging as a means
of investigating this further. To make live imaging possible it was therefore decided
to C-terminally tag the part length GIPC clone, selected from the cDNA library in
Chapter 3, with Green Fluorescence Protein (GFP). The cloning of this construct is
shown in Figure 4-5 and was called GIPC1.3-GFP. The GIPC1.3-GFP construct was
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designed to remove any sequence 5' or 3' not normally translated from the cDNA





1. A mouse GIPC image clone
(accession number BC003490) was
used as a PCR template. It also
contained nucleotide sequence 5'
and 3' of the GIPC sequence.
2. PCR primers GIPC 1 and GIPC 6A were designed to: 1) eliminate 5' and 3'
DNA that does not encode for GIPC amino acids (see 3.2.4). 2) to add the EcoRI
(GIPC 1) and BamHI (GIPC 3) restriction enzyme sites to the GIPC encoding
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3. The amplified PCR product "GIPC 1-6"
and the empty plasmid pSPORT were
digested with the restriction enzymes,
EcoRI and BamHI. The PCR product and
the cut vector were ligated together and
then transformed into DH5a. This
resulted in the production of a new
plasmid called pSPORT GIPC 1-6.
Figure 4-5. Continued on next page.
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4. The plasmid construct pSPORT
GIPC 1-3 was digested using
restriction enzymes EcoRI and
















5. The empty pEGFP plasmid was digested with restriction enzymes EcoRI and
BamHI, and then purified. The purified "GIPC 1 -3" DNA fragment and the cut
vector were ligated together and transformed into DH5a. This resulted in the
production of a new plasmid construct called GIPC1-3-GFP which was sent for
DNA sequencing.
Figure 4-5. Cloning strategy for the production of the plasmid GIPC1.3-GFP. Detail
of material and methods are described in Chapter 2 and accompanying text.
The GIPC1-3-GFP construct was transfected into COS-7 cells, HEK293 cells and
B104 cells (section 2.2.5). In all of the cell-lines examined, GIPC1.3-GFP expression
was not punctate (as had been recorded for endogenous GIPC (Figure 4-3 and Figure
4-4)) but was diffuse throughout the cytoplasm and nucleus of the cell. An example
of GIPC1-3-GFP in a COS-7 cell can be seen at Figure 4-6.
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Figure 4-6. t he expression pattern of GIPC1.3-GFP in a COS7 cell.
Despite this observation, the co-expression of NrCAM may have influenced the
distribution of GIPC1.3-GFP or vice versa. To test this HEK293 and COS-7 were
co-transfected with full length NrCAM (a kind gift from Prof. Vann Bennett, Howard
Hughes Medical Institute, Maryland, USA) and GIPC1.3-GFP. However, co-
expression of NrCAM and GIPC1.3-GFP did not show any detectable change in either
NrCAM or GIPC1-3-GFP distribution when compared to cells expressing either
NrCAM or GIPC1.3-GFP individually (image not shown). Thus, it was concluded
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that the GIPC1.3-GFP construct was not showing normal GIPC expression patterns
and did not show any distinguishable association with NrCAM.
4.2.1.4 Co-localisations studies of GIPC1-6-GFP with FIA-NrCAM
It had been noted when carrying other experiments discussed in Chapter 6 that a
partial length clone of ankyrin-GFP occasionally mistargeted to the nucleus and
whereas a full-length clone of ankyrin-GFP did not localise to the nucleus and co-
localised with NrCAM expression. Furthermore, the GIPC 1.3-GFP clone codes for
amino acid 1 to 215 of rat GIPC. Amino acid 215 is the last amino acid of the PDZ
domain and tagging a GFP protein to it may have interfered with correct folding of
the PDZ domain. It was also possible that amino acids 216 to 333 may be required
for the correct targeting of the protein to vesicles. Hence, it was decided to
C-terminally tag a full length GIPC construct with GFP and examine its cellular
localisation.
The cloning of this construct is shown in Figure 4-7 and the plasmid codes for full
length murine GIPC (accession number BC003490) obtained from a mammary
tumour library supplied by the IMAGE consortium (Lennon et al., 1996) followed by
the GFP protein. This plasmid construct was called GIPCi-e-GFP and was transfected






1. A mouse GIPC image clone
(accession number BC003490) was
used as a PCR template. It also
contained nucleotide sequence 5'
and 3' of the GIPC sequence.
2. PCR primers GIPC 1 and GIPC 6A were designed to: 1) eliminate 5' and 3'
DNA that does not encode for GIPC amino acids (see 3.2.4). 2) to add the EcoRI
(GIPC 1) and BamHI (GIPC 3) restriction enzyme sites to the GIPC encoding













3. The amplified PCR product "GIPC 1-6"
and the empty plasmid pSPORT were
digested with the restriction enzymes,
EcoRI and BamHI. The PCR product and
the cut vector were ligated together and
then transformed into DH5a. This
resulted in the production of a new
plasmid called pSPORT GIPC 1-6.
Figure 4-7. Continued on next page.
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4. The plasmid construct pSPORT
GIPC 1-6 was digested using
restriction enzymes EcoRI and
BamHl. The fragment containing
GIPC was purified.
5. The empty pEGFP plasmid was digested with restriction enzymes EcoRI and
BamHI, and then purified. The purified "GIPC 1 -6" DNA fragment and the cut
vector were ligated together and transformed into DH5a. This resulted in the
production of a new plasmid construct called GIPCi^-GFP which was sent for
DNA sequencing.
Figure 4-7. Cloning strategy for the production of the plasmid GIPCi^-GFP
Details of material and methods are described in Chapter 2 and accompanying text.
GIPCi-6-GFP showed a cytoplasmic expression pattern similar to that which was
observed with the truncated GIPC1-3-GFP construct. However, in at least 50 % of
both COS-7 and HEK293 cells examined it was excluded from the nucleus (data not
shown). Unfortunately, no punctate immunostaining of GIPCi.6-GFP was evident in














Figure 4-8. Transient expression in a COS-7 cell of NrCAM and GIPCi_6-GFP.
A) Full-length rat NrCAM (NrCAM immunostaining was performed using an
NrCAM rabbit polyclonal antibody and anti-rabbit Alexa 568 conjugated antibody
and is shown in red). B) full-length murine GIPCi_6-GFP (green). C) Co-
localisation between both proteins did not occur. See methods 2.2.10.
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4.2.2 SAP102 co-localisation studies.
4.2.2.1 GFP-SAP102 transfected cells.
As there was no antibody suitable for the immunocytochemistry of SAPI 02 it was
therefore decided to perform co-localisation of HA-NrCAM transfected cells with
full length rat SAPI 02 N-terminally tagged with GFP (a kind gift from Dr. N. Sans,
National Institute in Deafness and other Communication Disorders, Maryland,
USA ). This cDNA construct was transfected into both COS-7 cells and CGCs by Dr
F. Davey of the University of St Andrews. Unfortunately, Dr. Davey reported that
this construct mistargeted. This mistargeting could have been due to the large size of
the GFP proteins at the N-terminal end of the SAP102 protein. Therefore, it was
decided to N-terminal tag SAP102 with the smaller FLAG epitope (DYKDDDDKG).
4.2.2.2 Cloning and transfection of the FLAG-SAPI 02 plasmid construct.
A FLAG-tagged SAP102 construct (FLAG-SAP102) was generated by
sub-cloning the SAP102 cDNA isolated in the rat brain library screen (RL29B), into
pCMV-Tag 2A (Stratagene) by Dr F. Davey of the University of St Andrews (Davey
et al., 2005).
This construct was co-transfected with HA-NrCAM into COS-7 cells grown on
glass cover-slips as described in section 2.2.5. The cells were immunostained for
HA-NrCAM and FLAG-S API 02 using monoclonal antibodies to the N-terminal
epitopes as described in section 2.2.10. Figure 4-9 shows a Z-section of a single
COS-7 cell. Patches of co-localisation of HA-NrCAM and FLAG-SAPI 02 was seen
at or near the membrane of most COS-7 cells. However it was most noticable in a
small percentage of cells that had HA-NrCAM localised to "microvilli like"
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membrane protrusions (Figure 4-9). The localisation of HA-NrCAM to the membrane
protrusions occurred when SAP102 was not transfected and was therefore not
dependent on the presence of SAP102. Similarly, the localisation of SAP102 to the
membrane protrusions occasionally occurred when HA-NrCAM was not transfected
and was therefore not dependent on the presence of NrCAM in the cells. Therefore,
transiently expressed HA-NrCAM and FLAG-SAP102 co-localise at regions of
intense HA-NrCAM immunostaining in the plasma membrane of COS-7 cells. To
show that this was not cell type specific and that this could also occur in neurons.
CGCs were also transiently transfected by Dr F. Davey of the University of St
Andrews with HA-NrCAM and FLAG-SAP102. She reported punctate co-
localisation of both proteins at the cell body, along the axon and notably at the
endings of the neurons (Davey et al., 2005). Thus, FLAG-SAP102 co-localisation
with transiently expressed HA-NrCAM was not cell type specific.
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Figure 4-9. Transient expression in a COS-7 cell of HA-NrCAM and FLAG-
SAP 102. A) HA-NrCAM and B) FLAG-SAP 102. HA-NrCAM immunostaining
was performed using an anti-HA rat monoclonal antibody and anti-mouse Alexa
568 conjugated antibody and is shown in red. FLAG-SAP 102 immunostaining
was performed using a mouse monoclonal antibody to the N-terminal FLAG
epitope of FLAG-SAP 102 and an anti-mouse antibody conjugated to F1TC and is
shown in green C) Co-localisation between both proteins occurs close to the
membrane (yellow). See methods 2.2.10.
4.3 Immunoprecipitation studies.
4.3.1 Immunoprecipitations.
It had been shown that both GIPC and SAP102 could be expressed at the same
place and time as NrCAM. However to confirm that these proteins interact further
biochemical assays were necessary.
4.3.1.1 Immunoprecipitation of HA-NrCAM using protein A.
As the antibody to the extracellular portion of NrCAM was unsuitable for
immunoprecipitation (personal communication Dr. Faivre-Sarrailh, University of
Marseille, France) it was therefore decided to target the HA epitope of the HA-
NrCAM construct for immunoprecipitation. B104 cells stably expressing
HA-neurofascin had been successfully used to immunoprecipitate neurofascin
(Garver et al., 1997). It was therefore decided to try immunoprecipitating HA-
NrCAM from B104 cells stahly expressing rat HA NrCAM.
Initially an immunoprecipitation of HA-NrCAM and its binding partner(s) was
attempted using anti-HA antibodies complexed to protein A bound in turn to
sepharose beads as described in 2.3.12. This method is described diagrammatically
by Figure 4-10 (A). This assay was attempted several times. However, it was never
possible to immunoprecipitate out detectable levels of NrCAM using this method. A












Figure 4-10. Immunoprecipitation of HA-NrCAM using protein A. A) A
diagrammatic representation of the immunoprecipitation of HA-NrCAM using
protein A and antibodies to the HA epitope. B) A Western blot of an unsuccessful
attempt to immunoprecipitate HA-NrCAM using a polyclonal anti-HA anti body
and protein A. Lanes 1 and 2 are 75 pg of cell extract of B104 cells stably
expressing HA-NrCAM and lanes 3 and 4 are the proteins immunoprecipitated
from cell extract 1 and 2 respectively. The blot was probed with an anti-HA rat
monoclonal antibody as described in section 2.3.10 and appendix 3.
4.3.1.2 Immunoprecipitations of HA-NrCAM using anti-rat IgG beads.
Another approach was made to immunoprecipitate out HA-NrCAM and its
binding partner(s) using rat monoclonal anti-HA antibodies bound by anti-rat IgG
complexed in turn to agarose beads. This method is described diagrammatically by
Figure 4-11 (A) and is described in section 2.3.13. Briefly approximately 4 mg of
protein extract from B104 cells stably expressing HA-NrCAM extract was tumbled
with 4 pi rat monoclonal anti-HA antibodies and 8 pi of anti-rat IgG agarose beads.
Detectable levels of HA-NrCAM were immunoprecipitated using this method as
shown in Figure 4-11 (B). A 38 kDa band was present in the crude cell extract when
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the blot was probed with an anti-GIPC antibody (Figure 4-11 (C)). Two strong bands
of approximately 25 kDa and 49 kDa were present in the immunoprecipitated extract
probed with an anti-GIPC antibody (Figure 4-11 (C)). These bands were probably
the result of the secondary anti-mouse-HRP conjugated antibody binding to the light
and heavy chains of the anti-HA rat monoclonal antibody used in the
immunoprecipitation experiment. Between the IgG bands of lane 4 there were two
weaker bands of approximately 39 kDa and 42 kDa. As the lower of these two bands
could possibly be immunoprecipitated GIPC it was therefore decided to repeat the
experiment as before except the amount of HA-NrCAM expressing B104 cell extract
was increased to 7.5 mg. A 4-12% gel was run using a MES buffer as this favoured
the greater separation of lower molecular weight proteins
(http://www.invitrogen.com). Proteins were transferred to nitrocellulose and probed
for GIPC initially, stripped of antibodies and then probed for NrCAM (Figure 4-12).
As indicated by Figure 4-12, a 38 kDa band was present in the crude cell extract
when the blot was probed with an anti-GIPC antibody. Two strong bands of
approximately 25 kDa and 49 kDa were again present in the immunoprecipitated
extract probed with an anti-GIPC antibody, representing the light and heavy chains of
the anti-HA rat monoclonal antibody used in the immunoprecipitation experiment.
Between the IgG bands there were two weaker bands of approximately 30 kDa and
40 kDa. As it was possible that the 40 kDa band was GIPC it was decided to confirm
















Figure 4-11. Immunoprecipitations of HA-NrCAM using anti-rat IgG beads A)
A diagrammatic representation of the immunoprecipitation of HA-NrCAM using
protein Anti-rat IgG agarose beads and anti-HA rat antibodies.
B) A Western blot of an immunoprecipitatation of HA-NrCAM. Lane 1 is 75 pg
of cell extract of B104 cells stably expressing HA-NrCAM and lanes 2 is HA-
NrCAM immunoprecipitated from cell extract 1. HA- NrCAM was probed using
an anti-HA rat monoclonal antibody. C) The Western blot shown in (B) stripped
of primary and secondary antibodies and reprobed for GIPC. GIPC was probed






Figure 4-12. A Western blot of immunoprecipitated HA-NrCAM probed for
GIPC. Lane 1 is 75 pg of cell extract of B104 stably expressing HA-NrCAM and
lane 2 is all of the proteins immunoprecipitated from the cell extract in lane 1.
GIPC was probed using an N-terminal GIPC antibody. See section 2.3 for
methods and appendix 3.
4.3 .1.3 Immunoprecipitations of GIPC using anti-GIPC antibodies.
Approximately 75 mg of HA-NrCAM expressing B104 cell extract was prepared
as described in 2.3.5. This extract was divided into two. One-half was tumbled
with 8 pi anti Goat IgG conjugated agarose beads and 4 pi goat anti-GIPC antibody.
The second half was tumbled with 8 pi anti-mouse agarose beads and 4 pi
monoclonal mouse anti-c-Myc antibody. Immunoprecipitations were carried out as
described in 2.3.14. The immunoprecipitated products of both fractions were
separated on a NuPAGE® Novex 6-12% Bis-Tris gel. The gels was transferred onto
nitrocellulose membrane and probed for HA-NrCAM using a rabbit polyclonal
antibody to the IgG regions of NrCAM. The membrane was stripped of primary and
secondary antibodies and reprobed using a goat anti-GIPC antibody (section 2.3 for
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Figure 4-13 Immunoprecipitations of GIPC using anti-GLPC antibodies.
A) A diagrammatic representation of the immunoprecipitation of GIPC using
anti-goat IgG agarose beads and anti-GIPC antibodies raised in goat. B) A
negative control of anti c-Myc antibodies. C) and D ) Western blots of 75 pg of
crude cell extract of HA-NrCAM expressing B104 cells (lane 1) and of proteins
immunoprecipitated using anti c-Myc antibodies (lane 2) and anti-GIPC
antibodies (lane 3). C) was probed using a polyclonal anti-NrCAM. D) is the
same blot as C) stripped of anti-NrCAM antibody and reprobed for GIPC using a
goat anti-GIPC antibody. See section 2.3 for methods and appendix 3.
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As shown in Figure 4-13 (C) HA-NrCAM was present as a single band in the
crude cell extract (lane 1), it was not immunoprecipitated using anti c-Myc antibodies
(lane 2) or anti-GIPC antibodies (lane 3). The membrane was stripped and reprobed
with anti-GIPC antibodies (lanes 4 and 5). Strong bands of approximately 25 kDa
and 55 kDa were present in the immunoprecipitated extract of lane 5 but not lane 4.
These bands were the result of the secondary anti goat-HRP conjugated antibody
binding to the light and heavy chains of the anti-GIPC goat antibody used in the
immunoprecipitation experiment. These bands were highly immunoreactive and
masked any potential signal at 39 kDa from immunoprecipitated G1PC. Therefore,
using this approach it was not possible to determine whether GIPC had been
successfully immunoprecipitated.
4.3.2 The effect of furin cleavage on the immunoprecipitation ofNrCAM.
It has been reported that NrCAM, unlike neurofascin, can be cleaved within the
extracellular domain by furin like proteases (Grumet, 1997), thereby making
immunopiecipilation studies difficult for NrCAM. This was a possible explanation
for the two/three protein bands seen for NrCAM expression in brain extracts (Figure
4-1 (A)) and CGCs (Figure 4-2 (A)). If NrCAM is furin cleaved it may still associate
with itself (at its third FNIII-like domain) and it may be possible to
immunoprecipitate out cytoplasmic binding partners using an antibody to the
extracellular membrane region (Figure 4-14 (B)). For example it was possible to
immunoprecipitate both furin cleaved segments of tractin (the LI family member in
leech) (Xu et al., 2003). However, if NrCAM is furin cleaved and does not associate
with itself then antibodies to the extracellular domain N terminal of the FNIII-like
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domain will not immunoprecipitate out the cytoplasmic region of NrCAM.
Therefore, it will not immunoprecipitate any potential cytoplasmic binding partners
(Figure 4-14(C)). In all of the immunoprecipitations attempted above only one band
was seen for HA-NrCAM in B104 cells. It was important to establish whether this
band represented full-length HA-NrCAM or HA-NrCAM that had been furin cleaved
and this was studied in detail in Chapter 6. From this study, a HA-NrCAM construct
that did not contain the third FNIH-like domain was engineered and named
HA-NrCAM AFN2&3. HA-NrCAM AFN2&3 cannot be furin cleaved and was used
to design the immunoprecipitation experiment described by Figure 4-15(A).
A. Uncleaved NrCAM
B. Cleaved and self associating NrCAM
C. Cleaved NrCAM
O* *
Figure 4-14. Immunoprecipitations of cleaved and uncleaved HA-NrCAM. Anti-HA
antibodies and beads can be used to precipitate HA-NrCAM and its cytoplasmic
binding partners when A) NrCAM is not furin cleaved or B) NrCAM is cleaved but
still associated with itself at is third FNIII-like domain. However if C) NrCAM is
cleaved by furin but does not associate with itself, antibodies to HA will not
immunoprecipitate the cytoplasmic terminus ofNrCAM or any of its binding partners.
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4.3.2.1 Immunoprecipitations ofHA-NrCAM AFN2&3 using anti-HA beads.
HEK293 cells were transiently transfected with the HA-NrCAM AFN2&3
construct as described in section 2.2.5. Approximately 8 mg of transfected HEK293
cell extract was prepared as described in 2.3.5. This extract was divided in two.
One-half was tumbled with 40 pi anti-HA IgG conjugated agarose beads. The other
half was tumbled with 40 pi anti-mouse agarose beads. Immunoprecipitations were
carried out as described in 2.3.15. The immunoprecipitated products of both halves
were separated by SDS PAGE electrophoresis and a Western blot carried out using a
goat anti-GIPC antibody. The membrane was stripped and reprobed for
HA-NrCAM AFN2&3 using a rat anti-HA monoclonal antibody (see section 2.3). As
shown in Figure 4-15 (C) lane 5, HA-NrCAM AFN2&3 was successfully
immunoprecipitated as a single diffuse band of protein between 100 and 160 kDa. A
negative control using anti-mouse beads showed no immunoprecipitated protein as
would be expected (Figure 4-15 (C) lane 6). GIPC was present in the crude cell
extract (Figure 4-15 (C) lane 1 but was not immunoprecipitated with
HA-NrCAM AFN2&3 (Figure 4-15 (C) lane 3). Therefore GIPC had not been
successfully immunoprecipitated with HA-NrCAM AFN2&3 using the conditions



















Figure 4-15. Immunoprecipitation of HA-NrCAM AFN2&3 using anti-HA beads.
A) A diagrammatic representation of the immunoprecipitation of
HA-NrCAM AFN2&3 using agarose beads conjugated to monoclonal anti-HA
antibodies. B) A negative control were agarose beads conjugated to anti-mouse
IgG antibodies do not bind to HA-NrCAM AFN2&3 and so do not precipitate any
of HA-NrCAM AFN2&3's binding partners. C) Western blots of extracted cells
and immunoprecipitation products. Lane 1 and 2 are 100 pg of crude cell extract
of HA-NrCAM AFN2&3 expressing HEK293 cells probed for GIPC. Lane 4 and
6 are proteins immunoprecipitated using beads conjugated to anti-HA antibodies.
Lanes 5 and 7 are the negative controls of just beads conjugated to anti-mouse
antibodies. 1 to 4 were probed for GIPC using a goat anti-GIPC antibody. 5 and 6
is the same blot as 3 and 4 stripped of primary and secondary antibodies and
reprobed for HA-NrCAM AFN2&3 using a rat monoclonal anti-HA antibody.
For methods see section 2.3.10 and appendix 3.
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4.4 GST pull-down experiments
Despite various approaches the immunoprecipitation of NrCAM with a potential
binding partner had proven unsuccessful. Therefore it was decided to use a variation
of the technique called a GST pull-down. In a GST pull-down, the target protein is
fused to the enzyme glutathione S-transferase (GST). Beads coated with glutathione
select the hybrid GST-protein and its associated binding partners. This assay is
illustrated by Figure 4-16.
A. Positive interaction
potential
glutathione beads GST-NrCAM p. binding
partners
B. Negative control
Figure 4-16. A diagrammatic representation of the GST pull-down assay using
GST-NrCAM and glutathione coated beads. This compares to a negative control
were glutathione beads are coupled to GST only and subsequently do not bind to
any binding partners of the cytoplasmic terminus of NrCAM.
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4.4.1 Construction of GST-NrCAM
The DNA sequence encoding the intracellular C-terminal region of NrCAM
(amino acids 1102-1215 of accession number U81037) was amplified by PCR from a
developing rat optic nerve library and sub-cloned into pGEX-KG C-terminal to the
GST protein by Dr F. Davey of the University of St Andrews. The empty pGEX-KG
vector encoded for the cDNA of GST alone and was used as a negative control. Both
proteins were expressed in BL21 C+ E.coli and purified using an affinity matrix
column of glutathione beads as described in section 2.3.2.
4.4.2 Effect of increasing GIPC expression.
The immunocytochemistry data (Figure 4-3 and Figure 4-4) suggested that only a
small proportion of GIPC may be binding to NrCAM. Therefore, to increase the
expression of GIPC in the cell and thereby increase the amount available to bind to
NrCAM, the GIPC image clone (Figure 4-7, step 1) was transfected into HEK293
cells (section 2.2.5). A Western blot of extracted proteins from these transfected cells
indicated an inciease in GIPC expression level (Figure 4-17).
49 kDa
38 kDa
Figure 4-17. A Western blot of 90 pg of crude cell extract of HEK293 cells.
Lane 1 are untransfected cells. Lane 2 are cells transfected with murine GIPC
cDNA. Lane 1 to 2 was probed using a goat anti-GIPC antibody. For methods
see section 2.3.10 and appendix 3.
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It was also necessary to show that the over-expressed G1PC had a normal punclgtf?
distribution in cells before using it in GST pull-down experiments. Murine GIPC
transfected B104 cells, that stably expressed HA-NrCAM, showed a punctate staining
pattern for GIPC as expected (Figure 4-18). HA-NrCAM and GIPC co-localised as
before (Figure 4-18)). Similar images were seen for HEK293 cells stably expressing
HA-NrCAM and transiently transfected with the cDNA from the image clone of
GIPC (not shown). Thus, it was shown that transfected murine GIPC was expressing
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Figure 4-18. Stable expression of HA-NrCAM and transient expression of
murine GIPC expressed in a B104 cell. A) HA-NiCAM immunostaining was
performed using an NrCAM rabbit polyclonal antibody and anti-rabbit Alexa 568
conjugated antibody and is shown in red. B) Endogenous GIPC immunostaining
was performed using a goat antibody to the N-terminus of GIPC and an anti goat
FITC conjugated antibody and is shown in green. C) Co-localisation between both
proteins occurs in localised areas. See methods 2.2.10, appendix 3B.
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4.4.3 NrCAM GST pull-down experiments.
50-60 % confluent 90 mm dishes of HEK293 cells were transfected with the
murine GIPC cDNA (to increase GIPC expression) as described in section 2.2.5 and
cell extracts prepared in various extraction buffers as described in section 2.3.5.
These cell extracts were used to perform the GST pull-down assays as described
section 2.3.11. Briefly 10 pg GST or 10 pg GST-NrCAM was coupled to glutathione
beads and tumbled in murine GIPC transfected HEK293 cell extract. The GST-
beads and GST-NrCAM-beads were washed five to ten times in the extraction buffer
and separated on a SDS-PAGE gel, transferred to nitrocellulose and probed by
Western blot analysis. Both the buffer used to extract the HEK293 cells and the
amount of times the beads were washed was varied to find optimal GST-NrCAM
GIPC binding conditions.
The first GST pull-down experiment used radio-immunoprecipitation assay
(RIPA) buffer as the extraction buffer (tris-HCL 50 mM pH 7.4, 150 mM NaCl, 1 %
NP-40 (v/v), 0.25% Na-deoxycholate ). Beads were washed five times and the results
are shown in Figure 4-19.
Figure 4-19. A Western blot of a GST pull-down experiment. Lane 4 is 80 pg of
crude cell extract of murine GIPC transfected HEK293 cells. Lane 3 is 80 pg of
the same cell extract in lane 4 after being pre-cleared with glutathione beads for
one hour. Lane 2 is GIPC bound to GST glutathione beads and lane 4 is GIPC
bound to GST-NrCAM glutathione beads. Lanes 1 to 4 were probed using a goat
anti-GIPC antibody. For methods, see section 2.3.10 and appendix 3.
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More GIPC bound to GST alone than bound to GST-NrCAM under these
conditions. Therefore it was decided to repeat the experiment using the same RIPA
buffer but to increase the washes from five times to ten times. It was hoped that this
would eliminate unspecific binding to the GST protein and retain specific binding
between GIPC and NrCAM. The results are shown in Figure 4-20.
38 kDa
Figure 4-20. A Western blot of a GST pull-down experiment. Lane 1 is 80 pg of
crude cell extract of murine GIPC transfected HEK293 cells. Lane 2 is 80 pg of
the same cell extract as in lane 1 after being pre-cleared with glutathione beads for
one hour. Lane 3 is GIPC bound to GST glutathione beads and lane 4 is GIPC
bound to GST-NrCAM glutathione beads. Lanes 1 to 4 were probed using a goat
anti-GIPC antibody. For methods, see section 2.3.10 and appendix 3.
Under these conditions, no GIPC bound to either GST alone or GST-NrCAM.
This implied that all of the GIPC that bound in Figure 4-19 was unspecific binding to
the beads.
It was possible that the ionic strength of the 0.25 % (v/v) Na-deoxycholate
detergent used in the R1PA buffer was to too strong to allow a GIPC-NrCAM
interaction. Therefore, a series of RIPA buffers of varying Na-deoxycholate strength
between 0 and 0.2 % (v/v) were prepared and used to lyse the GIPC transfected
HEK293 cells. The beads were washed ten times. However, GIPC did not bind to
GST-NrCAM under any of these conditions (Figure 4-21).
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Figure 4-21. A Western blot of GST pull-down experiments. Lanes 1 to 4 are
80 pg of crude cell extracts of murine GIPC transfected HEK293 cells lysed in
RIPA buffer containing 0 %, 0.5 %, 0.15 % and 0.2 % (v/v) Na-deoxycholate
respectively. Lanes 5 to 8 are GIPC bound to GST glutathione beads when Na-
deoxycholate concentrations were 0 %, 0.5 %, 0.15 % and 0.2 % (v/v)
respectively and lane 9 to 12 are GIPC bound to GST-NrCAM glutathione beads
when Na-deoxycholate concentrations were 0 %, 0.5 %, 0.15 % and 0.2 % (v/v)
respectively. Lanes 1 to 12 were probed using a goat anti-GIPC antibody. For
methods see section 2.3.10 and appendix 3.
Three different buffers that had been used in the literature to perform GST
pull-downs with different GIPC binding partners were tested next (Cai and Reed,
1999; Wang et al., 1999; Lou et al., 2001). These buffers are described in full in
Appendix 2. The first buffer called GBH1 is a phosphate buffer and contains three
different ionic detergents 1 % Triton X-100, 0.2 SDS, 0.5 % Na-deoxycholate. The
second buffer GBH2 was a phosphate buffer without any detergent. The third buffer
GBH3 was a tris buffer with 1 % NP-40 non-ionic detergent. All three buffers
including buffer GBH2 extracted GIPC protein. However only buffer GBH1
suggested GIPC specifically binding to GST-NrCAM beads. No other bands were




Figure 4-22. A Western blot of GST pull-down experiment varying extraction
buffer conditions. Three different buffers were used to extract murine GIPC from
transfected HEK293 cells and couple it to GST-NrCAM. Lane 1 is a 100 pg
sample of rat brain extract at embryonic day 20. Lane 2 is 80 pg of HEK293 cell
extract using buffer GBH1, lane 3 is 80 pg of HEK293 cell extract using buffer
GBH2 and lane 4 is 80 pg of cell extract using buffer GBH3. Lanes 5 and 6 are
the results of the GST-pull-down assay using GBH1 with 5 being the GST-
NrCAM lane and 6 being the GST only lane. Lanes 7 and 8 are the results of the
GST-pull-down assay using GBH2 with 7 being the GST-NrCAM lane and 8
being the GST only lane. Lanes 9 and 10 are the results of the GST-pull-down
assay using GBH3 with 9 being the GST-NrCAM lane and 10 being the GST only
lane. Lanes 1 to 10 were probed using a goat anti-GIPC antibody. For methods
see section 2.3.10 and appendix 3.
Due to this potential positive result, instead of HEK293 cells 240 pg of mouse
cerebellum was extracted in GHB1 buffer. An additional negative control was added
which consisted of GST-NrCAM beads tumbled in 500 pi of GBH1 buffer only (i.e.




Figure 4-23. A Western blot of a GST pull-down experiment. Lane 1 is 45 pg of
cerebellum extracted in buffer GBHi. Lanes 2 and 3 are the results of the GST
pull-down assay with 2 being the GST only lane and 3 being the GST-NrCAM
lane. Lane 4 is lOpl GST-NrCAM beads tumbled in GBHI buffer only. Lanes 1
to 4 were probed using a goat anti-GIPC antibody. For methods see section
2.3.10 and appendix 3.
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In this experiment, no protein of 39 kDa molecular weight, appeared to have
bound to GST-NrCAM (Figure 4-23, lane 3) and thus it was concluded that cerebellar
GIPC was not binding to GST-NrCAM. Also noted was a 45 kDA molecular weight
protein band that was present in both lanes 3 and 4 of Figure 4-23. As lane 4 is GST-
NrCAM beads tumbled in buffer without any extracted proteins, it was evident that
the 45 kDA band was the GIPC antibody binding unspecifically to GST-NrCAM.
4.4.4 The production of a FLAG-GIPC construct.
The unspecificity of the GLPC antibody was disappointing. To try to overcome
this, it was decided to add an N-terminal FLAG epitope to the murine GIPC cDNA.






(see 3.2.4). 2) to add the BamHI
and Hindlll restriction enzyme sites
to the GIPC encoding sequence (see
appendix 4 for the sequences).
2. PCR primers GIPC 70F and
GIPC 71R were designed to: 1)
eliminate 5' and 3' cDNA that does
not encode for GIPC amino acids
Figure 4-24. Continued on next page.
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3. The amplified PCR product "GIPC 70-
71" and the empty plasmid pBluescript II
KS+ were digested with the restriction
enzymes, BamHI and Hindlll. The PCR
product and the cut vector were ligated
together and then transformed into DH5a.
This resulted in the production of a new




5. The empty pCMV-Tag2A plasmid was
digested with restriction enzymes BamHI and
Hindlll, and then purified. The purified
"GIPC 70-71" DNA fragment and the cut
vector were ligated together and transformed
into DH5a. This resulted in the production of
a new plasmid construct called FLAG-GIPC














pBluescript II KS+ MLacZ
Amp1
4. The plasmid construct pBS GIPC
70-71 was digested using restriction
enzymes BamHI and Hindlll. The










Figure 4-24. Cloning strategy for the production of the plasmid FLAG-GIPC.
Details of material and methods are described in Chapter 2 and accompanying text.
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This FLAG-GIPC cDNA construct and the murine GIPC cDNA were both
transfected into HEK293 cells and the GST-pull-down procedure was carried out as
before. Protein samples were separated on an NuPAGE® Novex 6-12% Bis-Tris gel,
transferred to a nitroceullose membrane and subsequently probed using an anti-FLAG
monoclonal antibody. The membrane was then stripped of its primary and secondary
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Figure 4-25. A Western blot of two GST pull-down experiments. Lanes 1
to 3 is a GST pull-down experiment carried out on cell extracts from FLAG-
GIPC expressing HEK293 cells. Lanes 4 to 6 is a GST pull-down
experiment carried out on cell extracts from murine GIPC expressing
HEK293 cells. A) This membrane was probed using an anti-FLAG
antibody. B) The membrane in (A) was stripped of primary and secondary
antihndies and re probed with a goat anti-GIPC antibody. Lane 1 and lane 4
are 90pg of cell extract of FLAG-GIPC expressing HEK293 cells and
murine GIPC expressing cells respectively. Lane 2 and Lane 5 are proteins
that bound to GST. Lane 3 and Lane 6 are proteins that bound to GST-
NrCAM. For methods see section 2.3.10 and appendix 3.
As expected the anti-FLAG antibodies showed a single band in the FLAG-GIPC
transfected cell extract (Figure 4-25 (A) lane 1) but no bands in the murine GIPC
antibodies
1 2 3 4 5 6
FLAG-GIPC murine GIPC
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cDNA transfected cell extract (Figure 4-25 (A), lane 4). Unfortunately, no FLAG-
GIPC bound to GST-NrCAM. The membrane was stripped of primary and secondary
antibodies and reprobed with an anti-GEPC anti-body in Figure 4-25(B). The FLAG-
GIPC cell extract showed two bands, with the higher molecular weight band being
FLAG-GIPC and the lower molecular weight band being endogenous GIPC (Figure
4-25 (B), lane 1). As before there were no protein bands seen in the GST lanes
(Figure 4-25, lane 2 and lane 5). However Figure 4-25 (B) lane 3 and lane 6 (the
GST-NrCAM lanes) showed three protein bands. One was the 45 kDa band seen
before, one the 39 kDa seen in transfected HEK293 samples and the other a new band
of approximately 33 kDa was observed for the first time. This assay was repeated
with similar results (blots not shown). However, the three bands in the GST-NrCAM
lanes (Figure 4-25 (B) lane 3 and lane 6) were non-specific binding of the GIPC
antibody binding to GST-NrCAM and its breakdown products. To illustrate this 5
pg of GST-NrCAM was separated on a NuPAGE® Novex 6-12% Bis-Tris gel,
transferred to nitrocellulose and probed with an antibody to the cytoplasmic terminus
of NrCAM (Figure 4-26). GST-NrCAM produced both a 45 kDa and a 39 kDa band,
suggesting that the 39 kDa band observed in Figure 4-25 is a breakdown product of




Figure 4-26. A Western blot of GST-NrCAM using an antibody to the
cytoplasmic terminus of NrCAM. For methods see section 2.3.10 and appendix 3.
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4.4.5 The confirmation of endogenous SAP102 binding with NrCAM but not
endogenous GTPC, using Tandem Affinity Purification analysis.
Dr. F. Davey of the University of St Andrews confirmed the binding of SAP 102
using the Tandem Affinity Purification Assay (Davey et al., 2005). The DNA
sequence encoding the intracellular C-terminal region of NrCAM (amino acids 1102-
1215 of accession number U81037) was amplified by PCR from a developing rat
optic nerve library and sub-cloned into a pCMV5/TAP vector (a gift from Prof. R.
Hay, University of St Andrews). This vector inserts a TAP tag on the N-terminal
region of the NrCAM construct, consisting of two IgG binding domains of protein A
from Staphylococcus aureus, a cleavage site for the tobacco etch virus (TEV)
protease, and a calmodulin-binding peptide. The TAP-tagged NrCAM protein was
transiently expressed in COS-7 cells and subjected to two successive purification
steps. The first purification step involves binding of the protein A tag to beads
conjugated to mouse IgG. TAP-NrCAM and the complexes of proteins that bind to it
are eluted from the IgG beads using TEV protease. The purified TAP-NrCAM
protein complexes were bound to calmodulin beads to remove TEV protease and
contaminants and eluted by adjusting the concentration of calcium ions with chelating
reagents. The highly purified TAP-NrCAM protein complexes were separated on an
SDS-PAGE gel and subjected to Western blot.
It was therefore decided to repeat this experiment using the NrCAM and SAP 102
interaction as a positive control to see if the NrCAM and GIPC interaction could also
be shown using this method. The method is described in full in 2.3.16. Briefly ten
140 mm plates of COS-7 cells were each transiently transfected with 10 pg TAP-
NrCAM cDNA or as a control the empty TAP vector cDNA as described 2.2.5. After
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48 hours the cells were lysed in 1ml lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% NP40, 15% glycerol, 1 mM PMSF, a mixture of protease
inhibitors). Cell debris was removed by centrifugation and 50 pi of crude cell extract
retained. The remaining cell extract was coupled to Rabbit IgG conjugated beads.
They were washed five times and the TAP protein complexes eluted using TEV
protease. The TAP protein complexes were resuspended in calmodulin binding
buffer (CBB) (10 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% NP40, 10 mM p-
mercaptoethanol, 1 mM imidazole, 1 mM magnesium acetate, 2 mM CaCl2) and a
further 3 mM CaCl2 and coupled to 40 pi of washed calmodulin beads. The beads
were thoroughly washed with CBB, then the remaining protein complex was eluted
by four washes of calmodulin elution buffer (10 mM Tris-HCl pH 8, 150 mM NaCl,
0.1% NP40, 10 mM P-mercaptoethanol, 1 mM imidazole, 1 mM magnesium acetate,
2 mM EGTA) and one wash of a high salt solution (50 mM Tris-HCl pH 8, 1 M
NaCl, 2 mM EGTA). These elutes were combined and immunoblotted.
As shown in Figure 4-27(A) endogenous SAP102 expressed in COS-7 cell extracts
(lanes 1 and 2), only associated with TAP-NrCAM (lane 3) and not TAP (lane 4)
expressing cells. As shown in Figure 4-27 (B), endogenous GIPC expressed in COS-
7 cell extracts (lanes 1 and 2) but did not associate with either TAP-NrCAM (lane 3)
or TAP expressing COS-7 cells (lane 4). Thus SAP102 but not GIPC binding has






Figure 4-27. A Western blot of a Tandem Affinity Purification Assay. A) The
membrane was probed using an anti-SAP102 antibody. B) The membrane was
probed using an anti-GIPC antibody. Lane 1 is the crude cell extract of COS-7
cells transfected with empty TAP vector. Lane 2 is the crude cell extract of
COS-7 cells transfected with empty TAP vector. Lane 3 are the proteins eluted
with TAP-NrCAM. Lane 4 are the proteins eluted with TAP.
4.5 Retesting of full-length GIPC and SAP 102 against NrCAM
CT and other members of the Ll-CAM family, using the
yeast two-hybrid technique.
4.5.1 Cloning of full length GIPC and SAP102 constructs.
Full-length cDNA encoding for GIPC and SAPI 02 had not been available when
the original yeast two-hybrid experiments were performed in Chapter 3. However, it
was important to show that the cytoplasmic terminus of NrCAM could bind to the
full-length of both of the PDZ domain containing proteins. Therefore, full-length
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murine GIPC cDNA and rat full-length SAPI02 cDNA were both sub-cloned into the





1. A mouse GIPC image clone
(accession number BC003490) was
used as a PCR template. It also
contained nucleotide sequence 5'
and 3' of the GIPC sequence.
Ampr
2. PCR primers GIPC 7 and GIPC 8 were designed to: 1) eliminate 5' and 3' cDNA
that does not encode for GIPC amino acids (see 3.2.4). 2) to add the BamHI and
EcoRI restriction enzyme sites to the GIPC encoding sequence (see appendix 4 for
the sequences).














3. The amplified PCR product "GIPC 7-8"
and the empty plasmid pSPORT were
digested with the restriction enzymes,
EcoRI and BamHI. The PCR product and
the cut vector were ligated together and
then transformed into DH5a. This
resulted in the production of a new
plasmid called pSPORT GIPC 7-8.
Figure 4-28. Continued on next page.
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BamHl^ 3' EcoRI 4. The plasmid construct pSPORT
/ GIPC 7-8 was digested using
DNA fragment "GIPC 7-8" restriction enzymes BamHl and












5. The empty pACT2 plasmid was digested with restriction enzymes BamHI and
EcoRI, and then purified. The purified "GIPC 7-8" DNA fragment and the cut
vector were ligated together and transformed into DH5a. This resulted in the
production of a new plasmid construct called pACT2 GIPC 7-8 which was sent
for DNA sequencing.
Figure 4-28. Cloning strategy for the production of the plasmid pACT2 GIPC 7-8
Details of material and methods are described in Chapter 2 and accompanying text.
Hindlll
Kanr
1. The plasmid GFP-SAP102 encoding
the rat sequence (Accession No: NM
031639.1; a gift from Dr. N. Sans
NIH/NIDCD, USA) was used as a PCR
template.
Figure 4-29. Continued on next page.
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2. PCR primers (SAP102H and SAP 1021: were used to incorporate EcoRI
restriction enzyme sites to the ends of the SAP102 coding sequence (see appendix
4 for the sequences).
SAP102H
PCR product "SAP 102 HI'
EcoRI
3. The amplified PCR product
"SAP102HI" and the empty plasmid
pSPORT were digested with the
restriction enzyme, EcoRI. Following
alkaline phosphatase treatment of the cut
pSPORT, the PCR product and the cut
vector were ligated together and then
transformed into DH5a. This resulted in
the production of a new plasmid













4. The plasmid construct, pSPORT-SAP102 HI was
digested using the restriction enzyme, EcoRI. The
fragment containing SAP! 02 was purified.












5. The empty plasmid pACT2 was
digested with restriction enzyme,
EcoRI, and then purified. Following
alkaline phosphatase treatment of the
cut pACT2, the purified S API 02
fragment and the cut vector were
ligated together and then transformed
into DH5a. This resulted in the
production of a new plasmid construct
called pACT2-SAP102 HI which was









Figure 4-29. Cloning strategy for the production of the plasmid pACT2 SAP 102 ED.
Details of material and methods are described in Chapter 2 and accompanying text.
4.5.2 Testing of full-length GIPC and SAP102 binding to NrCAM CT.
One pg of bait plasmid (pAS2-l NrCAM CT, pAS2-l NrCAM 1-32 APDZ, pAS2-
1 neurofascin CT or pAS2-l LI CT) was transformed together with one pg of prey
plasmid (pACT2 GIPC RL16B(C)2, pACT2 GIPC7-8, pACT2 SAP102 RL29B2 or
pACT2 SAP102 HI) into Y190 yeast and the filter lift assay was performed as
previously described in Chapter 3. The results are recorded in Figure 4-30.
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Figure 4-30. Testing of LI-CAM binding to the full length murine GIPC and
full-length rat SAP102 proteins using the yeast two-hybrid filter lift assay. The
LI-CAM plasmids and NrCAM plasmids have been shown diagrammatically.
Green boxes represent the ankyrin binding domain. The dark blue box is the
FERM binding domain in neurofascin and the paler blue boxes are the equivalent
amino acids in LI and NrCAM. The dark pink boxes are the PDZ binding
domains of neurofascin and NrCAM. The paler pink box is the equivalent amino
acids in LI. Binding strengths were scored using the system outlined in Table 3-
1.
As shown in Figure 4-30 the cytoplasmic terminus of NrCAM and neurofascin
both bound strongly to the GIPC clone, selected by the library screen in Chapter 3,
that coded for amino acids 1-215 of rat GIPC. Unexpectedly however neither
NrCAM nor neurofascin bound to the full-length murine GIPC protein (amino acids
1-333). This experiment was repeated several times with similar results.
As shown in Figure 4-30 the cytoplasmic terminus of NrCAM bound strongly to
the SAP102 clone, selected by the library screen in Chapter 3, which coded for amino
acids 54-623 of rat SAP102. The cytoplasmic terminus of NrCAM also bound
moderately to the full-length rat SAP102 protein (amino acids 1-835).
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4.6 Discussion of results.
The expression levels of NrCAM, GIPC and SAP102 in developing rat brain and
CGC cells grown in vitro were tested by Western blot for E14, E16, E20 and P7.
Both GIPC and NrCAM were expressed at all stages tested and SAP102 was present
from El 6. Thus NrCAM is developmentally regulated in a similar manner to both
of the PDZ proteins.
Co-localisation of stably expressed HA-NrCAM and endogenous GIPC only
occurred at small, localised areas of the plasma membrane. Co-localisation of HA-
NrCAM and FLAG-SAP102 also occurred at localised areas of the plasma
membrane. Thus, only a small percentage of NrCAM can be interacting with a small
percentage of GIPC or SAP102 at any one time. This is perhaps unsurprising as both
GIPC and SAP102 bind to numerous binding partners (see Table 3-5 and Table 3-6)
and are multifunctional proteins.
Various biochemical techniques were attempted to confirm the NrCAM and GIPC
interaction. Co-immunoprecipitations of NrCAM with GIPC and GIPC with NrCAM
were attempted but were difficult to prove due to the secondary antibody used in the
Western blot procedure cross reacting with one of the IgG domains of one of the
antibodies used in the immunoprecipitation. This was further complicated as NrCAM
may be furin cleaved in its third FN-III-like domain (Kayyem et al., 1992; Grumet,
1997) and though this may not necessary impair its ability to be immunoprecipitated
(Xu el al., 2003) this was difficult to prove without a specific antibody to the
cytoplasmic terminus of NrCAM (see Chapter 6). Therefore an attempt was made to
co-immunoprecipitate GIPC with an HA-tagged NrCAM protein that did not contain
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the third FNIII-like domain (NrCAM AFN2&3). This was unsuccessful and thus it
has been concluded that endogenous GIPC had not been successfully co-
immunoprecipitated with either HA-NrCAM or HA-NrCAM AFN2&3.
Because of the difficulties experienced with the immunoprecipitation procedure, I
tried verifying the NrCAM and GIPC interactions using a different biochemical
technique. The cytoplasmic terminus of rat NrCAM was N-terminally tagged with
GST and GST pull-downs attempted. One out of several buffering conditions tested
appeared to show that over expressed murine GIPC could bind to GST-NrCAM.
However, the validity of this result is questionable as the GIPC antibody appeared to
be binding to GST-NrCAM and one of the breakdown products of the GST-NrCAM
protein is 39kDa. To overcome the problem GIPC was N-terminally tagged with the
FLAG epitope, thus allowing the use of monoclonal antibodies to probe for GIPC.
FLAG-GIPC expressed at levels equal to endogenous levels of GIPC but
unfortunately failed to bind to GST-NrCAM and so it was concluded that the GEPC-
NrCAM interaction could not be shown using GST pull-downs.
Meanwhile the binding of NrCAM to endogenous SAPI 02 had been shown by
TAP analysis. This experiment was repeated and both of the NrCAM-SAP102 and
NrCAM-GIPC interactions were tested. The binding of NrCAM to SAP102 was
reconfirmed. However, NrCAM did not bind to endogenous GIPC.
The yeast two-hybrid analysis showed similar results. Full-length rat SAPI02
bound to NrCAM (though with a more moderate binding strength than between the
part-length library clone of SAPI 02 and NrCAM). Full-length murine GIPC
however did not show any binding to NrCAM.
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Proposed roles for NrCAM-SAP102 binding and whether NrCAM is believed to
be binding to GIPC are discussed further in Chapter 7.
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Chapter 5. The different binding abilities of
NrCAM, LI and neurofascin to members of the
4.1 Superfamily family.
5.0 Introduction. Members of the 4.1 superfamily of proteins
may link NrCAM to the cytoskeleton in the axonal growth
cone.
The neuronal growth cone advances when external substrate cues physically
anchor growth cone plasma membrane receptors to the internal actin retrograde flow
(Lin and Forscher, 1995). Both NrCAM and LI are known to be coupled to the actin
retrograde flow of the growth cone (Faivre-Sarrailh et al., 1999; Kamiguchi and
Yoshihara, 2001) but it is not yet fully understood how this coupling takes place.
One possibility is that NrCAM and LI bind to the retrogradely moving actin
cytoskeleton via ankyrin. NrCAM has an ankyrin-binding motif in its cytoplasmic
terminus and, at the node of Ranvier, NrCAM is linked to the actin cytoskeleton via
ankyrino (Davis et al., 1996). However ankyrino is not found in the growth cone
and ankyrinB is only found at the proximal region of the growth cone (Nishimura et
al., 2003). Furthermore ankyrinB-binding to LI has been shown to inhibit its
retrograde movement and to promote stationery behaviour (Gil et al., 2003). Thus, it
is likely that a protein(s) other than ankyrin is/are coupling NrCAM and LI to
retrogradely moving actin filaments in the giowth cone
Candidate proteins that may fulfil this role belong to the 4.1 superfamily. FERM
family proteins link membrane receptors to the actin cytoskeleton both directly and
indirectly (Bretscher et al., 2000). Direct interactions occur when the 4J_ ezrin
radixin moesin (FERM) domain of the protein binds to a cytoplasmic domain of the
membrane protein (Figure 5-1 (A)). Indirect interactions occur when the
cytoplasmic terminus of a membrane receptor binds to an adaptor protein such as
EBP50 that in turn binds to a member of the 4.1 superfamily member (Figure 5-1
(B))
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There is some evidence that suggest that 4.1 superfamily members suggests
binding to NrCAM in the growth cone. For example two members of the family,
radixin and moesin, are essential for neuronal growth cone motility and neurite
extension (Paglini et al., 1998) (Castelo and Jay, 1999) and NrCAM co-localises
with another family member, ezrin, at the membrane protrusions of renal carcinoma










Figure 5-1. A diagrammatic representation of how proteins of the 4.1
superfamily may link NrCAM and other members of the LI-CAM family to the
actin cytoskeleton. A) Shows a direct interaction between NrCAM and the FERM
domain containing protein. An amino acid sequence in the cytoplasmic terminus
of NrCAM binds to the FERM domain of the 4.1 superfamily protein, which in
turn binds to actin filaments via a C-terminal motif. B) Shows an indirect
interaction between NrCAM and the 4.1 superfamily protein. An amino acid
sequence in the cytoplasmic terminus of NrCAM binds to the PDZ domain of the
EBP50 protein, which in turn binds to a 4.1 superfamily protein, which then binds
to actin filaments. This Figure was adapted from (Bretscher et al., 2000).
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The strongest suggestion that NrCAM may bind to 4.1 superfamily members has
come from studies on neurofascin. The neurofascin cytoplasmic terminus has been
shown to bind to two members of the 4.1 superfamily by a yeast two-hybrid screen
performed by Dr. F. Gunn-Moore of the University of St Andrews. The first clone
identified was ezrin (amino acids 1 to 482) and the second clone identified was a
novel member of the 4.1 superfamily that has been termed willin (amino acids 1-
342). It is predicted that the last 28 amino acids of neurofascin bind to the FERM
domains of both clones (Gunn-Moore unpublished results). Within these 28 amino
acids is a 14 amino acid sequence that is a FERM binding consensus sequence
(Figure 5-2). Importantly NrCAM codes for 10 out of 14 of these amino acids see
Figure 5-2.
Neurofascin (aa 1148-1161) R KDKEETEGNESSE
NrCAM (aal 190-1203) KKEKEPAEGNESSE
Consensus + K-KEXXEGNESSE
Figure 5-2. An alignment of the amino acids of the proposed FERM binding
domain of neurofascin and the equivalent amino acids in NrCAM. When the
equivalent amino acids of NrCAM and neurofascin are of the same charge at
physiological pH their charge has been written in the amino acid sequence as a
+ or -. Only two amino acids are significantly different in NrCAM when
compared to neurofascin and have not been included in the consensus
sequence.
5.1 Results.
5.1.1 Do NrCAM and ezrin co-localise?
NrCAM must first co-localise with a member of the 4.1 superfamily in cells in
order for binding to occur. Therefore NrCAM and ezrin co-localisation was tested in
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various cell types. Dr F. Gunn-Moore of the University of St Andrews generated a
FLAG-tagged ezrin construct that coded for amino acid 1-482 of ezrin, N-terminally
tagged by the FLAG epitope (FLAG-ezrin). This construct was co-transfected with
HA-NrCAM into COS-7 cells growing on glass coverslips as described in section
2.2.5 and immunostained for HA-NrCAM and FLAG-ezrin using monoclonal
antibodies to the N-terminal epitopes as described in section 2.2.10. Figure 5-3
shows a Z-section of two COS-7 cells.
Figure 5-3. An image of transient expression of both HA-NrCAM and FLAG-
ezrin in COS-7 cells. A) HA-NrCAM immunostaining was performed using an
anti-HA rat monoclonal antibody and anti-mouse Alexa 568 conjugated antibody
and is shown in red. B) FLAG-ezrin immunostaining was performed using a
mouse monoclonal antibody to the N-terminal FLAG epitope of FLAG-ezrin and
an anti-mouse FITC conjugated antibody and is shown in green. C) Co-
localisation of both proteins occur at the plasma membrane (indicated by arrows).
The nuclei of the cells have been stained with DAPI and are shown in blue. See
methods 2.2.10, appendix 3B.
Co-localisation of HA-NrCAM and FLAG-ezrin occurred at the points within
plasma membrane of COS-7 cells (Figure 5-3 (C)). To show that this co-localisation
was not cell type specific and that it could occur in neurons, CGCs were also
transiently transfected by Dr F. Davey of the University of St Andrews with HA-
NrCAM and FLAG-ezrin. Transfected CGCs that had been growing on cover slips
for 4 days (i.e. 4 DIV) were immunostained for HA-NrCAM and FLAG-ezrin using
monoclonal antibodies to the N-terminal epitopes as described in section 2.2.10.
Figure 5-4 shows a Z section of a CGC transfected with HA-NrCAM and FLAG-
ezrin. Punctate HA-NrCAM staining was observed on the cell body, plasma
membrane and along the axon (Figure 5-4(A)). FLAG-ezrin was also expressed in
the cell body membrane and along the axon (Figure 5-4(B)). Co-localisation of both
proteins occurred in patches evenly distributed down the axon (Figure 5-4(C)).
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Figure 5-4. An image of transient expression of both HA-NrCAM and FLAG-
ezrin in a CGC. A) HA-NrCAM immunostaining was performed using an anti-
HA rat monoclonal antibody and anti-mouse Alexa 568 conjugated antibody and
is shown in red. B) FLAG-ezrin immunostaining was performed using a mouse
monoclonal antibody to the N-terminal FLAG epitope of FLAG-ezrin and an anti-
mouse FITC conjugated antibody and is shown in green. C) Co-localisation of
both proteins occur patches evenly distributed down the axon. The nucleus of the
cell has been stained with DAPI and is shown in blue. See methods 2.2.10.
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5.1.2 Does NrCAM bind to ezrin?
It was therefore decided to verify ifNrCAM interacts with ezrin using the yeast two-
hybrid technique. A bait plasmid that encoded for the neurofascin cytoplasmic
terminus (neurofascin CT) (amino acids number 1065 to 1175) was cloned in frame
into the pAS2-l plasmid and a prey plasmid that encoded for ezrin (amino acids 1-
482) that was in frame into the pACT2 plasmid by Dr F. Gunn-Moore. The
interaction of neurofascin CT and ezrin was used as a positive control. The cloning
of a bait plasmid NrCAM CT, that encoded for the rat NrCAM cytoplasmic terminus
(amino acids 1102- to 1215), in frame into the pAS2-l plasmid is described in
Chapter 3. A prey plasmid that encoded for ankyrinR (amino acids 14-515) that had
been cloned in frame into the pACT2 plasmid was a kind gift from Prof. P. Brophy
of the University of Edinburgh. The interaction of NrCAM CT and ankyrinR was
used as a second control. The interactions of all proteins were tested using the filter
lift assay as described in section 2.4.3. As shown Figure 5-5, neurofascin bound to
both ankyrinR and ezrin. However, NrCAM bound to ankyrinR but showed no
binding to ezrin. This was surprising considering the immunocytochemistry results
in Figure 5-1 and Figure 5-2. Therefore, using this technique NrCAM does not
appear to bind to ezrin; however, it was still possible that it may be able to bind to
another protein with a FERM domain. Therefore, two other members of the 4.1
superfamily were tested for their interaction with NrCAM. In particular, radixin was
tested as it is implicated in growth cone motility (Paglini et al., 1998; Castelo and
Jay, 1999). Willin was tested as hybridisation data had shown strong expression of
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1065 1175
Figure 5-5. Testing ofNrCAM binding to ezrin using the yeast two-hybrid assay.
Neurofascin binding to ezrin was used as a positive control. NrCAM and
neurofascin binding to ankyrinR was used as second positive control. The
NrCAM and neurofascin proteins have been shown diagrammatically. Green
boxes represent the ankyrin domain. The dark blue box is the proposed FERM
binding domain in neurofascin and the paler blue box is the equivalent amino
acids in NrCAM. The dark pink boxes are the PDZ domains. Binding strengths
were scored using the system outlined in Table 3-1.
5.1.3 Does NrCAM bind to radixin or willin?
A prey plasmid that encoded for radixin (amino acids 166 to 1575) had been
cloned in frame into the pACT2 plasmid, and was provided by Dr F. Davey. A prey
plasmid that encoded for willin (amino acids 1-341), that had been cloned in frame
into the pACT2 plasmid, was provided by Dr F. Gunn-Moore. The interactions of
the proteins were tested using the filter lift assay as described in section 2.4.3. As










Figure 5-6. Testing ofNrCAM binding to radixin and willin using the yeast two-
hybrid assay. The NrCAM and neurofascin proteins have been shown
diagrammatically. Green boxes represent the ankyrin domain. The dark blue box
is the proposed FERM domain in neurofascin and the paler blue box is the
equivalent amino acids in NrCAM. The dark pink boxes are the PDZ domains.
Binding strengths were scored using the system outlined in Table 3-1. 182
Neurofascin's binding to radixin had not been tested previously. Therefore, it was
notable that the strength of neurofascin's interaction with radixin was moderate when
compared to its interaction with the other 4.1 superfamily member ezrin. Thus,
neurofascin shows different binding abilities with different members of the 4.1
superfamily. NrCAM did not bind to either radixin or willin. Thus, NrCAM and
neurofascin showed different binding preferences for members of the 4.1
superfamily.
When comparing the predicted FERM domain binding sequence of neurofascin
to the equivalent NrCAM sequence two important amino acid substitutions were
noted (Figure 5-7). From the yellow highlighted section of Figure 5-7 neurofascin
has a large polar threonine that has been substituted with a small neutral alanine in
NrCAM but perhaps more significantly neurofascin has a small negatively charged
glutamic acid that has been substituted with a proline by NrCAM. Proline is a cyclic
secondary amino acid that has conformational constraints imposed by the cyclic
nature of its pyrrolidine side group (Voet and Voet, 1995). This proline substitution
effectively puts a kink in the amino acid chain of NrCAM in the middle of the
proposed FERM binding site. Thus, the proline amino acid substitution alone could
account for the different binding abilities of NrCAM and neurofascin for the FERM
family members.
Neurofascin (aa 1148-1161) R K D K E
NrCAM (aal 190-1203) K K E K E




E G N E S S E
E G N E S S E
E G N E S S E
Figure 5-7. An alignment of the amino acids of the proposed FERM binding
domain of neurofascin and the equivalent amino acids in NrCAM as already
described by Figure 5-2. Only two amino acids are significantly different in
NrCAM when compared to neurofascin and these residues have been highlighted
in yellow for clarity.
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As shown in Figure 5-8, the majority of the FERM binding residues in
neurofascin have been conserved in LI. Importantly it does not have a proline at
position 6 but an alanine. Like NrCAM, LI had been reported as associating with
FERM domain containing proteins (Mintz et al., 2003). Therefore, it was decided to
investigate whether LI could bind to FERM domain containing proteins using this
motif.
LI (aa 1231-1244) KKEKEAAGGNDSSG
Neurofascin (aa 1148-1161) RKDKEETEGNESSE
NrCAM (aal 190-1203) KKEKEPAEGNESSE
Consensus + K-KEXXXGN-SSX
Figure 5-8. An alignment of the amino acids of the proposed FERM binding
domain of neurofascin and the equivalent amino acids in NrCAM and LI. The
two amino acids that are significantly different in NrCAM when compared to
neurofascin (see figure 5-7) have been highlighted in yellow.
5.1.4 Does LI bind to ezrin, radixin or willin?
The bait plasmid that encoded for the cytoplasmic terminus of LI (Ll-CT, amino
acids 1143-1257; accession number NP 000416) was cloned in frame into pAS2-l.
(provided by Dr F. Gunn-Moore). LI binding to FERM domain-containing proteins
was tested against the ezrin, radixin and willin prey clones using the yeast two-
hybrid technique and filter lift assay. LI binding to ankyrinR was used as a positive
control. As shown in Figure 5-9, LI bound to ankyrin as expected. However, it did
not bind to ezrin or radixin and only showed a weak interaction with willin.
Therefore, LI also shows different binding ability for FERM domain containing
proteins when compared to neurofascin. Furthermore, the lack of interaction
between FERM domain containing proteins and NrCAM cannot be explained simply
by the conformational change to the amino acid chain imposed by the proline
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substitution in NrCAM. Thus, from these studies it seemed that only neurofascin
could bind to members of the 4.1 superfamily.
AnkyrinR Ezrin Radixin Willin
Ankyrin FERM PDZ (aa 14-515) (aa 1-482) (aa 166-1575) (aa 1-342)
li CT ^fig^HZZZZEEZZ] ++++ +
1143 1257
Figure 5-9. Testing of LI binding to ezrin, radixin and willin using the yeast
two-hybrid assay. The LI protein has been shown diagrammatically. The green
box is the ankyrin binding domain. The pale blue box is the equivalent amino
acids of the proposed FERM binding domain of neurofascin. The pale pink box
is the equivalent amino acids of the proposed PDZ binding domain of NrCAM
and neurofascin. Binding strengths were scored using the system outlined in
Table 3-1.
5.1.5 Does the presence of an RSLE motif allow NrCAM to bind to ezrin,
radixin or willin?
During the course of these experiments it was shown independently that ezrin
could bind to a specific isoform of the LI cytoplasmic terminus that contained a
RSLE motif (Dickson et al., 2002). This RSLE motif is normally spliced out of the
cytoplasmic portion of LI, but when present it is essential for both the sorting ofLI
to the growth cone and for the AP2 protein mediated endocytosis of LI (Kamiguchi
et al., 1998). Like LI, the human NrCAM gene encodes the RSLE amino acids and
also as with LI, these amino acids are normally spliced out (Dry et al., 2001). This
suggested that NrCAM containing an RSLE motif might also bind to ezrin. To see if
naturally occurring isoforms ofNrCAM retain the RSLE motif a search was made of
the NCBI database (http://www.ncbi.nlm.nih.gov). No sequences containing the
RSLE motif had been reported for rat or murine NrCAM. However a human
sequence was identified that contained the RSLE motif (accession number
AAF22282). Interestingly all chick NrCAM sequences contained the RSLE amino
acids. Therefore, it was decided to: 1) Test a LI clone with the RSLE sequence to
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independently reconfirm the Dickinson et al results; 2) Test an NrCAM clone with a
naturally occurring RSLE sequence to establish if NrCAM could bind to ezrin via
this motif.
The LI clone with the RSLE motif for the Dickinson et al paper was a kind gift
from Dr. Salton, the Mount Sciani School of Medicine, New York. This construct




1. The c-terminal amino acids of rat LI,
NILE (1146-1259) in the plasmid
pBTMl 16-KN-Ade2 was a kind gift
from Dr Stephen Salton, the Mount
Sciani School of Medicine, New York.
(Dickson et al., 2002)
.BamHI
2. The plasmid construct pBTM LexA LI
RSLE was digested using the restriction





















3. The empty pAS2-l plasmid was digested with BamHI restriction enzyme and
then purified and alkaline phosphatase treated. The purified "Ll-RSLE" DNA
fragment and the cut vector were ligated together and transformed into DH5a.
This resulted in the production of a new plasmid construct called pAS2-l LI
RSLE which was sent for DNA sequencing.
Figure 5-10. Cloning strategy for the production of the plasmid pAS2-l LI
RSLE. Details of material and methods are described in chapter 2 and
accompanying text. .
No human NrCAM clones containing the RSLE sequence were available,
however the amino acid sequence of the cytoplasmic portion of NrCAM has been
100% conserved from chick to human (Davis and Bennett, 1994; Lane et al., 1996).
Therefore, a chick EST clone was purchased from Ark-Genomics, the Roslin
Institute and cloned in frame into pAS2-l as described by Figure 5-11. This clone
codes for amino acids 1166 to 1260 of accession number P35331, which is the entire








1. A chick EST clone was purchased from Ark-
Genomics, the Roslin Institute. Its cDNA
matched to accession number P35331 (amino
acid numbers 1166 to 1260). The clone was used
as a PCR template.
2. PCR primers CN1 and CN6 were designed to :
1). add the EcoRI and BamHI restriction enzymes
sites to the NrCAM encoding sequence 2).
eliminate 5' cDNA that does not encode for the




PCR product "NrCAM CN1-4"









3. The amplified PCR product "NrCAM CN1-4" and the
empty pSPORT plasmid were digested with the restriction
Ampr enzymes, EcoRI and BamHI. The PCR product and the
cut vector were ligated together and then transformed into
DH5a. This resulted in the production of a new plasmid




Digested fragment "NrCAM CN1 A''
+
EcoRI
4. The plasmid construct pSPORT chick
NrCAM was digested using restriction
enzymes EcoRI and BamHI. The cDNA

















5. The empty pAS2-l plasmid was
digested with restriction enzymes EcoRI
and BamHI, and then purified. The
purified "NrCAM CN1-4" DNA
fragment and the cut vector were ligated
together and transformed into DH5a.
This resulted in a new plasmid construct
called pAS2-l NrCAM chick which was
sent for DNA sequencing.
CYH2
TRP1
Figure 5-11. The cloning strategy for the production of the plasmid pAS2-l
NrCAM chick. Details of material and methods are described in chapter 2 and
accompanying text.
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As LI RSLE and Chick NrCAM were both new baits they first needed to be
tested to ensure that they:
1. Did not auto-activate.
2. Behaved normally when binding to a known binding partner such as ankyrin.
Thus, both clones were tested against empty pACT2 vector and ankyrinR. The
interactions were tested using the filter lift assay as described in section 2.4.3. As
shown in Figure 5-12, LI showed weak auto-activation but interacted strongly with
ankyrin. Therefore, this clone was suitable for testing proteins that strongly interact
with LI RSLE only. The Chick NrCAM protein did not auto-activate and bound to
ankyrinR strongly.
empty AnkyrinR
RSLE Ankyrin FERM PDZ pACT2 (aa 14-515)
Ll-RSLE II^TlIVK'G 1 + ++-H-
1146 1259
Chick NrCAM - 1 1 1 1
1166 1260
Figure 5-12. Testing of Ll-RSLE and chick NrCAM for auto-activation and
normal binding to full-length ankyrinR. The LI and NrCAM proteins have been
shown diagrammatically. The red box indicates the presence of an alternatively
spliced RSLE motif. Green boxes represent the ankyrin domain. The blue box is
the equivalent amino acids of the FERM domain in neurofascin present in
NrCAM and LI. The pink box is the equivalent amino acids of the PDZ domain
of NrCAM present in LI. The chick NrCAM construct did not encode a PDZ
domain. Binding strengths were scored using the system outlined in Table 3-1.
LI RSLE and Chick NrCAM were then tested against the FERM domain
containing prey clones ezrin, radixin and willin. The interactions were tested using
the filter lift assay as described in section 2.4.3. As shown in Figure 5-13, Ll-RSLE
interacted strongly with ezrin, moderately with radixin but interactions with willin
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could not be distinguished over auto-activation levels. Chick NrCAM did not appear
to interact with any of the 4.1 superfamily proteins.
Ezrin Radixin Willin
RSLE Ankyrin FERM PDZ (aa 1-482) (aa 166-1575) (aa 1-342)
LI - RSLE 1 RSLEl FIGQ B I +++++ +
1146 1259
Chick NrCAM 1 RSl Fj FIGQ M ~~B
1166 1260
Figure 5-13. Testing of Ll-RSLE and chick NrCAM binding to ezrin, radixin
and willin. The LI and NrCAM proteins have been shown diagrammatically.
Green boxes represent the ankyrin domain. The red box indicates the presence of
an alternatively spliced RSLE motif. The blue box is the equivalent amino acids
of the FERM domain in neurofascin present in NrCAM and LI. The pink box is
the equivalent amino acids of the PDZ domain of NrCAM present in NrCAM.
The chick NrCAM construct did not encode a PDZ domain. Binding strengths
were scored using the system outlined in Table 3-1.
5.1.6 Does NrCAM to bind to EBP50?
Chapter 3 and 4 demonstrated the importance of the PDZ binding domain of
NrCAM. Ezrin binding protein 50 (EBP-50) has an ezrin-binding site in its first 28
residues and is recruited to regions in the cell where ezrin is activated and associated
with F-actin through its C-terminal F-actin binding site. It has two PDZ domains and
it may be involved in tethering membrane receptors to the cytoskeleton (Bretscher et
al., 2000) (see figure 5-13). Thus, it was decided to see if EBP50 could bind to
NrCAM via its PDZ binding domain.
A FLAG-tagged ezrin construct that coded for EBP50 N-terminally tagged by the
FLAG epitope (FLAG-EBP50) was generated by Dr. F. Gunn-Moore (aa 1-716).
This construct was co-transfected with HA-NrCAM into COS-7 cells growing on
glass cover-slips as described in section 2.2.5 and immunostained for HA-NrCAM
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and FLAG-EBP50 using monoclonal antibodies to the N-terminal epitopes as
described in section 2.2.10. Figure 5-14 shows a Z-section of a single COS-7 cell.
HA-NrCAM staining was seen predominantly in the membrane and membrane
protrusions of COS-7 cells (Figure 5-14 (A)). FLAG-EBP50 was also seen at the
plasma membrane as wells as in cytoplasmic regions of the cell (Figure 5-14 (B)).
Co-localisation of both proteins occurred in the membrane and membrane
protrusions of the COS-7 cells (Figure 5-14 (C)). Thus, transiently expressed HA-
NrCAM and FLAG-EBP50 did co-localise at the plasma membrane of COS-7 cells.
Figure 5-14, An image of transient expression of both HA-NrCAM and FLAG-
EBP50 in a COS-7 cell. A) FLAG-ezrin immunostaining was performed using a
mouse monoclonal antibody to the N-terminal FLAG epitope of FLAG-EBP50
and an anti-mouse FITC conjugated antibody and is shown in green. B) HA-
NrCAM immunostaining was performed using an anti-HA rat monoclonal
antibody and anti mouse Alexa 568 conjugated antibody and is shown in red. C).
Co-localisation of both proteins occur at localised areas of the plasma membrane.
The nucleus of the cell has been stained with DAPI and is shown in blue. See
methods 2.2.10, appendix 3B.
191
As the EBP50 construct could co-localise with NrCAM it was decided to test
whether EBP50 was binding directly to NrCAM. A prey plasmid that encoded for
EPB50 (amino acids 1-716), which had been cloned in frame into the pACT2
plasmid, was provided by Dr F. Gunn-Moore. The EBP50 prey plasmid was tested
against the NrCAM CT bait, the neurofascin CT bait, the LI CT bait and the Ll-
RSLE bait using the filter lift assay with the result that EBP50 did not bind to
NrCAM or LI but did bind to neurofascin (Figure 5-15).
EBP50
RSLE Ankyrin FERM PDZ (aa 1-716)
NrCAM CT mmIfjqoj1 1~1
1102
Neurofascin CT I^Hfigq |
1065
LI CT ■MIfigq | I
1146
LI - RSLE 1rsle|figq 11 1_J
1146 1259
Figure 5-15. Testing of the binding of various LI-CAM constructs to EBP50.
The LI-CAM proteins have been shown diagrammatically. The red box indicates
the presence of an alternatively spliced RSLE motif. Green boxes represent the
ankyrin domain. The dark blue box is the proposed FERM binding domain of
neurofascin. The pale blue box is the equivalent amino acids of the FERM
domain in neurofascin present in NrCAM and LI. The dark pink boxes are the
PDZ binding domains of NrCAM and neurofascin. The pale pink box is the
equivalent amino acids of the PDZ domain of NrCAM present in LI. Binding
strengths were scored using the system outlined in Table 3-1.
5.1.7 Does NrCAM bind to the cytoplasmic terminus of any other Ll-CAMs?
It is also possible that NrCAM binds indirectly to the FERM family members by
first binding to neurofascin or LI RSLE, which then recruits the required binding
partner. It is already known that the ectodomains of NrCAM can bind to the IgG
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domains of neurofascin (Volkmer et al., 1996). However, it was not known whether
NrCAM binds to the cytoplasmic domains of either LI or neurofascin. Therefore the
full-length cytoplasmic terminus of rat NrCAM (without the RSLE sequence) was









1. pAS2-1 NrCAM CT encoding the
rat NrCAM cytoplasmic terminus
sequence (amino acids 1102-1215,





2. PCR primers NrCAM 33 and 34 were designed
to add the BamHI and EcoRI restriction enzymes
sites to the NrCAM encoding sequence (see^




3. The amplified PCR product
"NrCAM 33-34" and the empty
p SPORT plasmid were digested with
the restriction enzymes, BamHI and
EcoRI. The PCR product and the cut
vector were ligated together and then
transformed into DH5a. This resulted
in the production of a new plasmid
called pSPORT NrCAM 33-34.




4. The plasmid construct pSPORT NrCAM
33-34 was digested using restriction
R1 enzymes BamHI and EcoRI. The cDNA








5. The empty pACT2 plasmid was digested
restriction enzymes BamHI and EcoRI, and
then purified. The purified "NrCAM 33-34"
DNA fragment and the cut vector were ligated
together and transformed into DH5a. This
resulted in a new plasmid construct called









Figure 5-16. The cloning strategy for the production of the plasmid pACT2
NrCAM 33-34. Details of material and methods are described in chapter 2 and
accompanying text.
This new prey plasmid was tested against the NrCAM CT bait, NrCAM chick
bait, the LI CT bait, Ll-RSLE bait and neurofascin CT bait using the filter lift assay.
As shown in Figure 5-17 the cytoplasmic terminus of NrCAM did not appear to bind
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Figure 5-17. Testing of the binding of various Ll-CAM constructs to NrCAM's
cytoplasmic terminus. The Ll-CAM constructs have been shown
diagrammatically. The red box indicates the presence of an alternatively spliced
RSLE motif. The green boxes represent the ankyrin domain. The dark blue box
is the proposed FERM binding domain of neurofascin. The pale blue box is the
equivalent amino acids of the FERM domain in neurofascin present in NrCAM
and LI. The dark pink boxes are the PDZ binding domains of NrCAM and
neurofascin. The pale pink box is the equivalent amino acids of the PDZ domain
ofNrCAM present in LI. Binding strengths were scored using the system outlined
in Table 3-1.
5.2 Discussion of the results.
From section 5.1.1 transiently expressed NrCAM and ezrin co-localise in COS-7
cells and CGCs. This finding agrees with studies that have shown the co-localisation
of NrCAM and ezrin in other cell lines (Conacci-Sorrell et al., 2002). It therefore
seemed likely that the two proteins would interact. However the yeast two-hybrid
results performed here suggest that NrCAM does not interact with ezrin, radixin or
willin directly, nor can NrCAM interact indirectly with members of the 4.1
superfamily via an adaptor protein such as EBP50 (5.1.6).
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These results are in contrast to studies performed on neurofascin and LI, both of
which have been shown to interact directly with the FERM domain containing
proteins. For example neurofascin interacts with ezrin and willin via the last 28
amino acids which contains a 14 amino acid motif that has strong similarity to
FERM domain binding sequences (Brophy, 2001). LI has been shown to bind to
ezrin via amino acids N-terminal to its ankyrin binding motif, and also only when a
RSLE motif is present (Dickson et al., 2002). Both the neurofascin and the LI
results were confirmed here. Additionally in the current studies it was shown that
neurofascin and LI both bind to radixin, though this interaction appears to be weaker
than the LI-ezrin and neurofascin-ezrin interactions. Interestingly neurofascin binds
strongly to willin but the other LI-CAMS do not, whilst neurofascin also binds to
EBP50 while the other Ll-CAMs do not. Thus, it appears that all Ll-CAM family
members show different abilities to interact with members of the 4.1 superfamily.
196
Chapter 6. Investigations into the tyrosine
phosphorylation of the cytoplasmic terminus
of NrCAM and its effect on binding to
ankyrin.
6.0 Tyrosine phosphorylation inhibits ankyrin binding to Ll-
CAMs.
Members of the LI-CAM family have four highly conserved tyrosine residues
on their cytoplasmic termini. Studies involving neurofascin show that all four
tyrosine residues of the neurofascin cytoplasmic terminus are subject to
phosphorylation and dephosphorylation by protein tyrosine kinases and protein
phosphatases (Garver et al., 1997). However, the principle site of tyrosine
phosphorylation is the tyrosine of the highly conserved amino acid sequence
phenylalanine-isoleucine-glycine-glutamine-tyrosine (FIGQY) that makes up
part of the ankyrin binding site (Garver et al., 1997). Importantly the
phosphorylation of the tyrosine residue of the FIGQY sequence has been shown
to prevent ankyrin binding both to LI and to neurofascin (Garver et al., 1997;
Tuvia et al., 1997; Jenkins et al., 2001).
NrCAM's interaction with ankyrin was first described by (Davis and Bennett,
1994) and until recently ankyrin was NrCAM's only known cytoplasmic binding
partner (Davey et al., 2005). NrCAM has all of the four tyrosine residues that
are subject to tyrosine phosphorylation in neurofascin (see Figure 6-1, red font)
and the tyrosine phosphorylation of NrCAM is developmentally regulated
(Garver et al., 1997), implying a developmental role for tyrosine phosphorylation
of NrCAM in brain development. However, it had not been reported whether the
phosphorylation of the tyrosine of the FIGQY sequence in NrCAM affects the
receptor's ability to bind to ankyrin.
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E Y R S L E S D A E D H K P L K K G S R T P S D R T V K K E D S D
D S L V D G E G V N G Q F N E D G S F 1 G Q S G K K E K E P A
E G N E S S E A P S P V N A M N S F V
Figure 6-1. The amino acid sequence of the cytoplasmic terminus of NrCAM.
Highlighted in green are the amino acids that make up the ankyrin binding site. In
red font are the tyrosine residues that are equivalent to the tyrosine residues which
are phosphorylated in neurofascin (Garver et al., 1997). The amino acids RSLE,
surrounded by a broken line, are present in some isoforms of NrCAM. Amino
acids highlighted in grey were selected as a suitable target for a new cytoplasmic
antibody (see results section 6.3 for details).
6.1 Immunoprecipitations of HA-NrCAM from B104 cells.
The immunoprecipitation of HA-neurofascin from B104 neuroblastoma cells
has been successfully used to study the upstream pathways involved in the
tyrosine phosphorylation of neurofascin (Garver et al., 1997). Therefore, it was
decided to test whether this assay could also be used to study the NrCAM
phosphorylation pathways. Immunoprecipitation of HA-NrCAM with GIPC (as
discussed in Chapter 4) was attempted more or less simultaneously and Chapter 4
describes many of the initial experiments. Briefly immunoprecipitation of HA-
NrCAM from B104 cells stably expressing HA-NrCAM was not possible using
protein A beads but was achieved using anti-rat IgG beads coupled to rat
monoclonal anti-HA-antibodies (see Figure 4-10 and Figure 4-11 in chapter 4).
6.1.1 Immunoprecipitation of HA-NrCAM from B104 cells treated with a
protein tyrosine phosphatase inhibitor.
Tyrosine phosphorylation of neurofascin in B104 cells has been achieved
using the protein tyrosine phosphatase inhibitor sodium orthovanadate (Garver et
al., 1997). It was decided to see if tyrosine phosphorylated NrCAM could also
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be induced by sodium orthovanadate. The activation of sodium orthovanadate
and the treatment of the cells with sodium orthovanadate have been described
previously 2.3.3 and 2.3.4. Briefly, B104 cells stably expressing HA-NrCAM
were serum starved for two to six hours. Activated sodium orthovanadate was
added to half of the dishes of cells to be tested. The remaining dishes of cells
had an equal volume of sterile water added (vehicle) and were negative controls.
After a five-minute incubation at 37 °C each dish was extracted in ice-cold radio-
immunoprecipitation assay (RJPA) buffer in the presence of protease inhibitors
and phosphatase inhibitors. The immunoprecipitation was carried out at 4°C as
described in 2.3.13. The proteins were transferred onto nitrocellulose by
Western blot and probed with an anti-phosphotyrosine antibody (Upstate) as
described by 2.3.10. The nitrocellulose membrane was stripped of primary and
secondary antibodies as described by 2.3.18 and reprobed using an anti-HA or an
anti-NrCAM antibody.
The results are shown in Figure 6-2. Crude protein samples of sodium
orthovanadate treated cells showed numerous bands of tyrosine-phosphorylated
proteins and these protein bands ranged in size from 39 kDa to over 191 kDa (see
Figure 6-2 lane 2). There were two bands of tyrosine-phosphorylated proteins in
vehicle treated samples and these protein bands were approximately 60 kDa and
100 kDa (see Figure 6-2, lane 1). NrCAM was successfully immunoprecipitated
as a band of approximately 100 kDa as shown by NrCAM immunostaining of a
Western blot (see Figure 6-2 lane 7-8). However, NrCAM immunostaining also
showed a second band of approximately 55 kDa in size in (Figure 6-2, lanes 5-8).
It was unclear whether this band represented the unspecific binding of the
NrCAM antibody to an unknown protein or the binding of the antibody to
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cleaved NrCAM. There were no proteins immunoprecipitated in vehicle treated
cells (Figure 6-2, lane 3); however, there was a 100 kDa protein
immunoprecipitated from the sodium orthovanadate treated cell extract (Figure
6-2, lane 4). The size of this band corresponded to NrCAM. Thus, it would
appear that the 100 kDa band represents immunoprecipitated tyrosine
phosphorylated NrCAM.






Figure 6-2. Immunoprecipitation of HA-NrCAM from B104 cells treated with a
protein tyrosine phosphatase inhibitor. Western blots of 75 pg of crude cell
extract of B104 cells stably expressing HA-NrCAM (1-2,5-6) and of proteins
immunoprecipitated using anti-HA antibodies (3-4,7-8). Lanes 1 to 4 were probed
using a monoclonal anti-phosphotyrosine antibody. Lanes 5 to 8 are the same blot
as lanes 1 to 4, stripped of anti-phosphotyrosine antibody and reprobed for
NrCAM using a rabbit polyclonal antibody to the extracellular IgG domains of
NrCAM. Lane 1/5 is a 75 pg protein sample of vehicle treated, HA-NrCAM
expressing B104 cells. Lane 2/6 is a 75 pg protein sample of sodium
orthovanadate treated HA-NrCAM expressing B104 cells. Lane 3/7 is the
immunoprecipitated proteins from the vehicle treated HA-NrCAM expressing
B104 cells. Lane 4/8 is the immunoprecipitated proteins from sodium
orthovanadate treated, HA-NrCAM expressing B104 cells. See section 2-3 for
methods and appendix 3.
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6.2 Furin cleavage of NrCAM.
The 75 pg crude protein sample in Figure 6-2 (lanes 5 and 6) showed a
100 kDa NrCAM band. However, when a 120 pg sample of the HA-NrCAM
expressing B104 crude cell extract was separated by SDS-PAGE electrophoresis
and probed by Western blot using an antibody to the extracellular region of HA-
NrCAM, then two bands of HA-NrCAM were observed, (see Figure 6-3 (A)).
One was a highly expressed band of approximately 100 kDa and a second band
between 111 kDa and 210 kDa. These two bands have been previously reported
(Kayyem et al., 1992; Grumet, 1997). The two NrCAM bands could be the
result of differential glycosylation of NrCAM or two different isoforms of
NrCAM but are generally believed to be the result of furin protease cleavage in
the extracellular third fibronectin type Ill-like (FNIII-like) domain of NrCAM
(Kayyem et al., 1992).
Furin cleavage in the extracellular third FNIII-like domain is postulated to
result in a situation demonstrated diagrammatically by Figure 6-3 (B and C). If
NrCAM is uncleaved as described by Figure 6-3 (Bl) then it would appear as
one single high molecular weight band on an SDS PAGE gel (Figure 6-3 (C,
lane 1)). If NrCAM is cleaved and self-associating as described by Figure 6-3
(B2) it would appear as two lower molecular weight bands on an SDS-PAGE gel
(Figure 6-3 (C, lane 2)). The majority of NrCAM is believed to be cleaved by
furin and the minority of NrCAM is believed to remain uncleaved and therefore
there should be three protein bands when samples of NrCAM are run on SDS-
PAGE gels as shown in Figure 6-3 (C, lane 3) (Kayyem et al., 1992).
Antibodies raised to targets in the cytoplasmic terminus of NrCAM theoretically
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would give rise to a Western blot as described by Figure 6-3 (C, lane 4).
Unfortunately, there have been no reports of a successful antibody raised to the
cytoplasmic terminus of NrCAM to test this hypothesis. Antibodies raised to
targets in the extracellular domain of NrCAM that are N-terminal to the third
FNIII-like repeat would therefore give a staining pattern as demonstrated by
Figure 6-3 (C, lane 5).
A. Western blot B. Immunoprecipitations






Figure 6-3. A diagiammalical representation of the current theory regarding
NrCAM protease cleavage. A) A Western blot of a 120 pg sample of HA-
NrCAM expressing B104 cells. B) Diagrammatical representations of
immunoprecipitations of HA-NrCAM that has been 1) uncleaved and 2) furin
cleaved and self associating at the third FNIII-like domain. (C) A hypothetical
SDS-PAGE gel and Western blot. Protein sizes are before post-translational
modifications. Lane 1 are the proteins which would be immunoprecipitated by
Bl, Lane 2 are the proteins which would be immunoprecipitated by B2. Lane 3
represents the approximate proportion of proteins expected from
immunoprecipitations in Bl and B2. Lane 4 represents the bands from lane 3 that
would be selected by an antibody to the cytoplasmic terminus ofNrCAM. Lane 5
are the bands in lane 3 that would be selected by an antibody to the extracellular
domain of NrCAM and N-terminal to the third FNIII-like of NrCAM.
The results in Figure 6-2 showed that the extracellular antibody recognised
bands of approximately 100 kDa and approximately 55 kDa of which only the
100 kDa band was tyrosine phosphorylated NrCAM, therefore suggesting that
the cytoplasmic terminus of NrCAM was not present. To try to overcome this
problem it was decided to raise an antibody to the cytoplasmic terminus of
NrCAM to both reconfirm this observation and to produce an antibody that could
immunoprecipitate out the C-terminus of NrCAM that could then be probed for
tyrosine phosphorylation.
6.3 Design and testing of a peptide antibody to the
cytoplasmic terminus of NrCAM.
An antibody was designed to the cytoplasmic terminus of NrCAM. The
cytoplasmic terminus of NrCAM was examined for a ten amino acid sequence
that was both hydrophilic and contained a low sequence homology to other
members of the LI-CAM family. Hydrophilicity was tested by manually
checking the amino acid sequence of NrCAM's cytoplasmic terminus (Figure 6-
1). The homology of different peptide sequences to other known protein
sequences was checked using the BLAST search facility at NCBI protein
database (www.ncbi.nlm.nih.gov/). The sequence KKGSRTPSDR (given in
single letter amino acid code) was chosen as the best sequence at filling both
criteria. The N-acetylated KKGSRTPSDR peptide was manufactured and
coupled to Keyhole limpet hemocyanin and then immunised into two rabbits by
ResGen™, Invitrogen. Serum from bleeds at 4 weeks, 8 weeks, 10 weeks and the
final bleeds were obtained from each rabbit. The different serums were tested by
Western blot analysis against either 0.5 gg of Glutathione S-transferase (GST) or
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0.5 pg of GST coupled to the cytoplasmic terminus of NrCAM (GST-NrCAM).
Week 8 was selected for further analyses as this serum gave the strongest
reaction with GST-NrCAM at dilutions from 1/1000 to 1/2000. The Week 8
serum from both rabbits was affinity purified as described by 2.3.17. The
affinity-purified antibodies were both tested against Western blots of GST and
GST-NrCAM. Dilutions from 1/50 to 1/100 of affinity-purified antibodies were
sufficient to select and bind GST-NrCAM but not to bind to GST alone.
Most cell lines do not express NrCAM. The antibodies were tested against
proteins samples from untransfected cell lines and cell lines that were transfected
with various plasmids encoding full length rat NrCAM, HA-NrCAM and a HA-
NrCAM construct missing the C-terminal 11 amino acids of the cytoplasmic
terminus of NrCAM (HA-NrCAM A11CT) (a kind gift from Dr. Catherine
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Figure 6-4. Western blots showing the testing of antibodies raised to the
cytoplasmic terminus of NrCAM. A) Blots were probed with an anti-HA
antibody. B) The same protein samples as the blots in (A) were probed with a
1/50 dilution of affinity purified antibody from rabbit 1 and rabbit 2 as indicated.
Lanes 1 to 4 are 75 pg protein samples of transiently transfected CHO cells. Lane
1 was untransfected, lane 2 was transfected with HA-NrCAM A11CT, lane 3 was
transfected with HA-NrCAM, lane 4 was transfected with full-length NrCAM.
Lanes 5 to 8 are 75pg protein samples of transiently transfected CHO cells. Lane
5 was untransfected, lane 6 was transfected with HA-NrCAM, lane 7 was
transfected with full length NrCAM, lanes 8 was transfected with HA-NrCAM
A11CT. See section 2-3 and appendix 3 for methods.
As shown in Figure 6-4, antibodies raised to this peptide of NrCAM were
either non-specific or gave no response. The antibodies picked up numerous
protein bands from approximately 20 kDa to 150 kDa. Unfortunately, no
antibody picked up a band in NrCAM transfected cells that did not also appear in
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the untransfected cells. Therefore it was concluded that the attempt to make a
cytoplasmic antibody to NrCAM was unsuccessful.
6.4 Accurate sizing of NrCAM fragments.
In the absence of an antibody to the cytoplasmic terminus of NrCAM it
became important to use a Western blot system that showed accurate sizing of
molecular weight proteins. The NuPAGE® Novex 3-8% Tris-Acetate together
with HiMark1M protein markers gives an accurate measurement of high
molecular weight proteins up to 500 kDa when compared to other SDS-PAGE
gels and markers (http://www.invitrogen.com) and thus this system was adopted
for all of the following experiments. Apparent molecular weight of protein bands
were calculated using the HIMark™ Molecular Weight Calculator at
www. invitrogen.com.
The predicted molecular weight was 127 kDa for full length NrCAM, 94 kDa
for the extracellular region to the furin cleavage site and 34 kDa from the furin
cleavage site to the C-terminal end of the cytoplasmic terminus (Figure 6-5).
The molecular weights of the molecules are before post-translational
modifications such as glycosylation.
The size of HA-NrCAM on Western blots was next determined using the
HIMark™ Molecular Weight Calculator. N-terminally HA tagged neurofascin
(isoform 186) (a kind gift from Dr Vann Bennett. Howard Hughes Medical
Institute, USA) was used as a positive control. Neurofascin does not have a furin
cleavage site (Hortsch, 1996) and therefore any band appearing on a Western
blot should not be furin cleaved. HA-NrCAM and HA-neurofascin cDNA was
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transfected into CHO cells as described by 2.2.5 and after 24 hours the
immunoprecipitation experiments were carried out using anti-HA antibodies














Figure 6-5. Western blots of 80 pg of crude cell extract of CHO cells. Lane 1
are cells transfected with HA-neurofascin. Lane 2 are cells transfected with HA-
NrCAM. Lane 3 is the immunoprecipitation of HA-neurofascin. Lane 4 is the
immunoprecipitation of HA-NrCAM. Lanes 1 to 4 were probed using a
monoclonal anti-HA antibody. See section 2-3 and appendix 3 for methods.
As shown in Figure 6-5 (lane 1) HA-neurofascin did not express as well as
HA-NrCAM and its size was approximately 185 kDa as previously reported
(Volkmer et al., 1992). HA-NrCAM was detected as two bands (Figure 6-5 (lane
2)). The higher band was between the 240 kDa and 160 kDa marker and was
calculated to be approximately 180 kDa (Figure 6-5 (2)). The lower band was
between the 160 kDa and 116 kDa markers and was calculated to be
approximately 140 kDa (Figure 6-5 (2)). Native NrCAM is normally reported as
being 140 kDa in brain extracts (Kayyem et al., 1992; Davis et al., 1996) and this
is believed to be the furin cleaved form (Kayyem et al., 1992; Grumet, 1997).
Interestingly the 140 kDa protein band from the CHO cell extract was of
approximately equal expression level when compared to the 180 kDa band. The
lower band was usually more highly expressing in other cell types (Chapter 4,
and Figure 6-3 (A) in this chapter). However, in all experiments done using
208
CHO cells the band was of approximately equal expression (see also Figure 6-4
(A)). This indicates that the expression levels of both isoforms are cell type
specific.
The immunoprecipitation of HA-NrCAM gave the same two bands already
observed in the crude cell extract. Surprisingly the immunoprecipitation of
HA-neurofascin also showed two protein bands. The higher band appears to be
the band of approximately 185 kDa already seen in the crude cell extract.
However, a band of approximately 175 kDa was also present. Neurofascin does
not have a furin cleavage site and is therefore unlikely to be furin cleaved
(Hortsch, 1996). Therefore, it was thought possible that both protein bands for
neurofascin may be due to differential post-translational modification of a
percentage of the protein. Neurofascin has been reported to be subject to both N-
linked and O-linked glycosylation (Volkmer et al., 1992). If the two proteins
bands for neurofascin were the results of different glycosylation of the proteins
then the two protein bands for NrCAM could also be the results of different
glycosylation and not cleavage as previously thought. It was therefore decided to
test whether the HA-NrCAM protein used in the immunoprecipitations above
was subject to N-linked glycosylation .
6.4.1 Examination of the N-linked glycosylation of NrCAM.
To examine N-linked glycosylation, protein extracts of HA-NrCAM were
treated with N-glycosidase F (PNGase F), which enzymatically removes N-
glycans (Maley et al., 1989) (2.3.19). The protein samples were run on
NuPAGE® Novex 3-8% Tris-Acetate gels with HiMark™ protein markers and
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the sizes of the glycosylated and de-glycosylated proteins were compared. A




Figure 6-6. Studying the effects of N-linked glycosylation on the size of
HA-NrCAM. Lanes 1 to 2 are HA-NrCAM immunoprecipitated from
HEK293 cells. Lane 1 was an untreated sample and lane 2 was treated
with PNGase F. Lanes 1 to 2 were probed using a monoclonal anti-HA
antibody. See section 2-3 and appendix 3 for methods.
Untreated samples, and therefore potentialy glycosylated showed the two
bands of molecular weight 180 kDa and 140 kDa as previously observed (Figure
6-6 (lane 1)). However, the addition of PNGase F resulted in a decrease in both
sizes to molecular weight 155 kDa and 105 kDa, indicating that there had been a
decrease of 25-30 kDa. Therefore, it would appear that both protein bands for
HA-NrCAM are glycosylated. The size difference between the two bands must
therefore be due to a different post-translational modification.
6.4.2 Examination of HA-NrCAM in the human carcinoma cell line,
LoVo.
The human carcinoma cell line LoVo does not express a functional furin
protease (Logeat et a/., 1998) and has been used successfully to study the effects
of furin cleavage on Tractin (the LI-CAM family member in leech) (Xu et al.,
2003). Therefore, HA-NrCAM was transiently transfected into LoVo cells as
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described in section 2.2.5. Western blots were carried out and the size of
HA-NrCAM in LoVo cells was compared to the size of HA-NrCAM in human
embryonic kidney (HEK293) cells. The results are shown in Figure 6-7.
240 kDa
Figure 6-7. Studying the effects of furin cleavage on the size of HA-
NrCAM. Lanes 1 is a 80 pg cell extract of HA-NrCAM expressing
HEK293 cells. Lane 2 is a 80 pg cell extract of HA-NrCAM expressing
LoVo cells. Lanes 1 to 2 were probed using a monoclonal anti-HA
antibody. See section 2-3 and appendix 3 for methods.
In HEK293 cells, NrCAM is expressed as two protein bands of
approximately 180 kDa and 140 kDa. In LoVo cells NrCAM is expressed as two
protein bands of approximately 210 kDa and 170 kDa. Therefore, both protein
bands of HA-NrCAM have increased in apparent molecular weight by
approximately 30 kDa. The molecular weight of the cleaved fragment of
NrCAM from the third FNIII-like domain to the cytoplasmic tail is estimated to
be 34 kDa (see Figure 6-3(C)). This finding suggested that both fragments of
HA-NrCAM may be furin cleaved and that the cytoplasmic terminus of
HA-NrCAM may not be present in any of the immunoprecipitations in the other
cell lines. Unfortunately, LoVo cells did not express HA-NrCAM at high
enough levels to make immunoprecipitation possible from this cell line. As the
cytoplasmic terminus is necessary for both the tyrosine phosphorylation
experiments being attempted above and the co-immunoprecipitation experiments
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attempted in Chapter 4 it was decided to design a HA-NrCAM clone that could
not be furin cleaved. This was done by removing the third FNIII-like repeat
from HA-NrCAM.
6.5 Cloning and analysis of HA-NrCAM AFN2&3.
The second and third FNIII-like repeats ofHA-NrCAM were deleted by PCR
and a new construct that coded for HA-NrCAM without the 2nd and 3rd FN1II-







A kind gift of pIRESneo HA-NrCAM
was received from Dr. C. Faivre-
Sarrailh, University of Marseille,
France. It encoded for the signal
peptide of NrCAM followed by the
HA epitope followed by full length
rat NrCAM (as published Davis et al
1996).
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2. The plasmid construct of pIRESneo HA-
NrCAM was digested using the restriction






3. The HA-NrCAM fragment was digested using
the restriction enzyme Apal. This resulted in
three fragments named top, bottom and middle
(after their relative positions on an agarose gel).
The largest fragment (2792bp, named top)
encoded for the HA epitope and 5' cDNA of
NrCAM to the end of the first FNIII-like domain.
The smallest fragment (479bp, named bottom)
contained the cDNA for second and third FNIII-
like domains. The remaining fragment (1229bp,
named middle) encoded for the cDNA from the
beginning of the forth FNIII-like domain, the









pBluescript II KS+ | LacZ
4. pBluescript a was digested with EcoRI
and Apal restriction enzymes, alakine
phosphatase treated, then ligated together
with either the "top" NrCAM cDNA
fragment or the ''middle" NrCAM cDNA
fragment. The ligations were transformed
into DH5a for amplification.This resulted
in the production of two new plasmid called







5. The plasmid construct pBluescript middle was not the correct ffame2. PCR primers
NrCAM F1 and NrCAM F2 were designed to: 1) put the NrCAM cDNA into the
correct frame 2) to retain the Apal and EcoRI restriction enzyme sites to the NrCAM





Figure 6-8. Continued on next page.
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6 The amplified PCR product
"m4" and the empty plasmid
pBluescript II KS+ were digested
with the restriction enzymes, Apal
and EcoRI. The PCR product and
the cut vector were ligated
together and then transformed into
DH5a. This resulted in the












7. The plasmid constructs pBluescript top and pBluescript m4 were digested
using restriction enzymes Apal and EcoRI. The two fragment containing
NrCAM were purified. The empty pSPORT plasmid was digested with the
restriction enzymes EcoRI, purified and alkaline phosphatases treated. The
purified "top" and "m4" cDNA fragments and the cut vector were ligated
together and transformed into DH5a. This resulted in the production of a
new plasmid construct called pSPORT HA-NrCAM ? FN2&3.






















8. The plasmid construct pSPORT HA-
NrCAM AFN2&3 was digested using the
restriction enzymes EcoRI. The fragment
containing HA-NrCAM AFN2&3 was
purified.
9. The empty pCMV-script plasmid
was digested with the restriction
enzyme EcoRI, alkaline phosphatase
treated and then purified. The purified
"HA-NrCAM AFN2&3" cDNA
fragment and the cut vector were
ligated together and transformed into
DH5a. This resulted in the production
of a new plasmid construct called HA-




EcoRI 5' HA-NRCAM AFN2&3
'EcoRI
Kanr
Figure 6-8. The cloning strategy for the production of the plasmid HA-
NrCAM AFN2&3. Details of material and methods are described in chapter 2
and accompanying text.
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6.5.1 HA-NrCAM AFN2&3 expression and glycosylation.
HA-NrCAM and HA-NrCAM AFN2&3 plasmids were transfected into
HEK293 cells as described by 2.2.5. Crude cell extracts were prepared and run







Figure 6-9. Expression of the HA-NrCAM AFN2&3 construct in HEK293 cells.
Lane 1 is a 80 pg crude cell extract of HA-NrCAM AFN2&3 expressing HEK293
cells. Lane 2 is a 80 pg crude cell extract of HA-NrCAM expressing HEK293 cells.
Lanes 3 to 4 are HA-NrCAM AFN2&3 immunoprecipitated from HEK293 cells.
Lane 3 was treated with PNGase F and lane 4 was left untreated. Lanes 1 to 4 were
probed using a monoclonal anti-HA antibody. See section 2-3 and appendix 3 for
methods.
As shown in Figure 6-9 crude cell extracts of HA-NrCAM AFN2&3 appeared
as a diffuse band from approximately 180 kDa to 140 kDa. To examine whether
this truncated form of NrCAM underwent N-linked glycosylation, HA-NrCAM
AFN2&3 cDNA was again transiently transfected into HEK293 cells,
immunoprecipitated, and then healed with or without PNGase F. The protein
samples were run on a NuPAGE® Novex 3-8% Tris-Acetate gel and sizes of the
glycosylated and de-glycosylated HA-NrCAM AFN2&3 proteins were
compared. The results are shown in Figure 6-9 (lanes 3 and 4). Untreated HA-
NrCAM AFN2&3 immunoprecipitated from a HEK293 cells as a single band of
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approximately 140 kDa. Deglycosylation reduced the apparent molecular weight
ofHA-NrCAM AFN2&3 by 30 kDa to approximately 100 kDa. This was similar
to the molecular weight reduction found for HA-NrCAM. Importantly the 100
kDa weight was close to the 110 kDa weight predicted for the HA-NrCAM
AFN2&3 protein. Therefore, HA-NrCAM AFN2&3 appeared to be uncleaved.
Three attempts were then made to transiently transfect HA-NrCAM AFN2&3
cDNA into LoVo cells. However, the HA-NrCAM AFN2&3 protein was not
expressed at a detectable levels (not shown). As HA-NrCAM AFN2&3 appears
to be uncleaved it was therefore decided to investigate whether the tyrosine-
phosphorylated protein could be immunoprecipitated from orthovanadate treated
HEK293 cells.
6.5.2 Immunoprecipitation of HA-NrCAM AFN2&3 protein from
HEK293 cells treated with a protein tyrosine phosphatase inhibitor.
HEK293 cells were transiently transfected with HA-NrCAM AFN2&3. After
24 hours the HEK293 cells were treated with either sterile water (vehicle) or
sodium orthovanadate as described previously. The immunoprecipitation was
carried out as described by 2.3.15 and Western blots were carried out. The
procedure was repeated on four separate occasions. Figure 6-10 is a typical blot
of one such experiment.
Immunostaining for HA-NrCAM AFN2&3 normally appeared as a band of
approximately 100 kDa (Figure 6-9, lane 3). As shown in Figure 6-10 (B, lanes
3 and 4) a band of this weight appeared in the immunoprecipitated extract when
it was reprobed with an anti-HA antibody. However, no 100 kDa tyrosine













Figure 6-10. Immunoprecipitation of HA-NrCAM AFN2&3 from sodium
orthovanadate treated HEK293 cells. A) Western blots (probing with a
monoclonal anti-phosophotyrosine anibody) of 80 pg of crude cell extract of
HEK293 cells transfected with HA-NrCAM AFN2&3 (lanes 1-2) and of proteins
immunoprecipitated from the HEK293 cells using anti-HA antibodies (lanes 3-4).
Lane 1 and lane 3 were the vehicle treated sample. Lane 2 and lane 4 were the
orthovanadate treated sample. B) The blot in (A) was stripped of primary and
secondary antibodies and reprobed with anti-HA antibodies. Arrow indicates
immunoprecipitated HA-NrCAM See section 2.3 and appendix 3 for methods.
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antibody (Figure 6-10 (A, lane 4). Thus it would appear that immunoprecipitated
HA-NrCAM AFN2&3 was not phosphorylated. However, two novel
phosphorylated bands were seen in Figure 6-10 (A, lane 4). A band of
approximately 80 kDa (that appeared in all of the immunoprecipitation attempts
of HA-NrCAM AFN2&3) and a second large molecular weight protein band of
approximately 400 kDa (that was visible in this immunoprecipitation attempt
only).
6.6 Ankyrin-GFP binding to NrCAM.
As the immunoprecipitations of various tyrosine phosphorylated NrCAM had
been unsuccessful it was decided to try a different assay to study the effects of
the tyrosine phosphorylation of the NrCAM cytoplasmic terminus. The assay
was based upon the ability of both neurofascin and LI to recruit the normally
cytoplasmic protein ankyrin-GFP to the plasma membrane of HEK293 cells
(Zhang et al., 1998b; Needham et al., 2001). It was decided to test whether this
assay could be used to show both the binding of ankyrin-GFP to NrCAM and
examine the effects of tyrosine phosphorylation on the ankyrin-GFP-NrCAM
interaction.
A plasmid encoding full-length ankyrinG C-terminally tagged with GFP
(ankyrin-GFP) was a kind gift from Dr Vann Bennett, Howard Hughes Medical
Institute, USA. HEK 293 cells were grown overnight to approximately 50%
confluence on standard glass cover slips. The HEK 293 cells were transfected
with 2.5 pg of ankyrin-GFP plasmid only, or 2.5 pg ankyrin-GFP plasmid and
2.5 pg of HA-NrCAM plasmid (2.2.5). The transfected cells were allowed to
grow for a further 24 hours, fixed, immunostained and imaged (section 2.2.10)
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Typical transfected HEK293 cells are shown in Figure 6-11 (A to E).
Ankyrin-GFP shows a cytoplasmic distribution in cells that are not expressing
NrCAM (Figure 6-11 (A and B)). However, expression of HA-NrCAM in
HEK293 cells recruited ankyrin-GFP to the plasma membrane (Figure 6-11 (D to
F)), thus suggesting that the two proteins are interacting. This was then tested in
other cell types such as CHO cells, B104 cells and COS-7 cells. However
intriguingly, the recruitment of ankyrin-GFP to the membrane only occurred in
the HEK293 cell line. This concurred with previous results for neurofascin and
ankyrin-GFP (Zhang et al., 1998a).
Despite the successful recruitment of ankyrin-GFP to the membrane Figure 6-
11 (F to H) demonstrated a technical problem. Namely, the expression level of
both proteins was critical to the recruitment of ankyrin-GFP. In Figure 6-12 (F)
the ankyrin-GFP plasmid is over expressed and while it has been noticeably
recruited to the plasma membrane, some of it has remained in the cytoplasm. A
similar situation occured when the expression level of NrCAM was low. It was
therefore difficult to score the effectiveness of NrCAM's ability to recruit
ankyrin-GFP under different phosphorylation conditions in a mixed population
of NrCAM/HA-NrCAM and ankyrin-GFP transfected cells. An attempt was
made at cloning out HEK293 cells that stably expressed HA-NrCAM to
overcome this difficulty. However, these clones, though expressing HA-NrCAM
at high level, had lost their contact inhibition and failed to grow as a monolayer,
making them difficult to image and thus unsuitable for phosphorylation studies
planned.
220
Figure 6-11. Ankyrin-GFP expression in HEK293 cells. A) and B) are
HEK293 cells transfected with ankyrin-GFP only. C), D) and E) is a HEK293
transfected with both HA-NrCAM and ankyrin-GFP. F), G) and H) is a
HEK293 transfected with both HA-NrCAM and ankyrin-GFP. Ankyrin-GFP is
shown in green (C,F). HA-NrCAM immunostaining was performed using an
anti-HA rat monoclonal antibody and anti-mouse Alexa 568 conjugated
antibody and is shown in red (D, G). Overlay of both ankyrin-GFP and HA-
NrCAM (E,H). See methods section 2.2.10..
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It was therefore decided to study individually transfected cells by live
imaging. Cells were to be treated with various growth factors to see if this could
influence the recruitment of ankyrin-GFP to the plasma membrane by
HA-NrCAM. Cells were transfected with both HA-NrCAM and ankyrin-GFP
and left in serum free media. However, it was noted that the transport of these
cells to the microscope caused ankyrin-GFP to move to the cytoplasm. The HA-
NrCAM and ankyrin-GFP transfected cells were then left at 37 °C in 5% CO2 on
the microscope for approximately one hour and it appeared that most of the
ankyrin-GFP had returned to the membrane. However another technical problem
arose as imaging the transfected cells using the Zeiss Axiovert SI00 2TV Delta-
Vision Restoration microscope proved impossible, as the process of shining the
laser on a cell seemed to cause the ankyrin-GFP to return once more to the
cytoplasm.
6.7 Discussion of results.
Previous chapters have shown that the NrCAM cytoplasmic terminus can bind
to ankyrin using the yeast two-hybrid system and that this binding occurred when
a 26 amino acid motif was present that ended in FIGQY. The mutation of the
tyrosine residue of the FIGQY motif to glutamate abolished ankyrin binding to
NrCAM and it was believed that this might mimic the phosphorylation of
NrCAM. Thus, there was evidence that NrCAM may be phosphorylated at the
FIGQY tyrosine in a similar manner to LI and neurofascin and that this
phosphorylation may prevent ankyrin binding. It was therefore decided to study
the tyrosine phosphorylation of NrCAM using other phosphorylation
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experiments. It was hoped that the immunoprecipitations experiments could be
used to establish whether tyrosine phosphorylation occurred mainly at the
FIGQY tyrosine (as for neurofascin) and to study the pathways involved in the
phosphorylation by the use of various growth factors, phosphatase inhibitors and
kinase inhibitors.
One immunoprecipitation experiment appeared to have been successful in
showing the tyrosine phosphorylation of NrCAM (Figure 6-2). It was notable
that this attempt was made on cell extracts of B104 cells that had grown to 100%
cell density and that attempts made at lower cell densities had been unsuccessful.
This could imply that at high levels of cell-to-cell contact either more NrCAM is
available for phosphorylation or there was more of a particular kinase available
to phosphorylate NrCAM. Similar findings have been found in investigations
into integrin signalling, where different kinases and phosphatases are present at
the points of cell-to-cell contact of fibroblasts grown in 3D cultures than in 2D
cultures and the phosphorylation of a5(31 was effected (DeMali et al., 2003).
The blot shown in Figure 6-2 has a band of approximately 100 kDa in the
unstimulated crude cell extract and that may indicate that a proportion of stably
expressed HA-NrCAM may always be constitutively phosphorylated. A similar
finding was also identified for stably expressed HA-neurofascin in B104 cells
(Garver et al., 1997). Therefore, it would appear that at a proportion ofNrCAM
and neurofascin may always remain phosphorylated. It would be interesting to
identify which sub-population of NrCAM/neurofascin remains phosphorylated
even under serum starvation conditions. One possibility is that
NrCAM/neurofascin are being transported to sites at the plasma membrane in
which they remain phosphorylated until reaching their final destination. Here it
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is then dephosphorylated by an unknown phosphatase and becomes available for
ankyrin binding. Another possibility is that there are always two pools of
NrCAM/neurofascin in the plasma membrane. One pool is unphosphorylated
and binds to ankyrin and the other pool is phosphorylated as has been reported
for the LI receptor (Gil et al., 2003). A third possibility is that tyrosine
phosphorylation is necessary for the binding of NrCAM to an as yet unidentified
protein. For example neurofascin has been reported to bind to doublecortin but
only when it is phosphorylated on its FIGQY tyrosine (Kizhatil et al., 2002).
It is normally believed within the literature that the majority of NrCAM is
furin cleaved (Kayyem et al., 1992; Davis et al., 1996). As the antibodies used
in this experiments were N-terminal to the furin cleavage site any
immunoprecipitated furin cleaved NrCAM would not have a cytoplasmic
terminus. An attempt was therefore made to raise antibodies to the cytoplasmic
terminus of NrCAM, so that these antibodies could be used to both verify the
results in 6-2 and for immunoprecipitation experiments. Despite initial positive
indications these antibodies failed to detect expression of NrCAM transfected
into mammalian cells. A second attempt to make antibodies to a different target
in the NrCAM cytoplasmic terminus has also been unsuccessful and has failed to
show convincing binding to NrCAM constructs (personal communication Dr. F.
Davey, University of St Andrews).
As no cytoplasmic antibody was available it was necessary to confirm that the
100 kDa tyrosine phosphorylated immunoprecipitated band in Figure 6-2
contained the cytoplasmic terminus of NrCAM using other methods. The
appearance of two bands for the immunoprecipitated HA-neurofascin isoform
186 (which does not have a furin cleavage site in its third FNIII-like domain)
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suggested that there may be another post-translational modification other than
furin cleavage that could explain the second band of neurofascin. The primary
post-translational modification studied in neurofascin has been N- and O-linked
glycosylation (Volkmer et al., 1992). NrCAM has two potential O-linked
glycosylation sites (NetOGlyc 3.1; http://www.cbs.dtu.dk/services/NetOGlyc/)
and has 16 potential N-linked glycosylation sites (NetNGlyc 1.0;
http://www.cbs.dtu.dk/services/NetNGlyc/). O-linked glycosylation has not been
found to result in a large difference in the molecular mass of neurofascin
(Volkmer et al., 1992). Therefore, NrCAM was tested for potential N-linked
glycosylation. If the two NrCAM bands could be explained by differently
glycosylated NrCAM populations then the removal of N-linked glycans from
NrCAM would result in a single band of the same molecular weight. However,
both NrCAM bands were reduced in size by approximately 25 to 30 kDa thus
suggesting that both bands were subject to equivalent N-linked glycosylation.
This indicated that the lower band of HA-NrCAM was due to furin cleavage.
If the lower band of HA-NrCAM was furin-cleaved, and the higher band was
uncleaved NrCAM, then the expression of NrCAM in a cell line deplete in
functional furin should result in the higher molecular weight band of NrCAM
only. This had already been reported for Tractin (the LI-CAM in leech) (Xu et
al., 2003). While cleavage products of Tractin were found in HEK293T cells no
cleavage products of Tractin were found in LoVo cells (a cell line without
functional furin) (Xu et al., 2003). However, when HA-NrCAM was expressed
in LoVo the apparent size of both NrCAM protein bands increased by 30 kDa.
The molecular weight of the cytoplasmic portion of cleaved NrCAM was
estimated to be 34 kDa. Therefore, it would appear that both protein bands of
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NrCAM in HEK293 cell represented fiirin-cleaved NrCAM and hence would not
contain the C-terminus.
To confirm if both bands of NrCAM are furin cleaved a future experiment
could be to add the furin enzyme to LoVo cell extracts containing HA-NrCAM.
IfNrCAM is furin cleaved both bands should decrease by approximately 30 kDa
when compared to bands from LoVo extracts untreated by furin.
At this stage, it had been determined that all of the expressed NrCAM was
cleaved in all cell lines except the LoVo cell line. However, the LoVo cell line
was not suitable for immunoprecipitation experiments (because of low
expression levels). Therefore, HA-NrCAM cDNA that did not encode for the
second or third FNIII-like domains of NrCAM was cloned into a mammalian
expression vector (HA-NrCAM AFN2&3). The furin cleavage site is within the
third FNIII-like repeat of NrCAM and so HA-NrCAM AFN2&3 should not be
furin cleaved. Indeed, the HA-NrCAM AFN2&3 protein appeared as a single
diffuse band in most Western blots and so did not appear to be furin cleaved.
Several attempts were made to immunoprecipitate out tyrosine-phosphorylated
HA-NrCAM AFN2&3 from HEK293 cells. Unfortunately, despite expression
and immunoprecipitation of HA-NrCAM AFN2&3, no phosphorylated protein
was observed. However, two new tyrosine-phosphorylated proteins were seen in
immunoprecipitations of orthovanadate treated cells The first protein was
approximately 80 kDa in size and highly expressed and it was seen in all four
attempts at immunoprecipitation of HA-NrCAM AFN2&3. The second protein
was between 260 kDa and 500 kDa in size and appeared only in one
immunoprecipitation attempt. Both of these proteins could be proteins that were
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binding unspecifically to the beads and/or antibodies used for the
immunoprecipitation. However, both proteins could also be potential binding
partners of NrCAM that were co-immunoprecipitated with the HA-NrCAM
AFN2&3 protein. For example ankyrin can be tyrosine phosphorylated
(Woroniecki et al., 2002) and isoforms of ankyrin range from 26 kDa to 480 kDa
(Mohler et al., 2002). Thus both proteins immunoprecipitated with HA-NrCAM
AFN2&3 in Figure 6-10 could be ankyrins.
The recruitment of ankyrin-GFP to the plasma membrane of HEK293 cells by
NrCAM and HA-NrCAM confirms the interaction of ankyrins and NrCAM
already shown in Chapter 3. Viewing the cells live appeared to indicate that this
interaction was highly dynamic as stresses such as moving the cells, or even use
of a laser abolished the NrCAM-ankyrin interaction causing ankyrin-GFP to
move back to the cytoplasm. Re-incubating the cells under normal growth
conditions did appear to result in a return of ankyrin-GFP to the membrane. This
phenomenon has implications for its role in dynamic structures such as the
growth cone. It is interesting to speculate that kinases could be phosphorylating
NrCAM in responses to stresses (resulting in reduced ankyrin binding) and that
phosphatases remove the phosphate groups under normal growth conditions
(resulting in increased ankyrin binding).
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Chapter 7. Overall discussion.
7.0 Introduction and aims.
NrCAM is a cell adhesion molecule of the LI-CAM family and together with the
other Ll-CAMs is important for the development of the mammalian nervous system
(Hortsch, 1996). Within the neuron, NrCAM is expressed at initial segments, the
node of Ranvier, growth cones, post and pre-synaptic densities (Jenkins and Bennett,
2001; Custer et al., 2003; Falk et al., 2004; Petralia et al., 2005).
At the start of this project, NrCAM's only known cytoplasmic binding partner
was ankyrin (Davis et al., 1996), a protein that couples membrane receptors to the
actin cytoskeleton via spectrin (Bennett and Chen, 2001). Ankyrin binding was
common to all the Ll-CAMs and ankyrin binding to both NrCAM and neurofascin
was known to play an important role in the development of the initial segment and
the node of Ranvier (Davis et al., 1996). However, ankyrin binding to NrCAM and
LI could not fully explain their behaviours in the growth cone and many authors
believed that another family of proteins may be binding to NrCAM and LI (Gil et
al., 2003a). Therefore, it was decided to both investigate whether NrCAM had any
other cytoplasmic binding partners and to investigate the effects of phosphorylation
on the dynamics of the ankyrin-NrCAM interaction. The strategy taken was three
pronged. Firstly, novel candidate binding partners of NrCAM were investigated
using a yeast two-hybrid library screen (Chapter 3). Potential interactions were re¬
confirmed, where possible, and the function of the NrCAM-candidate interaction
investigated (Chapter 4). Secondly, proteins of the 4.1 superfamily, that were
already suspected to bind to NrCAM, were investigate#d as potential binding
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partners (Chapter 5). Thirdly, an attempt was made to investigate the tyrosine
phosphorylation of NrCAM and the effects on ankyrin binding.
7.1 Identification of novel binding partner to NrCAM.
To identify cytoplasmic binding partners of NrCAM, a developing rat cDNA
library was screened using the yeast two-hybrid technique (Chapter 3). The screen
identified three potential binding partners ofNrCAM.
The first binding partner contained the Vps27, Hrs, STAM (VHS) domain of
Golgi-localized, gamma-ear-containing, Arf binding protein 1 (GGA1). The VHS
domain is present in several proteins and is known to bind to membrane receptors
(Lohi etal., 2002). The GGA1 protein is thought to sort bound membrane receptors
from the trans Golgi network to the endosome (Bonifacino, 2004). The VHS clone
selected by the library screen appeared to be binding to amino acid residues that
make up the ankyrin binding domain of NrCAM. Furthermore, the VHS clone
bound to a neurofascin clone that also contained the highly conserved ankyrin
binding domain. Interestingly the amino acid substitution of a glutamate residue for
a tyrosine in NrCAM's ankyrin binding domain or the deletion of the amino acids
LVDY from LI's ankyrin binding domain eliminated VHS binding. This appeared
to be consistent with other reports of important residues in VHS domain/receptor
binding (Bonifacino, 2004). Thus, it has been concluded that the VHS domain of
GGAl is binding to NrCAM at the ankyrin binding site. Unfortunately time
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constraints did not allow for further investigation of the full length GGA1 (GGA2,
and GGA3) interactions with NrCAM in the work done for this thesis.
The two other potential binding partners were GAIP interacting protein C
terminus (GIPC) and synapse associated protein 102 (SAPI 02). GIPC is found on
both coated and uncoated intracellular vesicles and is thought to be involved in
endocytosis and intracellular trafficking of receptors (Dance et al., 2004).
Importantly it also potentially links these receptors to G-protein signalling pathways
(De Vries et al., 1998). S API 02 is a member of the membrane-associated guanylate
kinase (MAGUK) family and is expressed early in brain development (Fujita and
Yoshihisa, 2000; Sans et al., 2000). It is involved in modulation of NMDA
receptors, anchoring of transmembrane proteins by multi protein complexes and
trafficking of NMDA receptors to the plasma membrane of the post-synaptic density
(Lau et al., 1996; Sans et al., 2000; Sans et al., 2003). Both the GIPC and the
SAP102 proteins selected by the yeast two-hybrid screen contained PDZ domains
and appeared to be binding to the last 28 amino acids of NrCAM. Further
investigation showed that the last three amino acids of NrCAM were necessary for
binding and thus it has been concluded that SAP102 and GIPC are binding to the
class 1 PDZ binding site of NrCAM. Both GIPC and SAP 102 are expressed at
similar times of development of the brain and neuron as NrCAM and both PDZ
proteins co-localised with NrCAM in the localised areas of the plasma membrane of
cells. Although the NrCAM-GIPC binding was not successfully reconfirmed the
NrCAM-SAP102 interaction was, using the Tandem Affinity Procedure (TAP).
NrCAM-SAP102 binding has been subsequently further reconfirmed a third time
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using the GST pull-down technique by Dr F. Davey (Davey et al., 2005). The















Figure 7-1. A diagrammatic representation of the results in Chapter 3 and 4. The
figure demonstrates three new novel binding partners of NrCAM, namely the
VHS domain of GGA1, GIPC and SAP102. LI did not bind to any of the
potential binding partners of NrCAM. Neurofascin bound to the VHS clone and
to the GIPC clone but not to the SAP 102 clone. The cytoplasmic termini of the
LI-CAM protein have been shown diagrammatically. The green boxes represent
the ankyrin-binding domain of neurofascin and NrCAM. The pale green box
represents the ankyrin-binding domain LI that was missing the LADY motif. The
dark blue box is the proposed FERM binding domain of neurofascin. The pale
blue box is the equivalent amino acids of the FERM domain in neurofascin
present in NrCAM and LI. The dark pink boxes are the PDZ binding domains of
NrCAM and neurofascin. The pale pink box is the equivalent amino acids of the
PDZ domain of NrCAM present in LI.
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7.2 Does NrCAM bind to proteins of the 4.1 Superfamily?
Proteins of the 4.1 superfamily that contain a FERM domain are good candidate
proteins to bind to NrCAM. These proteins also link membrane receptors to the
cortical cytoskeleton via their FERM domains (Bretscher et al., 2002). They are
also involved in inositol and kinase signaling pathways as well as growth cone
formation (Bretscher et al., 2000; Ramesh, 2004). Previous work done by Dr. F.
Gunn-Moore had shown that FERM domain containing proteins bound to the 28
C-terminal residues of neurofascin, 14 of which contain a sequence highly
homologous to a FERM domain-binding motif found in other receptors (Gunn-
Moore, unpublished results). An analysis of the amino acid sequence of NrCAM
showed that many of these amino acids had been conserved, suggesting it too may
bind to NrCAM's cytoplasmic sequence. Therefore, FERM domain containing
proteins were good candidate binding proteins for NrCAM, particularly in the
growth cone. Initial studies showed that one of the 4.1 Superfamily proteins Ezrin
was present at the same time and place in the cell and neuron. Yeast two hybrid
studies were performed to confirm the interaction for Ezrin and two other FERM
domain containing proteins radixin and willin. Unfortunately, despite the ability of
neurofascin to bind to the proteins, NrCAM itself showed no measurable interaction.
The LI-ezrin interaction with Ezrin was due to the presence of a RSLE motif
(Dickson et al., 2002). This motif is also found in certain isoforms of NrCAM.
However, NrCAM containing this motif did not bind to ezrin, radixin or willin.
Interestingly LI containing the RSLE sequence, despite binding strongly to ezrin,
did not show measurable binding ability to either radixin or willin. Finally, it was
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tested whether NrCAM could bind to EBP50, a protein known to couple proteins
with FERM domains to membrane receptors (Bretscher et al., 2000). However
though neurofascin did show measurable binding to EBP50 NrCAM did not. Thus,
it was concluded that NrCAM, LI and neurofascin all show different binding
abilities to members of the FERM family. The results of Chapter 5 have been
summarised by Figure 7-2.
7.3 How does tyrosine phosphorylation of NrCAM occur and
does it affect ankyrin binding.
NrCAM's only known signalling partner was ankyrin and the NrCAM-ankyrin
interaction was believed to be regulated by tyrosine phosphorylation of the tyrosine
of the amino acid motif FIGQY of the NrCAM cytoplasmic terminus. Much of the
previous work done on LI-CAM tyrosine phosphorylation had been completed on
neurofascin and LI and these findings were to be reconfirmed for NrCAM's
interaction with ankyrin. It was further hoped that some details of the pathways
upstream of FIGQY tyrosine phosphorylation could be elucidated. The two





Figure 7-2. A diagrammatic representation of the results in Chapter 5,
demonstrating how proteins of the 4.1 superfamily, that contain FERM domains,
may link members of the LI-CAM family to the actin cytoskeleton. The
cytoplasmic termini of the LI-CAM protein have been shown diagrammatically.
The red box in the cytoplasmic terminus of LI indicates the presence of an
alternatively spliced RSLE motif The green boxes represent the ankyrin-binding
domain. The dark blue box is the proposed FERM binding domain of
neurofascin. The pale blue box is the equivalent amino acids of the FERM
domain in neurofascin present in NrCAM and LI. The dark pink boxes are the
PDZ binding domains of NrCAM and neurofascin. The pale pink box is the
equivalent amino acids of the PDZ domain of NrCAM present in LI.
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The first approach involved the immunoprecipitation of NrCAM receptor from
cells that had been stimulated by a phosphatase inhibitor. The first attempts were
made to immunoprecipitate out HA-NrCAM using an antibody to the N-terminal
HA epitope. However, it became clear that NrCAM immunoprecipitated out was
subject to posttranslational cleavage by furin and thus may not have contained the
cytoplasmic terminus of NrCAM. It was therefore necessary to find a method that
was guaranteed to immunoprecipitate out NrCAM containing the cytoplasmic
terminus. In order to do this it was necessary to produce an antibody to the
cytoplasmic terminus of NrCAM. Unfortunately, the antibody produced could
identify purified chimeric GST-NrCAM but could not identify NrCAM transfected
into cell lines. It was therefore attempted to circumvent the furin cleavage problem
by producing a NrCAM clone that did not have the third fibronectin type Ill-like
(FNIII-like) repeat that is normally cleaved by furin. Unfortunately, the initial
attempts at immunoprecipitation using this clone were unsuccessful.
The second approach was to use the published observation that unphosphorylated
ncurofascin can bind to ankyrin-GFP such that the labeled protein translocates from
the cytoplasm to the plasma membrane in HEK293 cells. The initial experiments
looked promising, and ankyrin-GFP was observed translocating to the plasma
membrane only in cells transfected with NrCAM. However this interaction was
difficult to quantify, making it unsuitable for the assays that would be necessary to
establish the tyrosine phosphorylation signaling pathways. However viewing live
cells did show that the NrCAM-ankyrin interaction was highly dynamic and that
NrCAM in stressed cells did not appear to be binding to ankyrin. Indeed the
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dynamics of this interaction were so quick that it was impossible to image them
using the microscope and imaging software available.
7.4 Possible functions of the VHS-GGA/NrCAM interaction.
In Chapter 3 the VHS domain of GGA1 was also a potential binding candidate of
NrCAM. Though this interaction has yet to be reconfirmed there are some possible
functions of the interaction worth speculating about.
Most of the VHS-GGA/receptor interactions reported to date are believed to
traffic receptors from the TGN to the early/late endosome (Bonifacino, 2004).
Nothing is known about the trafficking of NrCAM to the cell surface. However
NrCAM is expected to be cleaved by furin and furin is localised principally in the
TGN where it cycles between the sorting compartment, the cell surface and the early
endosomes (reviewed Nakayama, 1997; Thomas, 2002). Other binding partners of
the GGA VHS domain such as BACE are also furin cleaved (Creemers et al., 2001).
Therefore, localisation of NrCAM to the TGN and the endosome could potentially
make it available to the activities of this enzyme before reaching the plasma
membrane.
Furthermore the major locations of endosomes and lysosomes within developing
neurons axon are around branch points and growth cones (Overly and Hollenbeck,
1996). NrCAM expression has been described as potentially being down stream of
branching events in the kidney (Valerius et al., 2002) and NrCAM has an important
role to play in the axonal growth cone (Faivre-Sarrailh et al., 1999). Thus, the
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GGA-VHS protein could be delivering NrCAM to locations within the axon close to
where it will be expressed.
Another possibility is that the GGA-VHS binding domain could target NrCAM to
the lysosome (via the endosome) for destruction when the receptor is over
expressed. This would require that the VHS binding motif be masked during normal
protein expression and unmasked during protein over expression.
It should also be noted that GGA-VHS interaction with membrane receptors may
have undefined role(s) other than its transport from the TGN to the endosome
(Bonifacino, 2004) and this role could also apply to a GGA-VHS/NrCAM
interaction.
However, the interaction of NrCAM and GGA still needs to be verified. A first
step in considering the validity of the NrCAM-GGA interaction would be to
establish does NrCAM localise to the TGN, for example does NrCAM co-localises
with a marker for the TGN such as TGN38? Secondly, does NrCAM bind to full
length GGA1/2/3 and can it be proven using a second biochemical technique such as
the Tandem Affinity Purification procedure? Thirdly, if you interfere with the
NrCAM/GGA interaction, for example by mutating the essential aspartate, will this
interfere with NrCAM's trafficking to the plasma membrane surface?
7.5 Does GIPC bind to NrCAM?
In Chapter 4 it was not possible to reconfirm the NrCAM-GIPC interaction using
a second biochemical technique, which suggested that NrCAM and GIPC are not
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binding partners. This is a common occurrence for PDZ interactions in the yeast
two-hybrid screen. For example, stargazin a protein in the post-synaptic density has
a class 1 PDZ domain. PSD-95, PSD-93, SAP97 and SAP102 were found to be
PDZ binding partners of stargazin, using a similar yeast two-hybrid system used in
this thesis. However further testing showed that only PSD-93 and PSD-95
interacted in vivo (Dakoji et al., 2003). Similarly other authors believe that it is
difficult to determine PDZ interactions using the yeast-two hybrid screen (where
tertiary and quaternary structural information is lost) or in over-expression studies
(where specificity due to binding affinities and cellular compartmentalization can be
masked)" (van Zundert et al., 2004). Thus binding of NrCAM to GIPC could be a
false positive of the yeast two-hybrid screen.
However proving a false positive is difficult. With the exception of TAP
analysis, all of the binding assays used to test the NrCAM-GIPC interaction
experienced technical difficulties and proving the binding of GIPC to any of its PDZ
domain binding-partners had been reported as difficult by other groups. In general,
this is believed to be due the transient nature of the GIPC-membrane receptor
interaction.
It is notable for example that the potential interaction shown for the GST pull¬
down of GIPC in Figure 4-22 was in the strongest ionic buffer. Though the antibody
to GIPC may have been unspecific, it is unlikely that this result was due to the
antibody binding to GST-NrCAM breakdown products as there was no 45 kDA band
(full-length GST-NrCAM) on the blot. The results have been discounted as they
could not be proven using the FLAG tagged GIPC construct and because the full-
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length GIPC protein did not bind using the yeast-two hybrid screen. However N-
terminally tagging the full-length GIPC construct with FLAG and Gal4 could have
affected its structure. Both the GH1 and GH2 domains of GIPC (Figure 3-6) are
believed to interact with each other (Bunn and Jensen, 1999). It is possible that an
N-terminal tag will interfere with this and cause the PDZ domain to be inaccessible
to its binding partners. It may also be possible that the presence of the GH2 domain
interfered with the binding of full-length GIPC to NrCAM using the yeast two-
hybrid assay. The function of the GH2 domain is still unknown. However it is
possible the GH2 domain may contain a competing organellular targeting sequences
that interferes with the targeting of the construct to the yeast nucleus and thus
prevent binding in the nucleus by (McAlister-Henn et al., 1999).
So does GIPC bind to NrCAM? GIPC is an attractive candidate to bind to
NrCAM for several reasons:
GIPC binds to proteins in similar neuronal locations and with similar functions as
NrCAM. For example GIPC binds to two members of the semaphorin family
neuropilin-1 and Semaphorin 4C (Cai and Reed, 1999; Wang et al., 1999). The
semaphorin family has an important role in axon repulsion and the trans binding of
LI to neuropilin-1 converts SEM 3A induced repulsion to attraction (Castellani,
2002; Castellani et al., 2002). Importantly Semaphorin 4C also binds to SAP102
(Inagaki et al., 2001).
Furthermore GIPC seems to function in the general trafficking of newly
synthesised membrane receptors from the trans Golgi network (TGN) to the plasma
membrane (De Vries et al., 1998; Blobe et al., 2001; Liu et al., 2001) and the
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endocytosis/retrograde transport of receptors at the plasma membrane (De Vries et
al., 1998; Wang et al., 1999; Lou et al., 2002) and it is not unreasonable to believe
that this rather general function could be its role in binding NrCAM..
Importantly one of GIPC's binding partners, myosin VI, does not bind to the PDZ
domain of GIPC (Bunn and Jensen, 1999) and it is conceivable that GIPC can bind
both PDZ domain containing receptors and myosin VI at the same time. Buss et al
describe three possible functions for myosin VI in cell migration based upon the
cellular locations mentioned above. 1. Myosin VI may be involved in recycling
adhesion molecules from the rear end of the cell to the leading edge of the growth
cone via clathrin mediated endocytosis. 2. newly synthesised adhesion molecules
may be delivered from the TGN to the leading edge or 3. myosin VI binds to a
stationery cell adhesion molecule complex associated with the ECM such as E-
cadherin and P-catenin. This holds myosin VI stationery with regard to the substrate
and as it pushes towards the minus end of the actin filament (from above actin
filaments are aligned with their plus ends toward the leading surface of the growth
cones) it geneiales the force necessary for membrane protrusion at the leading edge.
It is interesting that NrCAM in cerebellar granule cells shows retrograde actin
dependent movement from the leading edge to the base of the growth cone when
presented with F3 conjugated microspheres (Faivre-Sarrailh et al., 1999). One
speculation would be that bound GIPC and myosin VI allow this retrograde flow.
However, without a second biochemical assay that confirms the NrCAM-GIPC
interaction it would be unwise to conclude that the two proteins are binding.
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7.6 What is the function of NrCAM binding to SAP102?
The NrCAM-SAP102 interaction has been satisfactorily shown using yeast-two
hybrid, TAP analysis and GST-pulldowns (Davey etal., 2005). Further studies have
confirmed that the interaction of NrCAM and SAP102 occurs at the second PDZ
domain of NrCAM (communication Dr Davey, University of St Andrews). So what
is the function of this interaction?
NrCAM is involved in synaptogenesis (Backer et al., 2002). However until
recently it has been believed to be presynaptic only. Recently however a paper has
been published showing both NrCAM and SAP102 at the post-synaptic density of
P2 CA1 hippocampal synapses (Petralia et al., 2005). This is the first report of
NrCAM at this location. Importantly NrCAM was at both the pre-synaptic density
and post-synaptic density and was seen as clusters of gold particles across the
synaptic cleft suggesting that pre-synaptic and post-synaptic NrCAM may be
binding homophillically (Petralia et al., 2005). This may suggest a role for NrCAM
in the adhesiveness of the synapse. SAP102 could be trafficking NrCAM to this
post-synaptic location via the secretory pathway or it could be organizing NrCAM at
the post-synaptic density.
The secretory pathway describes a pathway where membrane and secretory
proteins are synthesised in the endoplasmic reticulum and sent to the Golgi
apparatus and subsequently to the trans Golgi network, where they are organised
into secretory vesicles and targeted to the plasma membrane (Burgess and Kelly,
1987; Guo et al., 2000). The exocyst complex (Sec6/8 complex) may aid targeting
of these secretory vesicles to the plasma membrane and consists of eight proteins
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Sec3, Sec5, Sec6, SeclO, Seel5, Exo70 and Exo84 (Hsu et al., 1996; Hsu et al.,
1999). This complex of proteins has been found in the growth cone of cultured
differentiated pheochromocytoma cells (PC 12) and hippocampal neurons (Hazuka et
al., 1999; Vega and Hsu, 2001). The exocyst complex is believed to be a
downstream effector of the NGF induced MAP kinase pathway and is essential for
neurite outgrowth (Vega and Hsu, 2001). The first two PDZ domain of SAP102
bind to sec8, a member of the exocyst complex (Sans et al., 2003). SAP102 co-
localises with Sec6-Sec8 at the rough endoplasmic reticulum, organelles and
vesicles of hippocampal neuronal soma, neurites, growth cones, early synaptic
contacts and post-synaptic densities (Sans et al., 2003). As discussed in Chapter 3
SAP102 binds to NR2B subunits of the NMDA receptor via its PDZ domains
(Muller et al., 1996). Disruption of the exocyst-SAP102 PDZ domain interaction
blocks delivery of NMDARS to the post synaptic density of neurons (Sans et al.,
2003). Thus, the exocyst-SAP102 interaction is currently believed to be necessary
for the correct targeting of at least one binding partner of SAP102 to the plasma
membrane of the post-synaptic density. The question remains could it also be
targeting NrCAM?
SAP 102 may also be acting as a scaffolding molecule that clusters membrane
receptors and cytoplasmic proteins to NrCAM. Details of SAP102's other binding
partners have been given in Table 3-5. Notably it binds to SynGAP, a synaptic
RasGAP that may regulate signal transduction via the Ras signalling pathway (Kim
et al 1998) and Pyk2, a tyrosine receptor kinase important in the calcium signalling
cascade (Seabold 2003).
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NrCAM has a class 1 PDZ domain and therefore, it may bind to other members
of the MAGUK family. Notably part length PSD-95 cDNA had been isolated by the
Yeast two-Hybrid screen in Chapter 3, although this interaction was not reconfirmed
by further screening. Co-localisation of full length PSD-95 and NrCAM was
attempted in COS-7 cells (Davey et al., 2005). The two proteins did not co-localise
with each other however. This shows that NrCAM can distinguish between both
proteins despite having the published binding motif for both (a situation similar to
that found for stargazin). This could be due to residues other than the P0 valine and
P-2 serine of NrCAMs PDZ binding domain. For example the P-l and P-6 residues
allow SAP102 to bind to 5HTc and not 5HT2A receptors (Becamel et al., 2004).
NrCAM's binding to the other MAGUKS PSD-93 and SAP97 has not been tested
yet. SAP97 is a particularly intriguing possibility as it is presynaptic (Muller et al.,
1995) and NrCAM staining has recently been shown to more dense at presynapses
than post synapses (Petralia et al., 2005).
7.7 Does NrCAM bind to members of the 4.1 superfamily?
The sequences within the cytoplasmic terminus of neurofascin and LI that bind to
FERM domain containing proteins may reflect the different functions of 4.1
superfamily binding to both proteins. Neurofascin binds to FERM domain
containing proteins at a sequence C-terminal to its ankyrin-binding site that is
present in all reported isoforms of neurofascin. LI however will only bind to ezrin if
the RSLE motif is present. The RSLE motif is only present in neuronal isoforms of
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LI and is responsible for sorting the receptor to the growth cone and its AP-2
mediated endocytosis within the growth cone (Kamiguchi and Lemmon, 1998;
Kamiguchi et al., 1998). Therefore this suggests that LI binding to ezrin may be
specific to neuronal growth cones and have a role in growth cone advance. As
NrCAM does not appear to interact directly with members of the 4.1 superfamily the
question remains how does it couple to retrograde flow in a growth cone? There are
several possibilities:
1. For example a-actinin has been suggested as a potential candidate to bind to
NrCAM (Falk et al., 2004). TAG-1 beads bind in trans to the extracellular part of
NrCAM in the plasma membrane of neuroblastoma cells and subsequently a-actinin
and F-actin are recruited to the site of cell contact with TAG-1 beads but ezrin is not
(Falk et al., 2004). 2. It is also possible that NrCAM is linked to the retrogradly
moving cytoskeleton solely via ankyrin. Ankyrin binding to LI has been shown to
induce stationary behaviour by LI in neuroblastomas (Gil et al., 2003b). However
ankyrin binding has also been shown to mediate rear-ward movement of LI in
neurite initiation (Nishimura et al., 2003). Therefore, there is potential for ankyrin
to play at least a small role in NrCAM retrograde movement. Furthermore, there is
potentially an as yet unidentified PDZ domain containing protein that could link
NrCAM to the retrogradly moving cytoskeleton.
3. EBP50 is not the only known protein that links membrane receptors to ezrin and
other FERMs. E3KARP is a protein that is closely related to EBP50 and which also
links membrane receptors to FERM proteins (Bretscher et al., 2000). If an, as yet,
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unidentified linker protein is binding to NrCAM and ezrin this could explain their
co-localisation?
4. NrCAM could be binding to a FERM domain containing protein other than ezrin,
radixin and willin. For example moesin has been shown to be important in growth
cone morphology (Paglini et al., 1998).
5. NrCAM may be binding in cis to another membrane receptor that in turn binds to
that actin cytoskeleton via an FERM domain containing protein. For example the
extracellular region of NrCAM binds to neurofascin and neurofascin binds to ezrin
(Grumet, 1997). Indeed deletion of NrCAM's cytoplasmic terminus does not reduce
its ability to move retrogradly in neuroblastoma cells (Falk et al., 2004).
Furthermore, deletion of the extracellular fibronectin type ID-like (FNDI-like)
repeats of NrCAM did not interfere with its retrograde movement. However,
deletion of both the FNIII-like domain and the cytoplasmic terminus together
eliminates NrCAM retrograde movement (Falk et al., 2004). This implies that
NrCAM must bind to both an extracellular molecule and intracellular molecule to
couple to the retrogradly moving cytoskeleton.
7.8 The tyrosine phosphorylation of NrCAM and its binding to
ankyrin.
Despite the technical problems in developing an assay to identify the signalling
pathways involved in the tyrosine phosphorylation of NrCAM in Chapter 6, the
search for cytoplasmic binding partners of NrCAM in chapter 3 and 4 have
identified two intriguing possibilities. One potential binding partner was the VHS
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domain of GGA1, which bound to the ankyrin binding site of the Ll-CAMs. As
speculated above GGA1 may be trafficking NrCAM to locations in the neuron.
However, it did not bind to NrCAM when the tyrosine of the FIGQY motif was
mutated to a glutamate. This is thought to mimic phosphorylation of the NrCAM
receptor, thus raising the possibility that tyrosine phosphorylation not only regulates
ankyrin binding but GGA1 binding and subsequently NrCAM's trafficking. The
other binding partner GIPC can also bind to TrkA, which is the neurotrophic
receptor for nerve growth factor. It is believed that GIPC simultaneously binds to
TrkA and a PDZ binding receptor (Lou et al., 2001). Thus, GIPC could be linking
TrkA to NrCAM. Hence, the phosphorylation of NrCAM may be a direct event
between the tyrosine kinase domain and of the Trk receptor and NrCAM. Before
either of these possibilities can be investigated further, the GGA1 and GIPC
interactions will have to be reconfirmed.
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Appendix 2: Lysis buffers
RIPA buffer:
tris-HCl 50 mM, pH 7.4, NP-40 1 %, Na-deoxycholate 0.25 %.
GIPC Buffer 1 (GB1):
lOmM Tris-HCl pH7.5, 150mM NaCl, 1% NP40.
GIPC HEK Buffer 1 (GBH1):
Dubleccos Phosphate buffered saline (DPBS) (SIGMA give code), 1% v/v triton x-100,
0.2% SDS, 0.5% deoxycholate and 1 mM PMSF.
GIPC HEK Buffer 2 (GHB2):
PBS (Sigma give code), 5mM EDTA, 5mMEGTA, O.lmM PMSF, lOu/ml aprotinin.
GIPC HEK Buffer 3 (GHB3):
lOOrnM Tris pH8.0, 150mM NaCl, ImM EDTA, 1% NP-40. 0.12mg/ml PMSF, 2mg/ml
leupeptin, lmg/ml aprotinin, lOmMNAF and ImM sodium orthovanadate.
Appendix3 Epitope FirstBlock Washes PrimaryAb Washes SecondaryAb Washes
ExtracellularN CAM TBS-T(0.5%)5%milk
2hoursroomtemperature threefivminuteTBS-T NrCAM(N-18)andr( -16) SantaCruzsc-18958andsc-18 60 1/1,000 TBS-T3%milk Overnight4°C threeenminuteTBS-T donkeyantigoatI GHRPco juga e SantaCruzsc-sc-2020 1/20,000 TBS-T5%milk roomtemperatureneh u twoenminuteTBS-T onetenmi uteTBS
ExtracellularN CAM TBS-T(0.5%)5%milk overnight4°C threefivminuteTBS-T Antil-4IgG C.FavireSarrailh, 1/1,000 TBS-T3%milk roomtemperatureneh u threeenminuteTBS-T goatanti-r bbitI GHRPc njuga e SantaCruzsc-2004 1/10,000 TBS-T5%milk roomtemperatureneh u twoenminuteTBS-T onetenminuteTBS
CytoplasmicNrCAM TBS-T(0.5%)5%milk overnight4°C threefivminuteTBS-T A2541and2 Invitrogen 1/1,000(or/1AP) TBS-T3%milk roomtemperatureneh u threeenminuteTBS-T goatanti-r bbitI GHRPc njugate SantaCruzsc-2004 1/10,000 TBS-T5%milk roomtemperatureneh u twoenminuteTBS-T onetenminuteTBS
SAP102 TBS-T(0.5%)5%milk
2hoursroomtemperature threefivminuteTBS-T anti-SAP102 AffinityBioreagents 1/300 TBS-T3%milk Overnight4°C threeenminuteTBS-T goatanti-r bbitI GHRPconjugate SantaCruzsc-2004 1/10,000 TBS-T3%milk roomtemperaturenehou twoenminuteTBS-T onetenmi uteTBS
Appendix3 Epitope FirstBlock Washes PrimaryAb Washes SecondaryAb Washes
FLAG-constructs FLAGGIPC,SA 102,FLAGEzrin TBS3%milk roomtemperature30inutes( rO/N4°C) onefivemi uteTBS anti-FLAGm2,ouseonoclonal SIGMAF3165 lOmg/mlor1/500 TBS3%milk roomtemperature30minutes onefivemi uteTBS goatanti-mouseI GHRPconjugate SantaCruzsc-2005 1/20,000 TBS3%milk roomtemperatureneh u eight2.5minutewas esTBS-T finalTBSw sh5minutes
GIPC TBS-T(0.5%)5%milk
2hoursRTrO/N4°C threefivminuteTBS-T GIPC(N-19),goatpolyclonal SantaCruzsc-9648 1/2,000 TBS-T3%milk roomtemperatureneh u threetenminuteTBS-T donkeyantigoatI GHRPco jugate SantaCruzsc-sc-2020 1/20,000 TBS-T5%milk roomtemperatureneh u twoenminuteTBS-T onetenminuteTBS
HA-NrCAM,H -NrCAMDPDZ HA-NrCAMDFN2&3,HA-Neurofascin TBS-T(0.5%)5%milk
2hoursRTO/N4°C threefivminuteTBS-T Anti-HAHighffinity,ramo oclonal Roche1867423 1/1,000 TBS-T3%milk roomtemperatureneh u threeenminuteTBS-T goatanti-mouseI GHRPc njugate SantaCruzsc-2005 1/20,000 TBS-T3%milk roomtemperatureneh u twotenminuteTBS-T onetenminuteTBS
PhosphorylatedTyrosines PBS3%milk
45minutesroomte perature nowashes anti-phosphotyrosine,cl ne4G10 Upstate,05-321 1/500 PBS3%milk Overnight4°C twoimesithater goatanti-mouseI GHRPconjugate SantaCruzsc-2005 1/20,000 PBS3%milk roomtemperatureneh u twoimesithwa er 5minutesiPBS-T(0.05%) fivet m switha er








GIPC 71R CCCAAGC1 1 1 1AGTAGCGGCCAACCTTGGC
GIPC 8 GGAATTCTTAGTAGCGGCCAACCTTGGAT
NrCAM 1 GGAATTCAGAAGAAACAAACAAGGGTGGT
NrCAM 2 CGGGATCCTTAAACAAAGGAGTTCATTGC
NrCAM 21 GGAATTCAGTGGTAAGAAAGAGAAAG
NrCAM 32 CGGGATCCTTAGTTCATTGCGTTGACAGGA
NrCAM 33 CGGGATCCGAAGAAGAAACAAGGGTGGT
NrCAM 34 GGAATTCTTAAACAAAGGAGTTCATTGCG
NrCAM F1 TCCGGGCCCGCCAGCGCCGACAGAGGCTTC
NrCAM F2 GGAATTCTTAAACAAAGGAGTCATTGCG
SAP102H GGAATTCGAATGCACAAGCACCAGCACTGC
SAP 1021 GGAATTCTCAGAGTTTTTCAGGGGATGGG
